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ABSTRACT 
Thiol proteinases synonymous with cysteine proteinases comprise a group of 
proteolytic enzymes which are widely distributed among living organisms They play 
very important role in the intracellular proteolysis such as catabolism of proteins and 
peptides, development and fimction of the immune system and tumor, cell invasion. It 
implies that their regulation is important otherwise it will cause uncontrolled 
proteolysis and tissue damage. In principle, cystatins provide this regulation. 
Cystatins are widespread, naturally occurring tight binding reversible inhibitors of 
cysteine proteinases found either within the cytosol or secreted from the cells 
[Kopitar-Jerala, 2006]. The diverse group of thiol proteinase inhibitors comprises the 
cystatin superfamily, divided into three main groups depending on the presence of 
single or muhiple 'cystatin domains', presence or absence of a signal sequence, 
carbohydrate content and sulphydryl groups. Family I- the stefins are cytosolic, 100-
residue single chain proteins with no disulphide bonds or carbohydrates. Family li-
the cystatins are mainly extracellular, 120 residue single chain proteins with two 
disulphide bonds but no carbohydrates and Family III- the kininogens are 
multidomain, blood plasma glycoproteins [Turk et al, 2008]. The importance of 
cystatins is underlined by the pathological conditions that arise upon loss or mutations 
of cystatin genes/function [Turk et al., 2008; Cox, 2009]. 
RESULTS OBTAINED IN THE STUDY ARE SUMMARIZED AS 
FOLLOWS: 
Clapttrl 
A 44 kDa thiol proteinase inhibitor (PTPI) has been purified and characterized from 
goat pancreas in terms of its biochemical and biophysical properties. Purification was 
achieved by a four step procedure involving alkaline treatment (pH 11.0), acetone 
fractionation, ammonium sulphate precipitation (20-80%) and gel filtration 
chromatography on Spehacryl S 100 HR column. The preparation was found 
homogenous on the basis of charge and molecular weight. The inhibitor was obtained 
with 20,4% yield and 500 fold purity. Pancreatic thiol proteinase inhibitor (PTPI) was 
found to have two subunits linked by non covalent interactions as determined by 
SDS-PAGE under reducing as well as non reducing conditions. The stokes radius, 
diffusion and sedimentation coefficients of PTPI were 27.3 A, 7.87 x 10'^  cm sec" 
and 3.83 s, respectively. It was stable in pH range 3-10 and upto 70°C. It possessed 
2.32% carbohydrate content and no disulphide bonds. PTPI was immunogenic and 
induced antibody formation in rabbits. However, it exhibited no immunogenic identity 
with cystatins isolated from goat lung and brain. 
The purified inhibitor inhibited papain and ficin very efficiently and to slightly lesser 
extent bromelain but failed to inhibit bovine trypsin, chymotrypsin and pepsin. The 
respective Ki values obtained for papain, ficin and bromelain were 5.88, 9.02 and 
22.28 nM. Association rate constant and hence the affinity of the inhibitor for 
proteinases was in the following order: papain (1.49 x lO"* M'^s'') > ficin (1.39 x lO'' 
M"^s'') > bromelain (5.94 x 10'' M"'s"'). The K.i values obtained for papain, ficin and 
bromelain were 8.76 x 10'^ 3.35 x 10'^  and 1.32 x 10"^  s\ respectively. The 
calculated half-life values of enzyme-inhibitor complex for papain, ficin and 
bromelain were 7.91 x 10 ,^ 5.51 x 10 ,^ and 5.23 x lO'' s and the IC50 values were, 
0.08, 0.078 and 0.154 [iM, respectively for the three proteinases; again reinforcing 
greater affinity of the inhibitor for papaya proteinase. 
The partial amino acid sequence analysis of the heavier subunit revealed that PTPI 
has highest sequence homology with bovine parotid and skin cystatin C. The glycine 
residue is present at 11"^  position rather than at conserved position 9 which has also 
been reported for human placental cystatin and human stefin A structure. The 
hydropathy plot of first 24 amino acid residues suggested that most amino acids of 
this stretch might be in hydrophobic core of the protein. 
Secondary structural composition of the inhibitor showed presence of 17.18% a 
helical content. The binding of PTPI to activated papain was accompanied by 
pronounced changes in the far ultraviolet circular dichroism, ultraviolet absorption 
and fluorescence emission spectra. These changes were compatible with perturbations 
of the environment of aromatic residues in one or both the proteins of the complex 
arising from a conformational change. 
The absence of disulphide bonds is a unique character of type 1 cystatin family 
members. Molecular masses of type 1 and 2 cystatin families range in 11 kDa to 13 
kDa [Turk and Bode, 1991]. Presence of carbohydrates is however limited only to 
kininogens, with few exceptions found for members of type 2 cystatin family. PTPI is 
devoid of any disulphide linkage, has high molecular mass (44 kDa) and bears 
sequence similarities to both stefins and cystatins. Studies on kinetics of inhibition as 
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well as on biophysical interaction of PTPI with thiol proteinases shows that it bears 
resemblances with other members of type 2 cystatin family. Based on above 
parameters PTPI can be regarded as a variant of type 1 and type 2 cystatin families. 
This is not unusual as there is growing list of proteins found to possess some of 
cystatin superfamily structural and fiinctional motifs, but bearing substantial 
differences causing them to be classified as variants of cystatin superfamily. 
Chipter 2 
Equilibrium studies of guanidine hydrochloride (GdnHCl) and urea induced unfolding 
of PTPI were also performed by monitoring the inhibitor activity, intrinsic 
fluorescence, circular dichroism (CD) and l-anilino-naphthalene-8-sulphonate 
binding. 
A sigmoidal dependence of inhibitory activity on GdnHCl concentration was 
observed. 65% inactivation occurred at 4 M GdnHCl, beyond this concentration PTPI 
was almost completely inactivated. The fluorescence emission spectrum of PTPI 
suffered a 15 nm red shift in wavelength of maximum emission (Xmax) (from 335 nm 
for native protein to 350 nm at higher concentrations of GdnHCl) with quenching of 
fluorescence intensity, suggesting the unfolding of PTPI. Secondary structure analysis 
of PTPI revealed minute effects on mean residue ellipticity (MRE222 nm) till 1 M 
GdnHCl. However, complete loss of signal was observed at higher concentrations of 
the denaturant. Midpoint of transition. Cm, deduced from normalized transition 
curves of activity, Xmax, and MRE222nm data was 3.2 M GdnHCl. Further, a shift in Cm 
was observed with PTPI concentration. Changes in molecular properties of PTPI such 
as inhibitory activity, MRE222 nm and Xmax with increasing GdnHCl concentration 
revealed a monophasic sigmoidal dependence with coincidental profiles, 
characteristic of cooperative unfolding, suggesting a two state model for denaturation 
of the inhibitor. 
In urea, unfolding pathway differed from that observed in GdnHCl. Almost complete 
inactivation was observed beyond 6 M urea. A gradual increase in X^ ax occurred with 
increasing urea concentration. It red shifted to 350 nm at 8 M urea indicating that 
treatment of PTPI with high concentrations of urea leads to unfolding of the inhibitor. 
A sigmoidal behaviour of decrease in MRE222 nm with increasing urea concentration 
was observed, with complete loss of signal noticeable above 5 M urea. The Cm value 
deduced from normalized transition curves for activity and MRE222nm was 3.6 M. No 
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dependence of Cm on concentration of the inhibitor was obtained. The Cm value 
determined from Imax curve was 4 M. The non coincidence of transition curves in urea 
denaturation as measured by probes sensitive to different levels of protein structure, 
are consistent with a mechanism involving intermediate state. However, intermediates 
are not clearly observed. 
The denaturation by both GdnHCl and urea was only partially reversible, with 
retrieval of only 10% of the native activity on extensive dilution only in case of 
GdnHCl denaturation. Also at all denaturant concentrations the inhibitor refolded to a 
species having significantly different spectroscopic properties from native PTPL 
Urea is known to be about half as effective as GdnHCl in inducing protein unfolding 
and dissociation, suggestive of a 2-fold rule. The results of the present study show that 
PTPI is an exception to this 2-fold rule. The Cm for urea unfolding was 3.6 M (4 M 
from Xmax curve) and that for GdnHCl was 3.2 M, pointing to significant contributions 
of both hydrophobic and electrostatic interactions in maintenance of active site and/or 
dimeric nature of the inhibitor. 
Cbaptfr 3 
Partially or totally unfolded states that are occasionally populated in vivo after 
biosynthesis on the ribosome, stress conditions or mutation and are favoured by 
changes on pH, ionic strength and mutations are most susceptible to initiate 
aggregation [Soldi et al., 2005]. 
We reasoned that aggregation and fibrillation of PTPI may also require the protein to 
access partially denatured states and thus explored existence of non native 
intermediates under experimentally imposed acidic conditions. PTPI was subjected to 
denaturation over a pH range of 1.0-7.0 and the conformational changes induced were 
studied by circular dichroism and intrinsic and extrinsic fluorescence. 
Till pH 5.0 no change in X^ ax of emission was observed. A decrease in pH to 3.0 
caused a 10 nm blue shift. Further lowering of pH to 2.0 was accompanied by a 2 nm 
red shift followed by a 3 nm red shift again at pH 1.0. ANS binding was initiated at 
pH 3.0 (with a blue shift in >^ ax of ANS emission to 490 nm) and reached a maximum 
at pH 1.0. Secondary structure analysis revealed -40% loss at pH 3.0 but at pH 1.0 
there was gain in secondary structure content (of -34%). Conclusively, PTPI at pH 
3.0 existed as partially unfolded intermediate having -60% residual secondary 
structure but almost completely aUered tertiary structure. PTPI at pH 1.0 exhibits 
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more of a molten globule like features having native like secondary structure contents 
and enhanced ability to bind ANS, however with tertiary contacts quite similar to 
native PTPI. 
The organic solvent 2, 2, 2-trifluoroethanol (TFE) is known to stabilize the partially 
unfolded proteins [Rashid et al., 2006b] and has been extensively employed for 
amyloid fibril induction in various proteins [Zerovnik et al, 2007]. From a range of 
concentrations used, in the present study 10% TFE induced native like secondary 
structure in pH 3.0 state of PTPL Similar results were also obtained for PTPI at pH 
1.0 and 2.0. 
Based on these results six solvent conditions were chosen to study amyloid fibril 
formation in PTPI. The inhibitor was incubated at pH 1.0, 2.0, 3.0 and at these three 
pH in presence of 10% (v/v) TFE. Two standard procedures were used to follow 
amyloid growth in above samples, Thioflavin T (ThT) fluorescence assay and 
transmission electron microscopy (TEM). 
Enhancement of ThT fluorescence was observed only after 55 days of incubation of 
PTPI at pH 2,0. Contrastingly at pH 3.0, enhancement was noticed within 5 days of 
incubation. Results obtained for PTPI incubated at pH 1.0 were quite similar to those 
obtained for pH 3.0 sample. The results revealed that amyloid type aggregates from 
PTPI form under acidic conditions and more readily at pH 3.0 and 1.0 than at pH 2.0. 
In the presence of TFE, amyloid growth was accelerated, for the sample at pH 2.0 
several fold enhancement in ThT fluorescence intensity was observed within 30 days 
of incubation. Similarly at pH 3.0, a profound increment was observed without any 
distinct lag phase. The characteristics of fibrillation at pH 1.0 were in similitude with 
sample at pH 3.0. Controls at each condition did not show any ThT binding. 
On subjection to transmission electron microscopy (TEM), after 15 days of incubation 
sharp fibrils were seen in pH 3.0 sample (in the presence of 10% (v/v) TFE) and 
peculiar foliage like pattern was observed for pH 1.0 sample (in the presence of 10% 
(v/v) TFE). The sample incubated at pH 2.0 (in the presence of 10% (v/v) TFE) also 
gave fibrils but after one month of incubation. 
Divalent metal ions (Zn^^ and Cu^^) effectuated a concentration dependent decline in 
ThT fluorescence of preformed fibrils at pH 3.0 suggesting deaggregation of the 
fibrils. When added prior to the initiation of fibrillation of PTPI (at pH 3.0, with 10% 
(v/v) TFE) 50 [iM Cu^^ and 10 |iM Zn^ "^  prevented any amyloid aggregation. 
These results corroborate with generic hypothesis of amyloid fibrillation proteins, 
outline the conditions necessary for PTPI fibrillation and point towards the strong 
influence of solvent conditions on fibril morphology. Use of divalent metal ions 
against amyloid formation is also suggested. 
Cliaiter 4 
In this chapter effect of reactive species on purified goat pancreatic thiol proteinase 
inhibitor has been evaluated. 
Riboflavin sensitized photodynamic modifications of PTPI lead to inactivation of its 
antiproteolytic activity and formation of aggregated products (at higher riboflavin 
concentrations). A continued disappearance of inhibitory activity towards papain was 
observed with increasing concentration of riboflavin and varying time periods of 
incubation reaching a maximum value of 83% (loss in activity). Sodium azide (a 
known singlet oxygen quencher) and potassium iodide (quencher of flavin triplet 
state) suppressed the activity loss as well as aggregation. Mannitol and thiourea failed 
to show any such protective effect. Natural antioxidants, curcumin (Cur), caffeic acid 
(CA) and quercetin (QE) diminished the riboflavin exerted damage which was evident 
by following observations, activity of treated PTPI was enhanced, aggregation was 
inhibited and tryptophan fluorescence retrieved back. Curcumin, however, provided 
only partial moderation. 
Hypochlorous acid and to lesser extent hydrogen peroxide destroyed the 
antiproteolytic potential of PTPI. HOCl even at low concentrations significantly 
decreased the functional integrity of the inhibitor (90% loss in activity). High 
concentrations of H2O2 also partially diminished proteinase inhibitory capacity of 
PTPI by a mechanism involving almost no contribution from hydroxyl radicals 
(sodium benzoate and thiourea afforded no protection and mannitol only to small 
extent). Structural analyses revealed fragmentation of PTPI upon HOCl exposure. 
H2O2 also caused loss in band intensity and appearance of some higher mobility 
material. Xmax suffered a red shift of 15 nm in the presence of H2O2. Diminution of the 
inflicted damage was observed on treatment with Cur, CA, QE, with former two being 
more effective than QE. There was subjugation of PTPI activity loss, fragmentation 
and changes in intrinsic fluorescence pattern in presence of bioflavonoids. 
The effect of nitric oxide on structure and fixnction of PTPI was also studied. There 
was a concentration dependent loss in activity. The Xmax red shifted to 350 nm (from 
335 nm for native PTPI) in the presence of NO. On the whole the inhibitor was 
VI 
severely compromised functionally (72% loss in activity) and structurally. The three 
natural antioxidants, Cur, CA and QE negated the loss in tryptophan fluorescence and 
PTPI inhibitory activity. Maximum protection was offered by Cur and CA. 
The results evinced the susceptibility of PTPI to aforementioned reactive species and 
the modifications induced included altered molecular weight (aggregation or 
fragmentation) and fluorescence characteristics and loss of inhibitory function. Also, 
Cur, CA and QE provided protection against the oxidative and nitrosative damage. 
Chapter 5 
Experiments were conducted to investigate the effects of sodium valproate, 
glimepiride, metformin hydrochloride and synthetic insulin on the structure and 
function of the inhibitor. 
Sodium valproate and glimepiride caused dose dependent loss of PTPI's inhibitory 
activity with almost 80% loss precipitating at 10 ^M sodium valproate and 40 ^M 
glimepiride concentrations. Drug interaction induced structural changes in PTPI were 
monitored by intrinsic fluorescence and UV vis spectrophotometric analyses. 
Complex changes were noticed in the fluorescence properties of PTPI indicating 
alteration in the environment of the aromatic amino acid residues induced on 
interaction with drugs. The difference spectra also showed profound changes 
suggesting involvement of tryptophan, tyrosine and phenylalanine residues in 
complexation. Secondary structural analysis of insulin-PTPI complexes revealed 
increase in ellipticity at 222 nm suggesting enhancement of native stability of the 
inhibitor. Metformin hydrochloride complexation caused only mild effects. 
The results implicate the loss of thiol proteinase inhibitor function in drug induced 
pancreatitis by sodium valproate. They also provide a platform for understanding the 
non responsiveness to antidiabetic drugs after a prolonged period and clues to enhance 
the insulin potency. 
Maintenance of appropriate equilibrium between free cysteine proteinases and their 
complexes with inhibitors is imperative for proper function of all living 
systems/tissues. This equilibrium in pancreas is critical for pancreatitis onset and its 
severity, diabetes and cancer [van Acker et al, 2002; Thrower et al., 2006; Rivenbark 
and Coleman, 2009]. The studies are worthy of future research with regards to 
interaction of PTPJ with pancreatic cathepsins and its role in pancreatic (patho) 
physiology. 
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ABSTRACT 
Thiol proteinases synonymous with cysteine proteinases comprise a group of 
proteolytic enzymes which are widely distributed among living organisms. They play 
very important role in the intracellular proteolysis such as catabolism of proteins and 
peptides, development and function of the immune system and tumor, cell invasion. It 
implies that their regulation is important otherwise it will cause uncontrolled 
proteolysis and tissue damage. In principle, cystatins provide this regulation. 
Cystatins are widespread, naturally occurring tight binding reversible inhibitors of 
cysteine proteinases found either within the cytosol or secreted from the cells 
[Kopitar-Jerala, 2006]. The diverse group of thiol proteinase inhibitors comprises the 
cystatin superfamily, divided into three main groups depending on the presence of 
single or multiple 'cystatin domains', presence or absence of a signal sequence, 
carbohydrate content and sulphydryl groups. Family I- the steflns are cytosolic, 100-
residue single chain proteins with no disulphide bonds or carbohydrates. Family li-
the cystatins are mainly extracellular, 120 residue single chain proteins with two 
disulphide bonds but no carbohydrates and Family HI- the kininogens are 
multidomain, blood plasma glycoproteins [Turk et al., 2008]. The importance of 
cystatins is underlined by the pathological conditions that arise upon loss or mutations 
of cystatin genes/function [Turk et al., 2008; Cox, 2009]. 
RESULTS OBTAINED IN THE STUDY ARE SUMMARIZED AS 
FOLLOWS: 
Clapttr 1 
A 44 kDa thiol proteinase inhibitor (PTPI) has been purified and characterized from 
goat pancreas in terms of its biochemical and biophysical properties. Purification was 
achieved by a four step procedure involving alkaline treatment (pH 11.0), acetone 
fractionation, ammonium sulphate precipitation (20-80%) and gel filtration 
chromatography on Spehacryl S 100 HR column. The preparation was found 
homogenous on the basis of charge and molecular weight. The inhibitor was obtained 
with 20.4% yield and 500 fold purity. Pancreatic thiol proteinase inhibitor (PTPI) was 
found to have two subunits linked by non covalent interactions as determined by 
SDS-PAGE under reducing as well as non reducing conditions. The stokes radius, 
via 
difilision and sedimentation coefficients of PTPI were 27.3 A, 7.87 x 10"^  cm^ sec' 
and 3.83 s, respectively. It was stable in pH range 3-10 and upto 70°C. It possessed 
2.32% carbohydrate content and no disulphide bonds. PTPI was immunogenic and 
induced antibody formation in rabbits. However, it exhibited no immunogenic identity 
with cystatins isolated from goat lung and brain. 
The purified inhibitor inhibited papain and ficin very efficiently and to slightly lesser 
extent bromelain but failed to inhibit bovine trypsin, chymotrypsin and pepsin. The 
respective Ki values obtained for papain, ficin and bromelain were 5.88, 9.02 and 
22.28 nM. Association rate constant and hence the affinity of the inhibitor for 
proteinases was in the following order: papain (1.49 x lO'* M"'s"') > ficin (1.39 x iC 
M'S"') > bromelain (5.94 x 10^  M"'s''). The K-i values obtained for papain, ficin and 
bromelain were 8.76 x 10"', 3.35 x 10"^  and 1.32 x 10"^  s'\ respectively. The 
calculated half-life values of enzyme-inhibitor complex for papain, ficin and 
bromelain were 7.91 x 10^ 5.51 x 10\ and 5.23 x 10^  s and the IC50 values were, 
0.08, 0.078 and 0.154 ^M, respectively for the three proteinases; again reinforcing 
greater affinity of the inhibitor for papaya proteinase. 
The partial amino acid sequence analysis of the heavier subunit revealed that PTPI 
has highest sequence homology with bovine parotid and skin cystatin C. The glycine 
residue is present at 11* position rather than at conserved position 9 which has also 
been reported for human placental cystatin and human stefin A structure. The 
hydropathy plot of first 24 amino acid residues suggested that most amino acids of 
this stretch might be in hydrophobic core of the protein. 
Secondary structural composition of the inhibitor showed presence of 17.18% a 
helical content. The binding of PTPI to activated papain was accompanied by 
pronounced changes in the far ultraviolet circular dichroism, uhraviolet absorption 
and fluorescence emission spectra. These changes were compatible with perturbations 
of the environment of aromatic residues in one or both the proteins of the complex 
arising from a conformational change. 
The absence of disulphide bonds is a unique character of type 1 cystatin family 
members. Molecular masses of type 1 and 2 cystafin families range in 11 kDa to 13 
kDa [Turk and Bode, 1991]. Presence of carbohydrates is however limited only to 
kininogens, with few exceptions found for members of type 2 cystatin family. PTPI is 
devoid of any disulphide linkage, has high molecular mass (44 kDa) and bears 
sequence similarities to both stefins and cystatins. Studies on kinetics of inhibition as 
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well as on biophysical interaction of PTPI with thiol proteinases shows that it bears 
resemblances with other members of type 2 cystatin family. Based on above 
parameters PTPI can be regarded as a variant of type 1 and type 2 cystatin families. 
This is not unusual as there is growing list of proteins found to possess some of 
cystatin superfamily structural and functional motifs, but bearing substantial 
differences causing them to be classified as variants of cystatin superfamily. 
Clapttr 2 
Equilibrium studies of guanidine hydrochloride (GdnHCl) and urea induced unfolding 
of PTPI were also performed by monitoring the inhibitor activity, intrinsic 
fluorescence, circular dichroism (CD) and l-aniIino-naphthalene-8-sulphonate 
binding. 
A sigmoidal dependence of inhibitory activity on GdnHCl concentration was 
observed. 65% inactivation occurred at 4 M GdnHCl, beyond this concentration PTPI 
was almost completely inactivated. The fluorescence emission spectrum of PTPI 
suffered a 15 nm red shift in wavelength of maximum emission (Xma.x) (from 335 nm 
for native protein to 350 nm at higher concentrations of GdnHCl) with quenching of 
fluorescence intensity, suggesting the unfolding of PTPI. Secondary structure analysis 
of PTPI revealed minute effects on mean residue ellipticity (MRE222 nm) till 1 M 
GdnHCl. However, complete loss of signal was observed at higher concentrations of 
the denaturant. Midpoint of transition, Cm, deduced fi-om normalized transition 
curves of activity, Xmax, and MRE222nm data was 3.2 M GdnHCl. Further, a shift in Cm 
was observed with PTPI concentration. Changes in molecular properties of PTPI such 
as inhibitory activity, MRE222 nm and X^ ax with increasing GdnHCl concentration 
revealed a monophasic sigmoidal dependence with coincidental profiles, 
characteristic of cooperative unfolding, suggesting a two state model for denaturation 
of the inhibitor. 
In urea, unfolding pathway differed from that observed in GdnHCl. Almost complete 
inactivation was observed beyond 6 M urea. A gradual increase in Xmax occurred with 
increasing urea concentration. It red shifted to 350 nm at 8 M urea indicating that 
treatment of PTPI with high concentrations of urea leads to unfolding of the inhibitor. 
A sigmoidal behaviour of decrease in MRE222 nm with increasing urea concentration 
was observed, with complete loss of signal noticeable above 5 M urea. The Cm value 
deduced from normalized transition curves for activity and MRE222nm was 3.6 M. No 
dependence of Cm on concentration of the inhibitor was obtained. The Cm value 
determined from X^ ax curve was 4 M. The non coincidence of transition curves in urea 
denaturation as measured by probes sensitive to different levels of protein structure, 
are consistent with a mechanism involving intermediate state. However, intermediates 
are not clearly observed. 
The denaturation by both GdnHCl and urea was only partially reversible, with 
retrieval of only 10% of the native activity on extensive dilution only in case of 
GdnHCl denaturation. Also at all denaturant concentrations the inhibitor refolded to a 
species having significantly different spectroscopic properties from native PTPI. 
Urea is known to be about half as effective as GdnHCl in inducing protein unfolding 
and dissociation, suggestive of a 2-fold rule. The results of the present study show that 
PTPI is an exception to this 2-fold rule. The Cm for urea unfolding was 3.6 M (4 M 
from Xroax curve) and that for GdnHCl was 3.2 M, pointing to significant contributions 
of both hydrophobic and electrostatic interactions in maintenance of active site and/or 
dimeric nature of the inhibitor. 
eiiMMr 3 
Partially or totally unfolded states that are occasionally populated in vivo after 
biosynthesis on the ribosome, stress conditions or mutation and are favoured by 
changes on pH, ionic strength and mutations are most susceptible to initiate 
aggregation [Soldi et al, 2005]. 
We reasoned that aggregation and fibrillation of PTPI may also require the protein to 
access partially denatured states and thus explored existence of non native 
intermediates under experimentally imposed acidic conditions. PTPI was subjected to 
denaturation over a pH range of 1.0-7.0 and the conformational changes induced were 
studied by circular dichroism and intrinsic and extrinsic fluorescence. 
Till pH 5.0 no change in Xmax of emission was observed. A decrease in pH to 3.0 
caused a 10 nm blue shift. Further lowering of pH to 2.0 was accompanied by a 2 nm 
red shift followed by a 3 nm red shift again at pH 1.0. ANS binding was initiated at 
pH 3.0 (with a blue shift in Xmax of ANS emission to 490 nm) and reached a maximum 
at pH 1.0. Secondary structure analysis revealed -40% loss at pH 3.0 but at pH 1.0 
there was gain in secondary structure content (of -34%). Conclusively, PTPI at pH 
3.0 existed as partially unfolded intermediate having -60% residual secondary 
structure but almost completely altered tertiary structure. PTPI at pH 1.0 exhibits 
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more of a molten globule like features having native like secondary structure contents 
and enhanced ability to bind ANS, however with tertiary contacts quite similar to 
native PTPI. 
The organic solvent 2, 2, 2-trifluoroethanol (TFE) is known to stabilize the partially 
unfolded proteins [Rashid et al, 2006b] and has been extensively employed for 
amyloid fibril induction in various proteins [Zerovnik et al., 2007]. From a range of 
concentrations used, in the present study 10% TFE induced native like secondary 
structure in pH 3.0 state of PTPI. Similar results were also obtained for PTPI at pH 
1.0 and 2.0. 
Based on these results six solvent conditions were chosen to study amyloid fibril 
formation in PTPI. The inhibitor was incubated at pH 1.0, 2.0, 3.0 and at these three 
pH in presence of 10% (v/v) TFE. Two standard procedures were used to follow 
amyloid growth in above samples, Thioflavin T (ThT) fluorescence assay and 
transmission electron microscopy (TEM). 
Enhancement of ThT fluorescence was observed only after 55 days of incubation of 
PTPI at pH 2.0. Contrastingly at pH 3.0, enhancement was noticed within 5 days of 
incubation. Results obtained for PTPI incubated at pH 1.0 were quite similar to those 
obtained for pH 3.0 sample. The results revealed that amyloid type aggregates from 
PTPI form under acidic conditions and more readily at pH 3.0 and 1.0 than at pH 2.0. 
In the presence of TFE, amyloid growth was accelerated, for the sample at pH 2.0 
several fold enhancement in ThT fluorescence intensity was observed within 30 days 
of incubation. Similarly at pH 3.0, a profound increment was observed without any 
distinct lag phase. The characteristics of fibrillation at pH 1.0 were in similitude with 
sample at pH 3.0. Controls at each condition did not show any ThT binding. 
On subjection to transmission electron microscopy (TEM), after 15 days of incubation 
sharp fibrils were seen in pH 3.0 sample (in the presence of 10% (v/v) TFE) and 
peculiar foliage like pattern was observed for pH 1.0 sample (in the presence of 10% 
(v/v) TFE). The sample incubated at pH 2.0 (in the presence of 10% (v/v) TFE) also 
gave fibrils but after one month of incubation. 
Divalent metal ions (Zn^ "^  and Cu^ )^ effectuated a concentration dependent decline in 
ThT fluorescence of preformed fibrils at pH 3.0 suggesting deaggregation of the 
fibrils. When added prior to the initiation of fibrillation of PTPI (at pH 3.0, with 10% 
(v/v) TFE) 50 ^ M Cu^ "^ and 10 \xM Zn^ * prevented any amyloid aggregation. 
These results corroborate with generic hypothesis of amyloid fibrillation proteins. 
Xll 
outline the conditions necessary for PTPI fibrillation and point towards the strong 
influence of solvent conditions on fibril morphology. Use of divalent metal ions 
against amyloid formation is also suggested. 
eiapttr4 
In this chapter effect of reactive species on purified goat pancreatic thiol proteinase 
inhibitor has been evaluated. 
Riboflavin sensitized photodynamic modifications of PTPI lead to inactivation of its 
antiproteolytic activity and formation of aggregated products (at higher riboflavin 
concentrations). A continued disappearance of inhibitory activity towards papain was 
observed with increasing concentration of riboflavin and varying time periods of 
incubation reaching a maximum value of 83% (loss in activity). Sodium azide (a 
known singlet oxygen quencher) and potassium iodide (quencher of flavin triplet 
state) suppressed the activity loss as well as aggregation. Mannitol and thiourea failed 
to show any such protective effect. Natural antioxidants, curcumin (Cur), caffeic acid 
(CA) and quercetin (QE) diminished the riboflavin exerted damage which was evident 
by following observations, activity of treated PTPI was enhanced, aggregation was 
inhibited and tryptophan fluorescence retrieved back. Curcumin, however, provided 
only partial moderation. 
Hypochlorous acid and to lesser extent hydrogen peroxide destroyed the 
antiproteolytic potential of PTPI. HOCl even at low concentrations significantly 
decreased the functional integrity of the inhibitor (90% loss in activity). High 
concentrations of H2O2 also partially diminished proteinase inhibitory capacity of 
PTPI by a mechanism involving almost no contribution from hydroxyl radicals 
(sodium benzoate and thiourea afforded no protection and mannitol only to small 
extent). Structural analyses revealed fragmentation of PTPI upon HOCl exposure. 
H2O2 also caused loss in band intensity and appearance of some higher mobility 
material. X^ ax suffered a red shift of 15 nm in the presence of H2O2. Diminution of the 
inflicted damage was observed on treatment with Cur, CA, QE, with former two being 
more effective than QE. There was subjugation of PTPI activity loss, fragmentation 
and changes in intrinsic fluorescence pattern in presence of bioflavonoids. 
The effect of nitric oxide on structure and function of PTPI was also studied. There 
was a concentration dependent loss in activity. The Xmax red shifted to 350 nm (from 
335 nm for native PTPI) in the presence of NO. On the whole the inhibitor was 
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severely compromised functionally (72% loss in activity) and structurally. The three 
natural antioxidants, Cur, CA and QE negated the loss in tryptophan fluorescence and 
PTPI inhibitory activity. Maximum protection was offered by Cur and C A. 
The results evinced the susceptibility of PTPI to aforementioned reactive species and 
the modifications induced included altered molecular weight (aggregation or 
fragmentation) and fluorescence characteristics and loss of inhibitory function. Also, 
Cur, CA and QE provided protection against the oxidative and nitrosative damage. 
CliRttr 5 
Experiments were conducted to investigate the effects of sodium valproate, 
glimepiride, metformin hydrochloride and synthetic insulin on the structure and 
function of the inhibitor. 
Sodium valproate and glimepiride caused dose dependent loss of PTPI's inhibitory 
activity with almost 80% loss precipitating at 10 nM sodium valproate and 40 ^M 
glimepiride concentrations. Drug interaction induced structural changes in PTPI were 
monitored by intrinsic fluorescence and UV vis spectrophotometric analyses. 
Complex changes were noticed in the fluorescence properties of PTPI indicating 
alteration in the environment of the aromatic amino acid residues induced on 
interaction with drugs. The difference spectra also showed profound changes 
suggesting involvement of tryptophan, tyrosine and phenylalanine residues in 
complexation. Secondary structural analysis of insulin-PTPI complexes revealed 
increase in ellipticity at 222 nm suggesting enhancement of native stability of the 
inhibitor. Metformin hydrochloride complexation caused only mild effects. 
The results implicate the loss of thiol proteinase inhibitor function in drug induced 
pancreatitis by sodium valproate. They also provide a platform for understanding the 
non responsiveness to antidiabetic drugs after a prolonged period and clues to enhance 
the insulin potency. 
Maintenance of appropriate equilibrium between free cysteine proteinases and their 
complexes with inhibitors is imperative for proper function of all living 
systems/tissues. This equilibrium in pancreas is critical for pancreatitis onset and its 
severity, diabetes and cancer [van Acker et al., 2002; Thrower et al., 2006; Rivenbark 
and Coleman, 2009]. The studies are worthy of future research with regards to 
interaction of PTPI with pancreatic cathepsins and its role inpancreatic (patho) 
physiology. 
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[I] INTRODUCTION 
1.1 GENERAL 
Proteolytic enzymes, also known as proteases/peptidases, are enzymes that catalyze 
the breakdown of proteins by hydrolysis of peptide bonds. Proteinases are essential 
for the survival of all kinds of organisms, and are encoded by approximately 2% of all 
genes [Rawlings et al., 2004b]. Proteases are customarily classified as exopeptidases 
when they hydrolyze only the N- or C- terminal bonds in proteins and endopeptidases 
(proteinases) when they hydrolyze internal peptide bonds. However, proteases and 
proteinases are synonymously used in literature. Based on the catalytic mechanism, 
there are four types of proteases, serine, cysteine, threonine or aspartic proteases and 
metallo proteases. There is a recent report on glutamic proteases, being the only 
subtype not found in mammals so far. The primary role of proteinases was long 
considered to be protein degradation relevant to food digestion and intracellular 
protein turnover [Barrett et al., 2004]. However, now it is known that proteinases are 
involved in control of large number of key physiological processes such as cell-cycle 
progression, cell proliferation and cell death, DNA replication, tissue remodelling, 
haemostasis (coagulation), wound healing and immune response [Turk, 2006]. 
Cysteine proteinases (CPs) are the proteins with molecular mass about 21-30 kDa, 
showing the highest hydrolytic activity at pH 4-6.5. CPs are present in all living 
organisms. They are synthesized in a precursor form in order to prevent unwanted 
proteolysis and later subjected to cotranslational and posttranslational modifications 
to convert them into catalytically active mature enzymes [Turk et al., 2000]. Till now, 
21 families of CPs have been discovered, almost half of them in viruses and rest of 
them in bacteria, protozoa, fungi, plants and mammals [Barrett et al., 2004; Barrett et 
al., 2001]. The first clearly recognized and extensively investigated cysteine 
proteinase is papain isolated from the latex of plant Carica papaya. Mammalian CPs 
are divided into 4 main groups namely; 
1. Lysosomal cathepsins 2. Caspases 
3. Calpains 4. Legumains 
Cathepsins comprise an important section of the papain family of CPs, sharing 
similar amino acid sequences and folds. There are eleven human cathepsins known at 
the sequence level [Turk et al., 2001; Rossi et al., 2004]. Out of which seven viz. 
cathepsins B, H, L, C, O, F and X are ubiquitous, such that they have a broad tissue 
distribution, but they may be involved in more specialized processes [Turk et al., 
2000; Buhling et al., 2000]. Cathepsins K, V and S are more tissue specific with 
cathepsin K expressed in osteoclasts only, cathepsin V in thymus and testis, and 
cathepsin S in spleen and lung [Turk et al., 2000; Buhling et al., 2000]. Recently, 
cathepsin K was found to be expressed by breast carcinoma cell, mature macrophages, 
and multinucleate giant cells adjacent to amyloid deposits in brain [Pvmturieri et al., 
2000; Zaidi et al., 2001; Rocken et al., 2001]. Cathepsins are all relatively small 
monomeric proteins with molecular mass (Mr) in the range of 24-35 kDa, with 
exception of cathepsin C, which is an oligomeric enzyme with Mr around 200 kDa 
[Turk et al., 2002]. All mature cathepsins are glycosylated at usually one or more 
glycosylation sites except cathepsin S. Himian cathepsins play very important role in 
intracellular protein turnover in lysosomes, processing and activation of other proteins 
including proteinases, antigen processing and presentation and in bone remodelling. 
However, their specific and individual functions are often associated with their 
restricted tissue localization [Brix et al., 2008]. Lysosomal CPs have been found to 
be critical for rheumatoid arthritis, osteoarthritis and osteoporosis [Vasiljeva et al., 
2007], neurological disorders [Nakanishi, 2003], pancreatitis [van Acker et al., 2002], 
cancer [Keppler, 2006; Gocheva and Joyce, 2007], cardiovascular diseases [Lutgens 
et al., 2007], etc. Cathepsins also participate in apoptosis, although there role is still 
not clear [Stoka et al., 2005; Turk and Stoka, 2007]. In some pathological conditions 
like ischemia, hypervitaminosis and exposure to UV radiations lysosomal enzymes 
are released in extracellular space and produce extensive damage to the extracellular 
matrix. 
Calpains and Caspases are cytoplasmic thiol proteinases. Calpains participate in 
many intracellular processes like turnover of cytoskeletal proteins, cell differentiation 
and regulation of signal peptides. They require Ca^* for activation. They are 
ubiquitously distributed and have been implicated in acute neurological disorders, 
Alzheimer's disease, muscular dystrophy and gastric cancer [Huang and Wang, 2001]. 
Caspases are cysteine dependent aspartate specific proteinases. They are involved in 
cytokine maturation, apoptosis signalling and mediation [Goyal, 2001]. 
Legumains are cysteine-dependent asparagine endopeptidases. They are involved in 
MHC class Il-restricted antigen presentation [Manoury et al., 1998] and local 
negative regulation of osteoclasts formation and activity [Choi et al., 1994]. 
REGULATION OF LYSOSOMAL THIOL PROTEINASE ACTIVITY 
Despite their life-giving functions, the enormous hydrolytic potential of cathepsins 
can be damaging in living systems and needs to be kept strictly under control. Failures 
in biological mechanisms controlling proteinase activities result in many diseases 
such as neurodegeneration, cardiovascular diseases, osteoporosis, arthritis and cancer. 
Cells have evolved several distinct mechanisms for the regulation of excessive CP 
activity via proper gene transcription, maintenance of the rate of proteinase synthesis 
and degradation and most importantly the interaction of CPs with the proteins that 
inhibit them, viz. cysteine proteinase inhibitors or thiol proteinase inhibitors (CPIs or 
TPIs) or more commonly cystatins. 
The cystatin superfamily comprises a large group of the cystatin domain containing 
proteins present in wide variety of organisms including humans. Cystatin inhibitory 
activity is vital for the regulation of normal physiological processes by limiting the 
potentially inappropriate activity of their target proteinases, cathepsins, mammalian 
legumain and some calpains [Alvarez-Fernandez et al., 1999; Crawford, 1987]. 
L2 DISCOVERY OF THE CYSTATIN SUPERFAMILY 
Hayashi et al., [1960] for the first time reported the presence of a factor capable of 
inhibiting the clotting activity of a thiol proteinase in mammalian system. The first 
isolated and partially characterized protein inhibitor of CPs was from chicken egg 
white and was shown to inhibit papain, ficin [Fossum and Whitaker, 1968; Sen and 
Whitaker, 1973] and cathepsins B and C [Keilova and Tomasek, 1975]. Later for the 
same protein term cystatin was proposed because of its unique property of arresting 
the activity of CPs [Barrett, 1981]. The first intracellular protein inhibitor of papain, 
cathepsin B and H was isolated and partially characterized from pig leucocytes and 
spleen [Kopitar et al., 1978]. The determined amino acid sequences of chicken 
cystatin [Turk et al., 1983; Schwabe et al., 1984] and human stefm (stefin A) from the 
c}'tosol of polymorphonuclear granulocytes [Machleidt et al., 1983] confirmed 
structural differences between these two homologous proteins. At the same time, 
inhibitors of CPs were isolated from sera of patients suffering from autoimmune 
diseases [Turk et al., 1983] and based on its sequence homology with chicken cystatin 
the name human cystatin was proposed [Brzin et al., 1984], soon renamed to human 
cystatin C (HCC) [Barrett et al., 1984]. Sequences of bovine and human kininogens 
were determined [Nawa et al., 1983; MuUer-Esterl et al., 1985a]. And concept of 
cystatin "superfamily" emerged precipitated by an observation that muhiple cystatin-
like sequences were present in kininogens and that stefms were related to both 
cystatins and repeats of kininogens [Ohkubo et al., 1984]. This data and First 
International Symposium on Cysteine Proteinases and their Inhibitors (Portoroz, 
Yugoslavia (now Slovenia) September 1985, organized by V. Turk) were crucial for 
nomenclature and classification of the cystatin superfamily [Barrett et al, 1986]. 
1.3 CLASSIFICATION OF THE CYSTATIN SUPERFAMILY 
The first classification of the cystatin superfamily into three families was based on at 
least 50% sequence identity, inhibition of their target enzymes and presence or 
absence of disulphide bonds [Barrett et al., 1986]. Three distinct families of the 
protein inhibitors comprise: family 1 or the stefin family, family 2 or the cystatin 
family and family 3 or the kininogen family. The first two families are single 
domain inhibitors whereas the kininogens are composed of three domains, two being 
inhibitory [Fig. 1]. A typical cystatin domain was defined to be an approximately 100-
amino acids polypeptide that folds into a five stranded P-sheet, which partially wraps 
around a central a-helix [Fig. 2] [Bode et al, 1988]. Later, the term 'type' was 
introduced and the mammalian cystatins were divided into types 1, 2 and 3 [Rawlings 
and Barrett, 1990]. However, an increasing number of cystatins from various sources 
introduced new subdivision of the cystatins into four families [Rawlings and Barrett, 
1990], the fourth family consisting of non-inhibitory homologues of two cystatin-like 
domains, such as human a2 SH-glycoprotein (feutin) and histidine-rich glycoprotein 
[Brown and Dziegielewska, 1997]. The cystatin superfamily also comprises of 
phytocystatins. According to recently proposed classification of peptidase inhibitors 
into families and clans [Rawlings et al, 2004a] cystatins are assigned to family 125 
which consists of three subfamilies, 125 A (stefms), I25B (cystatins), I25C (are mostly 
not proteinase inhibitors). 
Fig. 1 A diagrammatic representation of the chain structures of 
proteins in the cystatin superfamily 
The stefms are single chain proteins without disulphide linkages. The 
cystatins are also single chain but possess two disulphide bonds. The 
structure indicated for the kininogens is that of L- and T-kininogen; H-
kininogens have a longer carboxyl terminal extension. There is an 
additional disulphide link from segment 1 to the kinin segment. The 
symbol marks potential sites for the attachment of the carbohydrate side 
chains. 
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Fig. 2 FoldofcystatinC 
Cystatin C chain trace is shown in green in orientation which positions the 
N-terminal "elephant trunk" and the first and the second hairpin loops to 
the bottom fi-om left to right [Adapted from Bode et al. 1988, EMBO J, 
2593-2599]. 

1.4 GENERAL PROPERTIES OF CYSTATIN SUPERFAMILY 
TYPE 1 CYSTATINS (STEFINS) 
The protein inhibitors belonging to stefin family are acidic single chain proteins 
lacking disulphide bonds and carbohydrates, composed of-100 amino acid residues 
with Mr of 11 kDa. They are primarily intracellular cytoplasmic proteins of many cell 
types, ahhough they have been found in extracellular fluids as well [Abrahamson et 
al., 1986]. In mammals, including human, rat, bovine, mouse and porcine, two 
members of the stefm family, stefin A (cystatin A or a) and stefin B (cystatin B or P) 
have been identified [Turk et al, 1997; Barrett et al., 1986]. In addition stefin C was 
discovered in bovine thymus as the first tryptophan containing stefm with a prolonged 
N-terminus [Turk et al., 1993] and stefin D in pigs [Lenarcic et al., 1996]. Atleast 
three different stefin A variants are encoded within the mouse genome [Tsui et al., 
1993].The type 1 cystafins belong to the subfamily I25A [Rawlings et al., 2004a]. 
Cystatin A 
It is an inhibitor of cathepsin B in human skin discovered by Fraki [1976]. Later on 
Jarvinen [1978] studied it as 'acid cysteine proteinase inhibitor' (ACPI) because of its 
acidic pi at 4.7-5.0. Brzin et al. [1983] purified an inhibitor from blood leucocytes, 
and named it as "stefin'. The amino acid sequence was determined by Machleidt et al. 
[1983]. Green et al. [1984] characterized same type of CPI from human liver and 
latter renamed it as cystatin A. Cystatin A occurs in multiple isoelectric forms with 
predominantly acidic pi values in the range 4.5-5.0 [Hopsu-Havu et al., 1983a]. 
Rinnie et al. [1978] detected cystatin A in extracts of squamous epithelia from 
oesophagus. It was also found in dendritic reticulum cells of the lymph nodes [Rinnie 
et al., 1983], seminal plasma [Minakata and Asano, 1985], saliva, bovine skin [Turk 
et al., 1995] and in a number of epidermoid carcinomas [Rinnie et al., 1984]. 
Cystatin a is assumed to be a species variant of cystatin A found in rats. This 
protein was characterized by Jarvinen [1976] as a specific inhibitor of CP from rat 
skin having Mr of 13 kDa. Cystatin a is generally found on the epidermal layer 
[Jarvinen et al,, 1978] and various other squamous epithelia [Rinnie et al., 1978], 
Human stefin A is expressed at high levels in skin and presumably controls cysteine 
proteinases in the skin. Some cathepsins play a crucial role in the antigen presentation 
process indicating that the interactions between stefin A and cathepsins contribute to 
the species dependent diversity of the endosomal compartments which participate in 
the immune response [Mihelic et al., 2006]. 
Cystatin B 
Cystatin B was detected as an inhibitor of cathepsin B and H in human tissues by 
Lenney et al. [1979]. It has been purified fi"om human spleen and liver [Jarvinen and 
Rinnie, 1982; Green et al., 1984]. Cystatin B is relatively basic protein with pi values 
of 6.25 and 6.35 for its two forms [Green et al., 1984]. It forms dimer [Green et al,, 
1984] which shows no inhibitory activity. With ubiquitous distribution it appears to 
be general inhibitor in the cytoplasm. Cystatin P a species variant of cystatin B was 
isolated from rat liver [Finkelstadt, 1957; Lenney, 1979] with pi values ranging from 
5.04 to 5.6 [Kominami et al., 1981]. It has even distribution in tissues and is more 
abundant than cystatin a in all tissues except skin. In this it resembles cystatin B of 
human variant. 
Stefm C 
Stefin C is unique among the inhibitors from stefm family which was found in 
multiple forms resulting from the cleavage of Asn 5-Leu 6 bond of the inhibitor. Its 
MW is calculated to be 11,546 (101 amino acid residues). It was found to be acidic 
with pi values from 4.5 to 5.6 [Turk et al., 1993]. 
TYPE 2 CYSTATINS (CYSTATINS) 
Cystatins typically comprise -115 amino acids (Mr -13-15 kDa), are largely acidic 
(with exception of human cystatin C) contain four conserved cysteine residues known 
to form two disulphide bonds [Grubb et al., 1984], usually non-glycosylated with 
exceptions of cystatin E/M [Ni et al., 1997; Sotirpoulou et al., 1997], cystatin F [Ni et 
al., 1998] and cystatin S [Esnard et al., 1990] which are glycoproteins. They are 
synthesized with 20-26 residues long signal peptides and are mainly extracellular, 
secreted proteins, occurring at relatively high concentrations in body fluids 
[Abrahamson et al., 1986; Kopitar-Jerala, 2006]. Similar to stefms, the cystatins 
contain the conserved QXVXG region in the central part of the molecule and the P-W 
pair in the C-terminal part of cystatins [Turk and Bode, 1991]. Chicken cystatin and 
HCC represent founding members of this family [Turk and Bode, 1991; Abrahamson 
et al., 1986], Human type cystatins include cystatin C, D, S, SA and N with about 
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50% or less sequence identity [Turk and Bode, 1991; Abrahamson et al., 1986; Balbin 
et al., 1994]. The human type 2 cystatins are grouped in subfamily I25B of the 
cystatin family [Rawlings et al., 2004a]. 
Cystatin C 
Originally cystatin C was termed as y-trace or post-y-globulin isolated from human 
cerebrospinal fluid because of its basic nature and y electrophoretic mobility [Barrett 
et al., 1984; Brzin, 1984]. It was also found in the urine in renal failure patients 
[Butler and Flynn, 1961] and ascetic and pleural fluids [Hochwald and Thornbecke, 
1962], Cystatin C was also detected in saliva, normal serum [Cejka and Fleischmann, 
1973] and seminal plasma [Colle et al., 1976]. Preferentially abundant in 
cerebrospinal fluid, seminal plasma, milk, synovial fluid, urine, and blood plasma 
[Abrahamson et al., 1986] cystatin C has also been detected intracellularly in brain 
cortical nerves [Lofberg et al, 1981], normal and neoplastic neuroendocrine cells in 
the adrenal medulla [Lofberg et al, 1982], thyroid [Lofberg et al, 1983] and pituitary 
[Lofberg et al, 1983; Moller et al, 1985]. 
Cystatin D 
Cystatin D a member of human cystatin mukigene family and was cloned from a 
genomic library using cystatin C cDNA probe [Freije et al, 1991]. The inhibitor 
consists of 122 amino acids residues (Mr 13,885). The deduced amino acid 
composition includes a putative signal peptide and has 51-55% homology with either 
cystatin C or secretory gland cystatins S, SA and SN. It is a relatively neutral protein 
with pi in the range of 6.8- 7.0 [Freije et al, 1991]. It is expressed in parotid glands, 
saliva and tears [Balbin et al, 1994]. This tissue restricted expression is in marked 
contrast with a wider distribution of all other family 2 cystatins. 
Cystatin S 
Human saliva contains several low MW acidic proteins which include CPIs [Isemura 
et al, 1984b].The first salivary inhibitor purified and sequenced was SAP-I (salivary 
acid protein) by Isemura et al. [1984a], which was renamed as 'cystatin S'. It contains 
no phosphate, in contrast to other salivary proteins. This inhibitor has also been 
isolated from human submaxillary, submandibular and sublingual glands and found to 
be present in the serous cells of the parotid and submaxillary glands [Isemura et al. 
1984b]. The protein has also been found in tears, serum, urine, bile, pancreas and 
bronchus [Isemura et al., 1986]. 
Variants of cystatin S 
Several molecular variants of cystatin S have been studied by Isemura et al [1986] 
which differ in their N-terminal sequence and pi values. Differences in pi values 
resulted from phosphorylation of residues Ser3 and Serl in salivary cystatin [Isemura 
et al., 1991]. Cystatin SN: Originally known as cystatin SV or SA-1 [Abrahamson 
et al., 1986]. The protein consists of 121 amino acid residues (Mr 14,316). The pi 
values are in the range of 6.6-6.8. Cystatin SA consists of 122 amino acid residues 
(Mr 14,351) having acidic pi value of 4-6 [Isemura et al., 1991]. Cystatin SA isolated 
from saliva had N-terminal residue Glu [Isemura et al., 1986]. 
Cystatin E 
Human cystatin E from amniotic fluid and fetal skin epithelial cell was identified and 
recombinant cystatin E isolated [Ni et al., 1997]. Human cystatin M is expressed by 
normal mammary cells and a variety of human tissues [Sotirpoulou et al., 1997]. Both 
proteins are identical and were renamed as cystatin E/M (MEROPS, the peptidase 
database). Recently, the expression of cystatin M/E was found to be restricted to the 
epidermis [Cheng et al., 2006] and is most probably identical to cystatin E/M. 
Cystatin F 
Cystatin F (leukocystatin) (MW 14,543) is primarily found in peripheral blood cells, 
T cells, spleen, dendritic cells and selectively, in hematopoietic cells [Ni et al., 1998; 
Halfon et al., 1998]. Cystatin F has an additional disulphide bridge, thus stabilizing 
the N-terminal part of the molecule [Ni et al., 1998]. It is the only cystatin synthesized 
and secreted as an inactive disulphide-linked dimeric precursor which becomes active 
following reduction to monomeric from [Schuttelkopf et al., 2006]. 
TYPE 3 CYSTATINS (KININOGENS) 
Kininogens, the precursors of kinin, are large multifunctional glycoproteins in 
mammalian plasma and other secretions. Three different types of kininogens have 
been identified: high molecular weight kininogen (HK), low molecular weight 
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kininogen (LK) and T-kininogen an acute phase protein found only in rats [DeLa 
Cadena and Colman, 1991; Muller-Esterl, 1987]. Human HK and LK are single-chain 
proteins each composed of an N-terminal heavy chain, the kinin segment and a C-
terminal light chain. The light and heavy chains are interconnected by disulphide 
bridges. The heavy chains and kinin segments of both kininogens have identical 
amino acid sequences while the light chains are different [DeLa Cadena and Colman, 
1991; Salvesen et al., 1986a]. The heavy chain is composed of three cystatin domains 
[Fig. 1], D1-D3 [Salvesen et al., 1986a] with only D2 and D3 possessing papain 
inhibitory and D2 possessing calpain inhibitory activities. An inhibitory fragment, 
identical to the third domain of human kininogen, was isolated from human placenta 
and is inactivated by the lysosomal aspartic proteinase cathepsin D. Similarly HCC 
was also inactivated, suggesting a role for cathepsin D in regulating cysteine 
cathespin activity [Lenarcic et al., 1991]. Both inhibitory domains of LK and HK are 
grouped in subfamily I25B of the cystatin superfamily [Rawlings et al., 2004a]. 
Other type 2 cystatins 
There are a number of other cystatins or cystatin related proteins, which are 
structurally related to cystatins with no inhibitory activity against papain like enzymes 
[Turk and Turk, 2008]. CRES (Cystatin Related Epididymal Spermatogenic) protein 
[Sutton et al., 1999], testatin (expression restricted to mouse pre-Sartoli cells) 
[Tohonen et al., 1998], cystatin SC and cystatin TE-1 (expressed in testis and 
epididymis, respectively) pLi et al., 2002], and several other genes were found 
expressed specifically in the male reproductive tract [Hamil et al., 2002; Xiang et al., 
2005; Shoemaker et al., 2000], indicating the existence of a new subgroup in the type 
two cystatins [Cornwall et al., 2003; Sutton-Walsh et al., 2006]. These CREStatins 
show homology to cystatins, with the exception of the two hairpin loops responsible 
for the cysteine proteinase inhibition. Their role could be regulation of proteolysis in 
the reproductive tract as well as protection against invading pathogens, as shown by 
cystatin 11 [Hamil et al., 2002]. The CRES protein tend to form oligomers [Horsten et 
al., 2007], similar to cystatin C [Janowski et al., 2001; Wahlbom et al., 2007] and 
stefin B [Zerovnik et al., 2002a; Jenko-Kokalj et al., 2007]. Another type 2 cystatin, 
cystatin 10, expressed in cartilage, localized in prehypertrophic and hypertrophic 
chondrocytes is known to be an inducer of chondrocyte maturation followed by 
apoptosis [Koshizuka et al., 2003]. A novel cystatin type 2 protein namely CLM 
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expressed widely in noraial tissue playing role in hematopoietic differentiation or 
inflammation, different from CRES was characterized by Sun and coworkers [2003]. 
NEW MEMBERS OF THE CYSTATIN SUPERFAMILY 
The feutins and histidine-rich glycoproteins (HRG) comprise fourth family of 
cystatins. The feutin family consists of two tandem cystatin domains. Bovine feutin 
was first characterized by Pedersen in 1944, and its relation to cystatin superfamily 
described in 1988 [Elzanowski et al., 1988]. Human feutin (aa-HS glycoprotein) was 
confirmed in 1987 [Dziegielewska et al, 1987; 1990; Dziegielewska and Brown, 
1995]. Since then, protein and/or cDNA sequences have been reported for human, 
cow, pig, rat, mouse, Habu snake, feutins [Brown and Dziegielewska, 1997]. Almost 
all the feutin sequences contain 12 cysteine residues, showing homology to the 
cystatins and cystatin domains in kininogens [Dziegielewska and Brown, 1995]. HRG 
has been characterized in the plasma of man, mouse, rabbit, cow and pig [x^eung, 
1993], sharing good sequence homology with human and bovine HMW kininogen 
[Koide et al., 1986]. A large number of proteins have been discovered recently, which 
possess cystatin domains e.g. latexin [Aagaard et al., 2005]. However, feutin, HRG 
and latexin all seem to lack CPI activity. 
Thyropins constitute a new family of papain-like CP inhibitors [Lenarcic and Bevec, 
1998], classified as family 131 [Rawlings et al., 2004a]. The p41 invariant chain (li)-
fi-agment of the MHC class Il-Ii complex 104, 105 and equistatin from the sea 
anemone [Lenarcic et al., 1997] are best characterized members of this family. 
Thyropins show inhibitory activity against CPs and also towards aspartic and 
metalloproteinases [Mihelic and Turk, 2007; Lenarcic and Turk, 1999]. Tick 
cystatins: Syalostatin L [Kotsyfakis et al, 2006] and syalostatin L2 [Kotsyfakis et 
al., 2007] have been characterized from salivary glands of the tick Ixodes scapidaris. 
Both show 75% sequence identity and inhibit cathepsin L with a Ki of 4.7 nM and 
cathepsin V with Ki of 57 nM. Staphostatins are specific inhibitors of staphylococcal 
CPs. Three members of this family have been described-staphostatins A and B from 
Staphylococcus aureus and staphostatin A from Staphylococcus epidermidis [Filipek 
et al., 2003]. Clitocybin is a new type of CPI from a mushroom appearing to be 
related to fungal lectins and hence a new family of CPIs is suggested for them called 
mycocypins [Brzin et al., 2000]. Chagasin is a cysteine proteinase inhibitor from 
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Trypanozoma cruzi inhibiting both cruzipain and papain, but has no homology with 
cystatins [Monteiro et al., 2001]. 
Phytocystatins: In plants, inhibitors of CPs are known as phytocystatins. They 
contain the QXVXG region of type 2 cystatins, but also resemble stefins in the 
absence of disulphide bonds [Arai et al., 2002], providing a transitional link between 
type 1 and type 2 cystatins. There are numerous phytocystatins expressed and 
characterized on the protein level from com [Abe et al., 1992], rice [Chen et al, 1992], 
soyabean [Lalitha et al., 2005], sugarcane [Oliva et al., 2004] and others. C-terminal 
extended phytocystatins were found as bifiinctional inhibitors of papain and legumain 
[Martinez et al., 2007]. In addition, a "multicystatin" containing two cystatin like 
domains were isolated from cowpea leaves [Diop et al., 2004], tomato leaves [Wu and 
Haard, 2000]. Also there are certain plant proteins like monellin which lack the CPI 
activity but have a cystatin like three dimensional structure [Grzonka et al., 2001], 
Phytocystatins and other inhibitors are important for plant defence response to insect 
predation, may act to resist infection by some nematodes [Koiwa et al, 1997], play a 
crucial role in response to various conditions [Diop et al, 2004; Brzin and Kidric, 
1995] and show great potential tools for genetically engineered resistance of crop 
plants against pests [Aguiar et al, 2006]. 
Variant cystatins 
Divergent cystatins showing significant homology to stefins, cystatins and kininogens 
have been expressed/purified and characterized from venom of African puff adder 
(Bitis arietans) [Evans and Barrett, 1987]; from perilymph of flesh fly larvae [Suzuki 
and Natori, 1985]; ^ om Drosophila melanogaster [Delbridge and Kelly, 1990], Some 
of the mammalian and non mammalian sources from where CPIs have been isolated 
are summarized in Table 1. 
1.5 EVOLUTION 
The first two proposed evolutionary dendrograms for CPIs were made based on a 
small number of members of the cystatin superfamily [Muller-Esterl et al, 1985b; 
Salvesen et al, 1986b]. The new proposed evolutionary dendrograms followed the 
evolution of the proteins of the cystatin superfamily along four lineages, with special 
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TABLE 1: CPIs FROM SOME MAMMALIAN AND NON 
MAMMALLS.N SOURCES 
Source Tissue Reference 
Beef 
Bovine 
Dog 
Horse show crab 
Human 
Rabbit 
Spleen 
Brain 
Hoof 
Colostrums 
Colostrum 
Parotid gland & Kidney 
Hemocytes 
Liver 
Spleen 
Placenta 
Liver 
Skin 
Rat 
Ixodes scapularis 
Staphylococcus aureus 
& epidermidis 
Trypanosoma cruzi 
Fasciola hepatica 
Goat 
Spirometra erinacei 
Yellow croaker 
Brain 
Salivary gland 
Kidney 
Brain 
Lung 
Pancreas 
Spleen 
Brzinetal., 1982 
Aghajanyan et al., 1988 
Tsushima et al., 1996 
Hirado et al., 1985 
Pouliketal., 1981 
Sekine and Poulik, 1982 
Aggarwal et al., 1996 
Green etal., 1984 
Jarvinen and Rinnie, 1982 
Rashid et al., 2006a 
Pontremoli et al., 1983 
Kopitar et al., 1983 
Kotsyfakis et al., 2006 & 
2007 
FiUpek et al., 2003 
Monteiro et al, 2001 
Khaznadji et al., 2005 
Zehra et al, 2005 
Sumbul & Bano, 2006 
Khan & Bano, 2009a 
Priyadarshini & Bano, 2009 
Chung & Yang, 2008 
Li et al, 2009 
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attention that duplication of cystatin like segments has played important contribution 
to the understanding of the evolution of cystatins. According to the scheme of Muller-
Esterl et al. [1985b] constructed on the basis of sequence homology, the diversity of 
CPIs has evolved from two ancestral building blocks 'A' and 'B'. The stefin 
progenitor represents the whole superfamily comprising a single 'A' unit. Cystatin 
acquired a second element B, possibly by gene fusion, thus forming 'AB' unit. Gene 
triplication of the archetype inhibitor generated the kininogen heavy chain which 
contains 3 cystatin like copies (AB)3. The proposed evolutionary pathway also 
contmned a 'missing link', a two cystatin domain protein that evolved from the 
cystatins by duplication, with two candidates for such a protein: feutin and HRG. This 
scheme however seem unlikely most importantly because neither domain in 
feutins/HRG is inhibitory but two domains of kininogens have inhibitory activity. If 
feutin/HRG were the 'missing link', then the kininogens which have evolved from the 
two domain protein would have to re-evolve their proteinase inhibitory activity and 
sequences [Brown and Dziegielewska, 1997]. Brown and Dziegielewska [1997] 
proposed the following scheme for cystatin superfamily evolution, with features 
similar to Muller-Esterl et al., [1985b] scheme but vsdth a new missing link, a two 
cystatin domain protein in which both the domains were fiinctional cysteine 
proteinase inhibitors. From it, the kininogens, feutins, and HRG could have evolved 
separately or perhaps in parallel and retained or lost their proteinase-inhibitory 
activity and active site sequences. This scheme [Fig. 3] draws support from the 
observation of conserved sequences immediately around the cysteine at the C-
terminus of the feutins, HMW-kininogens and HRG, again suggesting a common 
origin for these three proteins. Based on this Lee et al., [2009] have recently grouped 
feutins, HRG and kininogens in a single family, type 3 cystatins. 
1.6 STRUCTURE OF CYSTATINS 
PRIMARY STRUCTURE 
Most of the members of cystatin superfamily are polypeptides of 98-126 amino acid 
residues with Mr values in the range of 11-14 kDa. As regards to the amino acid 
composition of cystatins few distinctive features can be attributed to the subfamilies. 
Stefms are devoid of disulphide linkages (human cystatin A and rat cystatin a lack 
cysteine residues while human cystatin B and rat cystatin p have 1 and 2 cysteine 
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Fig. 3 Evolution of cystatin superfamily 
A. Scheme from Muller-Esterl et al. [1985b] 
B. Scheme proposed by Brown & Dziegielewska [1997] 
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residues, respectively) and tryptophan. Turk et al. [1993] however reported the 
presence of tryptophan in stefin C. A unique feature of stefin B is the conserved 
QWAG region in the stefins of mammalian origin, with Val54 replaced by Leu54. 
Ni et al. [1998] reported the presence of an additional disulphide bridge in cystatin F, 
for stabilizing the N-terminal part of the molecule in addition to the presence of 
second tryptophan residue, along with the conserved Trp 106, characteristic of type 2 
cystatins. The alignment of sequences of cystatins reveals common features, 
significant to the structure and activity of the proteins. Four residues are common to 
all the sequences of cystatins and inhibitory kininogen segments: Gly9, Gln53, Val55 
and Gly57. These residues are considered to be of functional importance since they 
are absent from the non-inhibitory segment Dl of kininogens. Another six conserved 
residues are Val47, Val55, Ala56, Tyr60, Cys71 and TyrlOO. The segment Gln53 to 
Gly57 is the most highly conserved region. 
SECONDARY STRUCTURE 
The crystalline form of chicken cystatin reported by Bode et al. [1988] revealed a new 
fold, the cystatin fold which is, a five stranded anti-parallel P-sheet wrapped around 
the central N-terminal helix [Fig. 2]. This fold has been shown to exist in HCC, 
chicken cystatin, cystatin D, as well as in family 1 cystatins A and B [Martin et al, 
1994; 1995; Alvarez-Fernandez et al, 2005; Stubbs et al, 1990]. An appending 
segment of partial a-helical geometry is present in chicken cystatin [Saxena and 
Tayyab, 1997], but absent in HCC [Bode et al, 1988]. Tryptophan was found only in 
the second hairpin loop of cystatins [Bode et al, 1988]. A unique feature was 
observed in crystal structure of cystatin F in its dimeric 'off state. The two monomers 
interacted in a fashion not seen before for cystatins or cystatin like proteins, crucially 
dependent on an unusual intermolecular disulphide bridge. The core sugars for one of 
the two N-linked glycosylation sites for cystatin F are well ordered and probably their 
conformation and interactions with the protein modulate hs inhibitory properties in 
particular its reduced affinity toward asparaginyl endopeptidase compared with other 
cystatins [Schuttelkopf et al, 2006]. 
There is considerable similarity between the structural features of stefms A 
and B [Fig. 4], but there are also some important differences in the regions which are 
fundamental to proteinase binding. The difference primarily consists of the two 
regions of high conformational heterogeneity in free stefin A which correspond in 
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Fig. 4 (A) Three dimensional structure of stefin A (where, A, B, C, D, E are the 
five antiparallel p sheets strands) 
(B) Three dimensional structure of stefm B (antiparallel p sheets are in 
green colour and a-helix is in red colour) 
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(A) 
(B) 
stefin B to two of the components of the tripartite wedge that docks into the active site 
of target proteinases. These regions which are mobile in solutions are the five N-
terminal residues and the second binding loop. In the bound conformation of stefin B 
they form a turn and a short helix, respectively. 
Circular dichroism and computer prediction of secondary structure from the sequence 
indicates that chicken cystatin has about 20% a-helix, 42% p-structure, 24% P-turn 
and 12% random coil [Schawbe et al., 1984]. Recombinant human cystatin A in good 
comparison to cystatin A, in far UV-CD spectrum revealed -45% p -structure and a 
low a -helix content (-15%) [Pol et al., 1995]. 
1.7 INfflBITION OF PROTEINASES 
Specificity 
Cystatins are highly specific for CPs except for thyropins which show inhibitory 
activity against aspartic and metalloproteinases [Mihelic and Turk, 2007; Lenarcic 
and Turk, 1999]. However there are few cystatins capable of inhibiting mammalian 
legumain [Alvarez-Fernandez et al., 1999] and calpains [Crawford, 1987]. To date, 
none of the cytoplasmic inhibitors have been tested on ubiquitin processing and 
recycling proteinases [Keppler, 2006]. Stefin A and B are potent inhibitors of papain, 
cathepsin L, S and H but have decreased activity against cathepsin B [Musil et al., 
1991]. Type 2 cystatins are important endogenous inhibitors of papain like CPs 
including cathepsins, parasite proteinases like cruzipain and mammalian legumain 
[Turk et al., 2005; Turk and Bode, 1991]. HCC and chicken cystatin inhibit papain, 
cathepsin L and S [Abrahamson et al., 2003]. HCC shows strong inhibitory capacity 
for rapid binding thus neutralizing proteinase activity in an emergency inhibition 
[Turk et al., 2005]. It also inhibits cruzipain, suggesting its possible defensive role 
after infection [Stoka et al, 1995]. Cystatin F inhibits cathepsin F, K, V, S, L and H 
[Langerholc et al., 2005] and weakly legumain [Alvarez-Fernandez et al., 1999] 
More recently it was found that the intracellular form of cystatin F, after N-terminal 
truncation of the first 15 residues including cysteine, inhibits cathepsin C [Hamilton et 
al., 2008]. Cystatin D inhibits cathepsin S, H and L but not cathepsin B or pig 
legumain [Alvarez-Fernandez et al., 2005]. Human cystatin E/M inhibits papain, 
cathepsin B, L, V and legumain [Ni et al., 1997; Sotiropoulou et al., 1997; Cheng et 
al., 2006; Alvarez-Fernandez et al., 1999]. Clostripain (proteinase not belonging to 
papain family) is also inhibited by cystatins [Barrett et al., 1986]. 
Kinetic behaviour 
Cystatins are the first group of protein inhibitors of CPs for which the mechanism of 
inhibition was investigated. All the cystatins are non-covalent, competitive, reversible, 
tight binding inhibitors which inhibit the target enzymes in micromolar to picomolar 
range [Turk et al., 1997]. They form tight equimolar complexes with CPs [Anastasi et 
al., 1983]. Some of the reported values of equihbrium constants for dissociation of 
complexes between human cystatins and lysosomal CPs are summarized in Table 2 
The affinity differences can be explained by the differences in the active site regions 
of endo- and exopeptidases. The access of the inhibitor to the active site of 
exopeptidases is partially obstructed by occluding loops in cathepsin B [Musil et al., 
1991], cathepsin X [Guncar et al., 2000], propeptide parts in cathepsin H [Guncar et 
al., 1998] and cathepsin C [Turk et al., 2001]. 
Reactive site and mechanism of action 
It has been established that no disulphide bond is formed between the active site 
cysteine residue and the inhibitor because the complexes dissociated when denatured 
without reduction as was found in chicken cystatin [Nicklin and Barrett, 1984] and 
kininogens [Gounaris et al., 1984]. The complex formation is accompanied by 
pronounced spectroscopic changes [Bjork et al., 1989]. On the basis of cystatin 
domain structure, it was proposed that there are three regions crucial for interaction 
with proteinases: the amino terminus and two P-hairpin loops, one in the middle and 
one in the C-terminal segment of the protein. The first loop contains a QXVXG 
sequence conserved in almost all inhibitory members of cystatins, whereas the second 
loop contains a P-W motif, which is also highly conserved [Table 3]. Both these loops 
and the amino terminus forms a wedge shaped edge, which is highly complementary 
to the active site of the enzyme. The N-terminally truncated forms of chicken cystatin 
confirmed the crucial importance for the binding of the residues preceding the 
conserved Gly-9 residue [Machleidt et al., 1989]. The essential interactive elements of 
this hypothetical complex are shown in figure 5. Complex formed on interaction of 
stefin B with cathepsin H is shown in figure 6. 
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TABLE 2: EQUILIBRIUM CONSTANTS FOR DISSOCIATION (Ki) OF 
COMPLEXES BETWEEN HUMAN CYSTATINS AND CHICKEN 
CYSTATIN WITH LYSOSOMAL CYSTEINE PROTEINASES 
(PAPAIN, HUMAN CATHEPSINS AND CRUZIPAIN) 
CPI Ki (nM) 
Cystatin 
Stefin A 
Stefin B 
Cystatin C 
Cystatin D 
Cystatin 
E/M 
Cystatin F 
Cystatin S 
Cystatin SA 
Cystatin SN 
Chicken 
cystatin 
L-
kininogen 
H-
kininogen 
Papain Cathepsin B Cathepsin H Cathepsin L Cruzipain 
0.019 
0.12 
0.00001 
1.2 
0.39 
1.1 
108 
0.32 
0.016 
0.005 
0.015 
0.02 
8.2 
73 
0.27 
>1000 
32 
>1000 
n.d. 
n.d. 
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1.7 
600 
400 
0.31 
0.58 
0.28 
7.5 
n.d. 
n.d. 
n.d. 
n.d. 
n.d. 
0.06 
0.72 
1.1 
1.3 
0.23 
18 
n.d. 
0.31 
n.d. 
n.d. 
n.d. 
0.019 
0.017 
0.109 
0.0072 
0.060 
<0.005 0.014 
n.d. 
n.d. 
n.d. 
n.d 
n.d. 
n.d. 
0.001 
0.041 
n.d. 
n.d. (not determined), Ki values for human cystatins [Abrahamson et al., 2003]. chicken cystatin 
[Barrett et al.. 1986] and cruzipain inhibition by cystatins [Stoka et al., 1995]. 
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Table 3: CONSERVED AMINO-ACID RESIDUES IN BINDING 
SEGMENTS OF HUMAN CYSTATINS "^ '  
Cystatin 
A 
B 
C 
D 
E 
F 
S 
SA 
SN 
H-kininogen 
l-domain 
2-doinain 
3-doinain 
Lrkininogen 
l-domain 
2-doinain 
3-doinain 
N-terminus 
MIPGG 
AcMMCGA 
RLVGG 
TLAGG 
RMVGE 
VKPGF 
IIPGG 
IffiGG 
IIPGG 
(QESQS) 
DCLGC 
ICVGC 
(QESQS) 
DCLGC 
ICVGC 
Hoop 
QWAG 
QVVAG 
QIVAG 
QIVAG 
QLVAG 
QIVKG 
QTFGG 
QIVGG 
QTVGG 
(TVGSD) 
QVVAG 
QWAG 
(TVGSD) 
QWAG 
QWAG 
Ilioop 
VPWQ 
VPWE 
VPWQ 
VPWL 
VPWE 
VPWE 
VPWE 
(RSST) 
(DIQL) 
VPWE 
(RSST) 
(DIQL) 
VPWE 
^ Sequences in parenthesis correspond to the appropriate binding sequences of 
cystatins. 
''Grzonkaetal., 2001. 
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Fig. 5 Scheme of the proposed model for the interaction of chicken 
egg white-cystatin and papain 
(Adapted from Turk and Bode, FEES Lett 1991; 285:213-219) 
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Fig. 6 Three dimensional structure of the complex formed between 
stefin A and cathepsin H 
Binding of stefin A into cathepsin H active site. Stefin A fold is shown as a 
green chain trace. Whereas cathepsin H fold is shown in yellow. Cathepsin 
H mini-chain residues are shown as red sticks which are thicker for the 
main chain. The mini-chain is attached to the body of cathepsin H with a 
disulfide shown as red yellow chain. The identified carbohydrate rings are 
shown in cyan. The N-terminus of stefin A displaces the C-terminus of the 
minichain by pushing its residues outside the binding cleft. Adopted from 
Turk and Turk, Acta Chim Slov 2008; 55:727-738. 
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Bode et al. [1988] demonstrated that the major contribution is from the first hairpin 
loop containing Q W A G sequence [Turk et al., 1985]. According to the model the N-
terminal segment of cystatin which is more flexible bridges over the active site Cys 25 
of papain without completely burying it and additionally the side chain of Leu 8 binds 
to S2 subsite of papain which determines the substrate specificity of papain [Asboth et 
al., 1988]. This was supported by Brzin et al. [1984] who demonstrated that the 
truncated form of HCC starting with Leu-Val before Gly-U (corresponding to Gly-9 
of chicken cystatin) has virtually the same affinity for papain as the full length form 
whereas the truncated form starting with Gly-12 has been reported to show 1000 fold 
weaker inhibition [Abrahamson et al., 1987a]. However, Nycander and Bjork [1990] 
emphasized the role of Trp-104 in the inhibition of CP. According to their model, 
Trp-104 of cystatin interacts primarily with two Trp side chains in the active side cleft 
of papain, Trp 177 and Trp 181, in such a manner that the indole ring of Trp-104 
stacks on the side chain of Trp 177 and the edge lies on the indole ring of Trp 181. A 
two step mechanism of inhibition of the lysosomal CP cathepsin B by its endogenous 
inhibitor cystatin C was observed by Nycander et al. [1998]. An initial weak 
interaction in which N-terminal of the inhibitor binds to the proteinase is followed by 
a conformational change. Subsequently, the occluding loop of the proteinase that 
partially obscures the active site is displaced by the inhibitor bringing about another 
conformational change. The presence of occluding loop of cathepsin B renders it 
much less susceptible to inhibition by cystatin than other proteinases. A similar two 
step binding of cystatin A to CP was suggested by Estrada and Bjork [2000]. 
The flexible N-terminal region of the cystatin binds independently to the target 
proteinases after the binding of hairpin loops. It is interesting to note that the 
replacement of the three N-terminal residues preceding the conserved Gly of stefin A 
by the corresponding 10-residues long segment of cystatin C increased the affinity of 
the inhibitor for cathepsin B by about 15-fold [Pavlova and Bjork, 2003], suggesting 
that the inhibitory potency of cystatin can be substantially improved by protein 
engineering. The crystal structure of human stefin A-porcine cathepsin H complex 
showed small distortion of the structure upon formation of the complex [Jenko et al., 
2003]. In addition to the structurally derived data, the contribution of the individual 
residues within proteinase binding region of cystatins was additionally investigated by 
mutational analysis and kinetic studies performed by several different groups [Pol and 
Bjork, 2001; Auerswald et al., 1994; Estrada et al., 1999; Pavlova et al, 2000]. 
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1.8 BIOLOGICAL ASPECTS AND PATHOPHYSIOLOGY OF 
CYSTATINS 
Proteinases and their natural inhibitors may co-exist at different levels of cellular 
evolution. Disturbing the harmony of the normal balance of enzymatic activities of 
proteinases and their natural inhibitors may lead to severe biological effects. 
Cystatins constitute a powerful regulatory system for endogenous CPs which are often 
secreted or leaked from the lysosomes of dying and diseased cells [Ekiel et al, 1997] 
Besides regulation of the enormous hydrolytic potential of CPs, plethora of actions 
has now been ascribed to cystatins. They are known to play important roles in various 
pathophysiologic conditions such as sepsis [Assfalg-Machleidt et al., 1988], cancer 
[Cox, 2009], rheumatoid arthritis [Trabandt et al., 1991], purulent bronchiectasis 
[Buttle et al., 1990], multiple sclerosis [Bever and Garver, 1995], muscular dystrophy 
[Sohar et al., 1988], etc. which indicate that a tight enzyme regulation by cystatin is a 
necessity in the normal state. 
Cystatins and cancer: Cathepsins involved in the degradation of extracellular 
matrix facilitate the growth, invasion and metastasis of tumour cells and also in 
tumour angiogenesis [Gocheva and Joyce, 2007; Mohamed and Sloane, 2006; Turk et 
al., 2004; Vasiljeva et al., 2006]. A broad spectrum of cysteine proteinase inhibitor 
was shown to inhibit tumour angiogenesis [Joyce et al., 2004]. 
Generally, cathepsin to cystatin ratio is found to be increased in most tumour types 
compared to normal tissues [Paraoan et al., 2009; Rivenbark and Coleman, 2009]. 
Elevated TPI level in various tumour types have been correlated to better prognosis 
like, stefin A positive breast cancer patients are less likely to develop distant 
metastasis [Parker et al., 2008], stefin A and B in non small cell lung cancer [Werle et 
al., 2006], cystatin SN is upregulated in gastric cancer [Choi et al., 2009], cystatin C 
[Sokol and Schiemann, 2004], cystatin M [Zhang et al., 2004], cystatin F 
[Utosunomiya et al., 2002], were found to be expressed in epithelial and 
mesenchymal tumour cells. Cystatin M is oflen hailed as tumour suppressor. 
Stefin A and cystatin C overexpression has been shown to inhibit cancer cell invasion 
and metastasis [Li et al., 2005; Kopitz et al., 2005]. Cystatins may also inhibit cell 
migration by interfering with cell signalling pathways, by direct cathepsin and 
calpain inhibition [ Cox, 2009]. Cathepsins B, L and S promote tumour growth in a 
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murine model of pancreatic tumourigenesis [Gocheva et al., 2006]. The tumour 
microvascular density declined by about half in pancreatic tumours in cathepsin B or 
cathepsin S null mice. Significant increases in apoptosis were also noted in cathepsin 
B, L and S null pancreatic tumours. 
Cystatins and neurodegeneration: Though CPs are implicated in various 
pathologies of brain, there are only few studies concerning the role of cystatins in 
pathologies of brain. Only two genetic diseases are known in which mutations in 
cystatin C and stefin B are associated with disease status. Hereditary cystatin C 
amyloid angiopathy (HCCAA) the first human disorder known to be caused by 
deposition of cystatin C amyloid fibrils in walls of brain arteries leading to single to 
multiple strokes with fatal outcomes [Jensson et al., 1987]. The amyloid deposited is 
composed mainly of the Leu 68 Gin variant of cystatin C [Wei et al., 1998] and is 
associated with mutation in cystatin C gene [Palsdottir et al., 2006]. Normal cystatin 
C may protect pathogenesis of Alzheimer's disease by binding to soluble amyloid-P-
peptide and preventing its deposition [Mi et al., 2007]. 
Progressive myoclonus epilepsy [EPMl] is exhibited by a group of inherited 
diseases characterized by myoclonic seizures, generalized epilepsy and progressive 
neurological degeneration caused by mutations in cystatin B gene (in the conserved 
QWAG region) [Pennacchio et al., 1997; Joensuu et al., 2007]. 
Cystatins and cell death: Cystatins are shown to be involved in normal cell 
apoptosis, and most dramatically in selective tissue type for example in EPMl 
[Lieuallen et al., 2001]. In fibrosarcoma cells, cystatins regulate cell death in response 
to TNFa [Foghsgaard et al., 2001]. An elevated cystatin C/cathepsin B ratio was 
found to be associated with chemoresistance in non-small cell lung carcinoma patients 
[Petty et al., 2006]. Intracellular cystatins normally inhibit low level lysosomal 
leakage. High cystatin levels are expected to be protective for general cathepsin 
mediated cell death. 
Cystatins and immunomodulation: Cystatins have emerged as effector 
molecules of immunomodulation [Zavasnik-Bergant, 2008]. They can stimulate nitric 
oxide release from macrophages [Verdot et al., 1999]; modulate respiratory burst and 
phagocytosis in neutrophils [Leung-Tack et al., 1990]; and interleukin, cytokine 
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production in T-cells and fibroblasts [Schierack et al., 2003; Kato et al., 2002; 2004]. 
Most of these functions operate via putative cell surface cystatin-binding molecules or 
membrane domains [Kato et al., 2002]. Cystatin C has been shown to be a TGFp 
receptor antagonist and TGFp signalling pathway blocker [Sokol and Schiemann, 
2004; Sokol et al, 2005]. Type 2 cystatins are also known to increase interleukin-6 
expression in fibroblasts and splenocytes [Kato et al, 2000]. Cystatin C is a potent, 
reversible inhibitor in vitro of the human lysosomal CPs e.g., cathepsin S (Ki = 8 pM), 
cathepsin L (Ki = 8 pM) and cathepsin H (Ki = 220 pM). These proteinases are 
located all along the endocytic pathway of dendritic cell and are involved in the 
controlled proteolysis associated with the degradation of antigenic peptides [Pluger et 
al, 2002]. Cystatin F by targeting cathepsin C is known to regulate diverse immune 
cell effector functions [Hamilton et al., 2008]. 
Cystatins as antimicrobial and antiviral agents: Horse-shoe crab hemocyte 
cystatin has antimicrobial activity against Gram negative bacteria with IC50s against 
S. typhimurium, E. coli and K. pneumoniae in the 80-100 ng/ml range [Agarwala et al, 
1996]. Both chicken and human cystatins were found to inhibit the growth of P. 
gingivalis with an IC50 of 1.1 and 1.2 fM, respectively [Blank et al., 1996]. Cystatin 
C is also an effective inhibitor of replication of coronavirus [Collins and Grubb, 1998]. 
Sialostatin L displays anti-inflammatory role and inhibits proliferation of cytotoxic T-
lymphocytes [Kotsyfakis et al, 2006]. 
Cystatin C in clinical diagnostics: Cystatin C was the first protein to be used in 
clinical diagnostics. Levels of cystatin C in various body fluids is used as a barometer 
of disease [Shah and Bano, 2009]. Recent studies indicate that it is a better marker of 
glomerular filtration rate and is a stronger predictor of cardiovascular disease and 
mortality than serum creatinine [Fried, 2009]. Cystatin C levels can also be used to 
reflect the characteristics of peritoneal membrane in dialysis patients [Al-Wakeel et 
al, 2009]. Korolenko et al. [2008] recently found that serum cystatin C concentration 
can be used as one of the prognostic criteria in patients with several kinds of 
hemoblastoses. IL-6 levels along with that of cystatin C may be regarded as markers 
of increased osteoblastic activity associated to bisphosphate treatments in prostrate 
cancer patients with bone metastases [Tumminello et al, 2009]. Yang et al. [2009] 
found that its levels decrease significantly in cerebrospinal fluids of patients with 
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Guillain-Barre syndrome and may be involved in its pathophysiology. Cystatin B was 
found to be specifically over expressed in most hepatocellular carcinomas and alone 
or in combination v i^th a-fetoprotein may be a useful marker for diagnosis of the 
diseases [Lee et al., 2008]. 
Role of cystatins in other diseases: Cystatins are now known to participate in 
neuronal differentiation [Taupin et al., 2000]. Numerous studies have demonstrated 
that cathepsin K, L and S are involved in elastic fibre degradation, associated with the 
development of different pathological conditions of cardiovascular system. 
Elastinolytic activities of cathepsin K, L and S can be blocked by cystatins [Novinec 
et al., 2007]. Equistatin is known to inhibit the growth of the red flour beetle 
Triboleum castaneum [Oppert et al., 2003], suggesting to be promising candidate for 
the transgenic seed technology to enhance seed resistance to storage pests. Heparin 
binding and cell-binding domain 5 (light chain) of H-kininogen has antibacterial 
acitivity against E. coli, P. aeruginosa and Enterococcus faecalis [Andersson et al, 
2005]. Bradykinin induces dendritic cell maturation and can modulate innate or 
adaptive immunity [Aliberti et al., 2003; Scharfstein et al., 2007]. Cystatin C appears 
to be up-regulated in response to injury in the brain [Shah and Bano, 2009]. Cystatin 
M/E is a key molecule in a biochemical pathway that controls skin barrier formation 
by the regulation of both crosslinking and desquamation of stratum comeum 
[Zeeuwen et al, 2009]. Lower cystatin C level is also implicated in retinal 
degeneration in (rdl) mouse model of retinitis pigmentation [Ahuja et al, 2008]. An 
imbalance in cathepsin B/cystatin C level may contribute to the progression of pelvic 
inflammatory disease [Tsai et al, 2009], There are many other diseases with 
decreased cystatin levels, such as inflammatory diseases, osteoporosis, arthritis, and 
diabetes as well as a number of other neurodegenerative diseases [Turk et al, 2008], 
1.9 PANCREAS 
Pancreas, the capital of proteolytic power, plays important role in digestion and in 
maintenance of glucose homeostasis in body. A soft lobulated, greyish-pink gland, 
12-15 cm long (in humans), it extends nearly transversely across the posterior 
abdominal wall, behind stomach, fi-om duodenum to spleen. The pancreas is 
composed of two separate types of glandular tissue [Fig. 7], main mass of which is 
exocrine, embedded in which are clusters of endocrine cells constituting pancreatic 
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Fig. 7 Anatomy of pancreas 
Adopted from McGraw Hills Access medicine, The McGraw Hill 
Companies Inc., www.accessmedicine.com 
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islets. The exocrine part of pancreas is a lobulated, branched, acinar gland [Beck and 
Sinclair, 1971]. The acinar cells are zymogenic containing secretory granules laden 
with powerfiil enzymic constituents of pancreatic secretion. The endocrine pancreas 
consists of pancreatic islets (of Langerhans) spheroidal or ellipsoidal clusters or 
solitary or randomly embedded in the exocrine part of the pancreas [Heitz et al., 1976]. 
The islets contain three major types of cells, alpha [glucagon secreting; Baum et al., 
1962], beta [most abundant and insulin secreting; Lacy and Davies, 1957] and delta 
[somatostatin secreting; Orci et al., 1975] cells. In addition, PP cell is also present in 
pancreas secreting hormone pancreatic polypeptide [Buffa et al., 1977]. 
Two major functions of the pancreas are release of insulin and glucagon in response 
to body glucose levels indirectly regulating protein, carbohydrate and lipid 
metabolism and acting as a switch between carbohydrate and lipid metabolism. 
Dysregulation of insulin and glucagon production causes diabetes mellitus, 
hyperinsulinism and hyperglycemia, respectively. Pancreatic acini secrete digestive 
enzymes and large volumes of sodium bicarbonate responsible for digestion of all 
three major food types- proteins, carbohydrates and fats. The proteolytic enzymes of 
the pancreatic juice are secreted in their zymogenic form. 
1.10 PROTEIN UNFOLDING STUDIES 
Proteins are synthesized as a linear chain of amino acids which in order to become 
biologically active must fold and adopt one out of an enormous number of possible 
conformations. This conformation referred to as native state, exists in solution as a 
very compact and highly ordered structure. Under physiological conditions the native 
(folded) and the denatured (unfolded) states of a protein are in equilibrium and the 
free energy change, AG, for the equilibrium reaction 
Native (N) ^=? Denatured (D) 
is referred to as the conformational stability of a protein. The determinants of native 
state stability in aqueous solutions are the amino acids sequence of protein as well as 
the variable conditions of pH, temperature, and the concentration of salts and ligands 
[Alber, 1989; Pace, 1990]. Although the native conformation is essential for activity, 
the conformational stability is remarkably low. The native state of most naturally 
occurring proteins is only about 5-15 kCal/ mol more stable than its unfolded 
conformations [Pace, 1975]. The conformational stability of proteins (monomeric or 
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multimeric) can be measured by equilibrium unfolding studies using guanidine 
hydrochloride (GdnHCl) or urea [Pace, 1986], the two agents commonly employed as 
protein denaturants. Analysis of the solvent denaturant curves using these denaturants 
can provide measure of the conformational stability of protein [Pace, 1986; Yao and 
Bolen, 1995]. Protein unfolding/folding studies in GdnHCl and urea solutions have 
focused on the identifications of equilibrium and kinetic intermediates [Kim and 
Baldwin, 1990; Jaenicke, 1987]. Equilibrium denaturation studies using 
physical/chemical denaturants have been very useful in understanding the structure, 
stabilization and folding of small monomeric proteins [Tanford, 1968; Pace, 1986; 
1990]. Lately, these techniques have been applied to oligomeric proteins also [Neet 
and Timm, 1994; Prakash et al., 2002; Akhtar et al., 2002], Though inter- and 
intrasubunit reactions in oligomeric and monomeric proteins are of same physical 
nature, the denaturation/renaturation reactions in oligomeric proteins are more 
complex, usually multiphasic processes with stabilized partially folded intermediates 
Jaenicke and Lilie, 2000; Hornby et al., 2000], occurring either by sequential or 
concerted mechanisms [Jaenicke, 1987; Seckler and Jaenicke, 1992]. 
With dimeric (or oligomeric) proteins additional modes of stabilization are available 
at the quaternary structural level. A general three-state model of the equilibrium 
dissociation and unfolding of the dimeric protein involving native dimer (N2), native 
monomer (N) or a monomeric intermediate (I) and denatured monomer (D) is 
described by following equation 
N2^=^2N^=7 2D or N2^=^2I^=7 2D 
Completely unfolded dimers (D2) are not likely to exist, but evidence for partially 
unfolded dimeric intermediates (I2) is reported [Blackburn and Noltmann, 1981]. The 
compact monomeric intermediate structure may not be identical to the conformation 
of the subunits in the native dimer, but some native-like secondary or tertiary folding 
may exist e.g. denaturation of superoxide dismutase [Mei et al., 1992], glutathione-S-
transferase [Sacchetta et al., 1993], etc. Dimeric proteins can follow a 2-state 
transition, N2^=7 2D, where N2 is native dimer and D is the denatured monomer. The 
2-state model implies that the native monomer (or a monomeric intermediate) does 
not exist at significant concentration at equilibrium i.e. the quaternary interactions are 
necessary for stabilization of the folded monomeric state. Two-state denaturation of 
dimeric proteins have been reported for Arc repressor [Milla and Sauer, 1994], SIV 
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protease [Grant et al., 1992], HIV protease [Grant et al., 1992], repressor of primer 
[Steif et al., 1993], neurotrophin-3 and neurotrophin-4/5 [Timm et al., 1994], etc. 
The midpoint of thermal [Pakula and Sauer, 1989] or chemical [Bowie and Sauer, 
1989b] denaturation transition can also be computed from the denaturation curves and 
can be used to compare 2 different proteins or a single protein behaving differently 
under the effects of different denaturing conditions. There are various reports 
available which have shown different effects of GdnHCl and urea on protein 
unfolding like mushroom tyrosinase which shows different behaviour towards 
GdnHCl, urea and SDS in terms of different transition processes for these denaturants 
[Park et al., 2003]. Behaviour of human placental and goat lung cystatins towards 
these denaturants was also found to be different in terms of midpoint of transition and 
presence of intermediate states [Rashid et al., 2005; Khan and Bano, 2009b]. 
Increasing inclination in protein folding/unfolding is due to the recognition that 
failure of cellular protein folding mechanisms is associated with a variety of important 
human disorders ranging from cystic fibrosis to Alzheimer's disease. There is a 
growing body of evidence indicating a critical role for partially folded protein 
conformers in the process of conversion of normal cellular proteins into disease 
causing, proteinase-resistant protein aggregates of various morphologies [Kelly, 1998; 
Dobson, 2004]. 
1.11 AMYLOID FIBRIL FORIVIATION 
Amyloidogenesis is the aggregation of soluble proteins into structurally conserved 
fibers. Amyloid fibers are distinguished by their resistance to proteinase K and 
detergent, tinctorial properties and P-sheet rich secondary structure [Hammer et al., 
2008]. Amyloid formation is a hallmark of many human diseases like Alzheimer's 
[Gotz et al., 2009], diabetes mellitus [Engel et al., 2008], autosomal hereditary 
systemic amyloidosis [De Felice, 2004], prions diseases and more than 20 different 
human disorders like, HCCAA, Parkinson's disease, Huntington's disease, etc. 
[Merlini and Bellotti, 2003]. Amyloid fibres are incredibly stable P-sheet rich 
structures that many proteins can form [Smith et al., 2006; Holm et al., 2007]. 
The ability to fibrillate is independent of the original native structure of protein 
[Khurana et al., 2003] and overall yield and stability of the fibrils [Hortscansky et al., 
2005]. This led Dobson and coauthors to propose that amyloid-fibril formation is a 
generic property of proteins [Dobson, 1999; Fandrich et al., 2001]. Fibrillation 
generally starts from an intermediate state, either partially unfolded or partially folded, 
molten globule or native like intermediate [Rochet and Lansbury, 2000]. In case of 
globular proteins such as cystatin C [Ekiel and Abrahamson, 1996], stefm B 
[Zerovnik et al., 2007], partial unfolding and in case of unfolded polypeptides such as 
a-synuclein [Uversky et al., 2001] and islet amyloid peptide partial folding is must. In 
vitro, variation of solvent conditions by changing pH or adding organic solvents can 
lead to partial unfolding and subsequent protein fibril formation. With unfolded 
polypeptides, partial folding can be obtained by lowering pH or by heating. In vivo, 
partial unfolding may happen as a consequence of lowered protein stability due to 
mutation, local change in pH in membranes, oxidative and heat stress, whereas partial 
folding may happen on exposure to environmental hydrophobic substances, such as 
pesticides [Uversky et al., 2001]. 
Amyloidogenic conformation and common structural traits of fibrils 
Ordered fibrillar aggregates and the amyloid-fibrils can be studied at lower resolution 
by transmission electron microscopy (TEM), atomic force microscopy (AFM) 
[Goldsbury et al., 1997; Ding and Harper, 1999], cryo-electron microscopy. X-ray 
diffraction and solid state NMR. Common features of the fibrils are [Serpell, 2000a], 
P-strands (separated by 4.7 A) running perpendicular to the long axis of the fibrils and 
P-sheets extending parallel to the axis. The P-strands form a P-helical twist with usual 
repeat at every 115 or 250 A [Serpell, 2000a]. There are two main types of fibrils, 
type 2 are built from two intertwined filaments, with a diameter fi-om 80-130 A. Type 
1 fibrils are thinner and are formed fi'om one filament only. There are other types of 
fibrils for e.g., a fibril and untwisted filaments of human stefm B [Zerovnik et al., 
2002a]. The fibrils generally consist of 2-6 protofilaments, each -2-5 nm in diameter, 
that generally twist together to form fibrils that are typically 7-13 nm wide [Serpell et 
al., 2000b]. The fibrils have the ability to bind specific dyes such as thioflavin T 
(ThT) and congo red (CR) [Krebs et al., 2005; Klunk et al., 1999]. 
Kinetic basis of fibriilogenesis 
Fibrillogenesis often starts with dimers as building blocks which oligomerize to 
tetramers, octamers etc., constituting the prefibrillar aggregates composed of fluid 
nuclei [Lomakin et al., 1996]. From these, protofibrils grow upto 200 nm in length 
and are slightly curved [Lomakin et al., 1996]. All these species accumulate in the lag 
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phase which is followed by an exponential growth phase in which protofibrils merge 
into filaments. Fully made fibrils are then made from filaments added laterally or by 
end to end [Aggeli et al., 2001]. Thioflavin T fluorescence is generally used to follow 
kinetics of fibril formation [Sabate and Saupe, 2007]. Addition of preformed fibrils 
(seeding) is known to speed up the process of fibrillation [Jenko et al., 2004]. These 
events are depicted in figure 8. Several amyloidogenic proteins form domain swapped 
dimers like cystatin C [Janowski et al., 2001], human stefin A [Staniforth et al., 2001], 
stefin B [Skerget et al., 2009]. It has been proposed that domain swapped dimers 
could lead to higher oUgomerisation and amyloid fibriilization [Liu et al., 2001]. 
Fibrillogenic cystatins 
Cystatins are prone to form amyloids [Morgan et al., 2008; Turk et al., 2008]. Human 
cystatin C is highly amyloidogenic protein. The fibril formation is also known to 
occur in chicken cystatin [Staniforth et al., 2001], stefin B under in vitro conditions 
[Zerovnik et al., 2007], stefin A [Jenko et al., 2004], latexin [Pallares et al, 2007], 
CRES protein [von Horsten et al., 2007]. In the case of HCC the oligomers and fibrils 
are formed by propagated domain swapping. This model is not compatible with stefin 
B, in which proline (Pro) isomerization is important in preventing steric clashing 
[Morgan et al., 2008]. Trans to cis isomerization of Pro 74 is involved in formation of 
stefin B dimers. Since this Pro is widely conserved in cystatin superfamily its 
isomerization can play role in amyloidogenesis [Jenko-Kokalj et al., 2007]. 
Protein fibrillation: connection to pathophysiology and disease 
About 20 human proteins have been found in proteinaceous deposits in various 
conformational diseases [Zerovnik, 2002]. There is absence of any sequence or 
structural homology in these proteins, but a common event is thought to be a 
conformational change leading to lack of biological function or gain of toxic activity, 
and possibly formation of amyloid fibrils. Co-localization of protein aggregates with 
degenerating tissue and association of their presence with disease symptoms indicate 
the involvement of amyloid deposition in the pathogenesis of conformational diseases 
[Soio, 2001]. Amyloid cytotoxicity appears to be associated with prefibrillar 
aggregated states either because of their ability to permealize cell membranes to 
general ion flux [Ceru et al.; 2008; Rabzelj et al., 2008] or because the rather diffuse 
hydrophobic surface may catalyze unwanted reactions [Bucciantini et al., 2004]. 
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Fig. 8 Properties of amyloid polymerization 
(A) A graphic representation of amyloid fiber polymerization 
displaying nucleus dependent kinetics (black line). Preformed amyloid 
fibers can act as seeds to speed the kinetics of fiber polymerization (grey 
line). This process eliminates the lag phase associated with nucleus 
formation. 
(B) Model of amyloid fiber polymerization. A build up of 
monomer occurs which leads to the formation of multimers and finally the 
amyloid fiber end product. Large arrows represent processes that are 
energetically favourable while small arrows represent energetically 
unfavourable processes. 
Adopted from Hammer et al. JAlzheimers Dis 2008; 13:407-419. 
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Anti-amyloidogenic and fibril destabilizing agents 
A number of agents are employed with the aim to either inhibit or reverse the 
conformational change, or to dissolve the smaller aggregates and disassemble the 
amyloid fibrils. Few such approaches include 'P-sheet breakers' or 'mini-chaperones' 
[Soto, 2001], nicotine and melatonin [Findeis, 2000], apomorphine [Lashuel et al., 
2002], various antibiotics [Zerovnik, 2002]. There are controversial reports 
on the inhibitory effects of metal ions on amyloid fibril formation. Recently, it was 
shown by Raman et al. [2005] and Zerovnik et al. [2006] that binding of Cu^ ^ and 
Zn^* but not Fe^* to amyloid-P-peptide retards amyloid fibril formation and Cu^ ^ 
binding to stefin B inhibits amyloid fibrillation. Contrarily, promotion of aggregation 
and fibrillation by presence of Cu^^ has been shown for prion protein [Brown et al., 
1997], a-synuclein [Rasia et al., 2005], amyloid-P-protein [Atwood et al, 1998]. 
Recently, several natural compounds, like polyphenols, curcumin etc., have been 
demonstrated to remarkably inhibit the formation of fibrillar assemblies in vitro and 
their associated cytotoxcity [Riviere et al., 2008]. 
1.12 REACTIVE SPECIES MEDIATED PROTEIN DAMAGE 
Radical mediated damage to proteins, initiated by electron leakage, metal-ion-
dependent reactions and auto-oxidation of lipids and sugars results in production of 
protein hydroperoxides and aggregation or fragmentation of proteins. Damaged 
proteins are often functionally inactive and their unfolding is associated with 
enhanced susceptibility to proteinases. 
Reactive species 
Free radicals such as reactive oxygen (ROS) and reactive nitrogen species (RNS) are 
well recognised for playing a dual role as both deleterious and beneficial species 
[Valko et al., 2007]. Important physiological functions that involve free radicals or 
their derivatives are summarized in Table 4. Besides these, free radicals are also 
involved in ATP generation, apoptosis of effete or defective cells, production of 
prostaglandins and leukotrienes etc. [Devasagayam et al., 2004]. 
Nature has endowed cells with protective antioxidant mechanisms to neutralize and 
eliminate the harmful reactive species. However, oxidative stress can occur when 
there is a disturbance in the pro-oxidant/antioxidant systems in favour of the former 
[Seis, 1985]. Overproduction of RNS is termed as nitrosative stress [Ridnour et al., 
2004]. The uncontrolled oxidative stress initiates a series of harmful biochemical 
events associated with diverse pathological processes [Juranek and Bezek, 2005]. 
Reactive species are small molecules with an oxygen or nitrogen atom in their 
structure [Halliwell and Gutteridge, 2007], These ROS and RNS can be free radicals 
with an unpaired electron [e.g. "NO (nitric oxide radical), 02*" (superoxide radical) 
and OH* (hydroxyl radical)] or non-radicals (e.g. H2O2). They can be anions [e.g. 02~ 
(superoxide) and ONOO" (peroxynitrite)] or non-ions (e.g. H2O2, *N0, OH"). 
Superoxide (O2* ~) 
It is relatively innocuous, however, its reaction with other radicals like "NO and iron 
clusters in some of the enzymes makes it the mother of potent reactive species 
collectively called as ROS. The mitochondrial respiratory chain is the most important 
site of 02'" generation [Turrens, 2003]. In biological tissues 02*" can be converted 
non-enzymically into non-radical species H2O2 and singlet oxygen [Steinbeck et al., 
1993]. The electronic ground state of dioxygen is a triplet (^02), having two unpaired 
electrons with same spin and hence a diradical, and a one-electron poor oxidant. 
Pairing these electrons in opposite spins give singlet oxygen (^ Oj) a two electron 
potent oxidant. Singlet oxygen is produced in several physiological processes for e.g. 
by reaction of H2O2 and hypochlorous acid (HOCl) in neutrophils, 
H2O2 + HOCI •^Oi + H2O + HCI 
ROS has been implicated in etiology of various diseases [Droge, 2002; Halliwell and 
Gutteridge, 2007]. 
Riboflavin 
It is an important constituent of our daily diet, present in free and conjugated forms in 
almost all biological tissues and fluids [Spector, 1980; Rose et al., 1986]. Flavins are 
known to photooxidize amino acids and effect the conformation of proteins [Joshi, 
1985; Baba et al., 2004]. They are known to generate 'O2, OH', flavin triplet state, 
02*" and H2O2 which can modify proteins and other biological macromolecules 
[Keynes et al., 2003; Cardoso et al, 2006]. 
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Hydrogen peroxide 
It is produced continuously in all cells and is often employed as a signalling molecule. 
Although not a fi"ee radical, it has a great physiological relevance because of its ability 
to penetrate biological membranes and to act like an intermediate in the production of 
more reactive oxygen species, namely hydroxyl radical and hypochlorous acid 
[Nordberg and Arner, 2001]. It does not readily oxidize most proteins, lipids or DNA 
but is cytotoxic at micromolar concentrations and has been implicated in number of 
diseased states [Pryor et al., 2006]. 
Nitric oxide ('NO) 
It is a free radical endogenously produced in a variety of mammalian cells by both 
constitutive and inducible forms of nitric oxide synthase [Ghafourifar and Cadenas, 
2005]. *N0 is an important mediator of a variety of diverse biochemical and 
physiological processes, like signal transduction, neurotransmission, smooth muscle 
relaxation, platelet inhibition, blood pressure modulation, immune system control, 
macrophage mediated cytotoxicity [Blaise et al., 2005]. Reactivity of *N0 as a free 
radical species is quite weak which combined with its lipophilicity allows it to be 
remarkably diffusible [Denicola et al., 2002]. In vivo, this diffusion is largely 
regulated by its reaction with haemoglobin [Liu et al., 1998]. *N0 is a mother to a 
family of reactive compounds, collectively called RNS [Table 5]. Their production 
and pathophysiological effects are represented in Fig. 9. "NO can also react with 02*" 
to give peroxynitrite. *N02 can also react with 02*" giving peroxynitrate, a more 
powerfiil oxidant than peroxynitrite. Biological oxidations by peroxynitrate could 
result either directly or by its decomposition products [Pryor et al, 2006]. 
NOi + O2" • O2NOO-
(Nitrogen (Superoxide (Peroxynitrate) 
dioxide) radical) 
O2NOO- >, ^02 + NO2-
(Peroxj-nitrate) (Singlet (Nitrate) 
oxygen) 
Peroxynitrite can react with carbon dioxide generating nitrosoperoxocarboxylate 
(NPC), another potent protein damaging agent [Tien et al., 1999]. Overproduction of 
"NO can mediate toxic effects, e.g., DNA fragmentation, cell damage and neuronal 
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TABLE 4: IMPORTANT PHYSIOLOGICAL FUNCTIONS THAT 
INVOLVE FREE RADICALS OR THEIR DERIVATIVES" 
Type of Radical 
Nitric oxide (*NO) 
Superoxide (02^) 
and related ROS 
Superoxide (02*') 
and related ROS 
Source of Radical 
Nitric oxide synthase 
NAD(P)H oxidase 
Any Source 
Physiological Process 
Smooth muscle relaxation (control of vascular 
tone) and various other cGMP dependent 
functions 
Control of ventilation 
Control of erythropoietin production and other 
hypoxide inducible functions 
Smooth muscle relaxation 
Signal transduction firom various membrane 
receptors/enhancement of immunological 
functions 
Oxidative stress responses and the maintenance 
of redox homeostasis 
* Adopted from Droge [2002]. 
TABLE 5: NITROGEN OXIDES IMPLICATED IN THE BIOLOGICAL 
SEQUEL OF NITRIC OXIDE FORMATION 
Nitrogen Oxide 
•NO 
NO^ 
NQ-
NO2 
N2O3 
ONOQ-
N02^ 
Common Name 
Nitric Oxide 
Nitrosonium 
Nitroxyl 
Nitrogen Dioxide 
Dinitrogen Trioxide 
Peroxynitrite 
Nitronium 
Reactivity and 
Reaction Types 
Weak nitrosylation 
Moderate 
nitrosation 
Strong oxidation 
Strong oxidation, 
nitration 
Strong nitrosation, 
oxidation 
Strong nitration, 
nitrosation, 
oxidation 
Strong nitration 
Substrates 
Transition metals, 
radicals, oxygen 
Thiols, amines 
Thiols, lipids, metals, 
oxygen, DNA 
Antioxidants, thiols, 
lipids 
Thiols, amines, lipids, 
antioxidants 
Lipids, tyrosine, 
phenylalanine, DNA, 
thiols, antioxidants 
Tyrosine, amines, 
phenylalanine 
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Fig. 9 A schematic diagram of the conversion of nitric oxide (NO) to 
other nitrogen oxides 
Hydrophilic interior of membranes will act as a lens to magnify the 
oxidation of NO to NO2 or N203.The profound reactivity of these nitrogen 
oxides, as well as the formation of the highly cytotoxic peroxynitrite 
(0N00~), likely mediates cellular injury and tissue dysfunction in 
response to augmented NO production. 
PARP (poly-ADP ribose polymerase); MMP (matrix metalloproteinase). 
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cell death [Dawson et al., 1992]. *N0 also shows neurotoxicity and act as pathological 
mediator in cerebral ischemia, epilepsy, Alzheimer's disease, Parkinson's disease and 
certain neurodegenerative diseases [Moncada et al., 1991] and it is also involved in 
toxicity associated with diabetes [Pacher et al., 2005] and pancreatitis [Chvanov et al., 
2005]. 
Hypochlorous acid (HOCl) 
One of the strongest physiological oxidants known, is produced in vivo at 
inflammation sites by enzymatic oxidation of chloride ions, 
H2O2 + Cr <^ "^^  • HOCl + OH-
(H^rogen (Chloride i(Hi) (HypocMorous (Hydroityl Ion) 
peroxide) add) 
Where, MPO is eiuyme myeloperoxidase. 
It is estimated that between 25 and 40% of H2O2 generated by activated neutrophils is 
used to form HOCl [Babior, 2000]. An additional reaction of HOCl is with nitrite 
(N02~) to form nitryl chloride (NO2CI), a reaction favoured with decreasing pH 
[Eiserich et al., 1998], 
HOCl + NO2- + H^ • NO2CI + H2O 
(Hypochlorous (Nitrite) (Nitryl chloride) (Water) 
acid) 
HOCl is a reactive chlorine species (RCS) capable of chlorinating protein tyrosine and 
oxidising many important biomolecules like DNA, collagen and ATPase, etc. and 
causing cell death [Winterboum and Kettle, 2000; Jenner et al., 2002]. Nitryl chloride 
is capable of nitrating, chlorinating and dimerizing phenol compounds such as 
tyrosine [Eiserich etal., 1998]. 
Protein modification by reactive species 
Free amino acids and amino acid residues in proteins are highly susceptible to 
oxidation by one or more reactive species (ROS/RNS/RCS) that (a) are present as 
pollutant in atmosphere (b) are generated as by products of normal metabolic 
processes and (c) are formed during exposure to X, 7, or UV radiations. Studies have 
shown that oxidation of proteins can lead to hydroxylation of aromatic groups and 
aliphatic amino acid side chains, nitration of amino acid residues, nitrosylation of 
sulphydrj'l groups, sulphoxidation of methionine residues, chlorination of aromatic 
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and primary amino groups, and conversion of some amino acid residues to carbonyl 
derivatives [Stadtman and Levine, 2003; Dean et al., 1997; Yan and Sohal, 2002; 
Davies et al., 1987a; 1987b; Peskin and Winterboum, 2001]. The oxidation of 
proteins by reactive species can also lead to the cleavage of peptide bonds [Garrison, 
1987; Uchidaetal., 1990]. 
Exposure of proteins to free radicals causes (a) protein inactivation, e.g., of catalase 
and Mn superoxide dismutase by "NO [Sigfrid et al., 2003; Castro et al., 2004], a2-
macroglobulin by HOCl and H2O2 [Khan and Khan, 2004], goat lung cystatin by "NO 
[Khan et al., 2009] and sheep plasma kininogen by ROS [Baba et al., 2004], etc. (b) 
protein aggregation, fragmentation or cross linking [Davies and Delsignmore, 1987; 
Hawkins and Davies, 1998; Chapman et al., 2003; Verzyl et al., 2000; Di Mascio et 
al., 2000], 
Modestly oxidized proteins are usually more sensitive to proteolytic attacks by most 
proteinases [Davies et al., 1987b; Wolff and Dean, 1986] whereas heavily oxidized 
proteins have decreased susceptibility [Davies et al., 1987b] and can be a 
cause/consequence of certain diseased states like aging, atherosclerosis and 
neurodegeneration. 
Vulnerability of pancreas to free radical damage 
Pancreas is highly susceptible to free radical attack. Enzymatic antioxidant defence 
mechanisms of pancreatic P-cells are particularly weak [Cobianchi et al., 2008; 
Lenzen, 2008a] and can be overwhelmed by redox imbalance arising from 
overproduction of ROS/RNS. The consequence of this redox imbalance are lipid 
peroxidation, protein oxidation, DNA damage and interference of reactive species 
with signal transduction pathways which contribute significantly to P-cell dysfunction 
and death in Type 1 and Type 2 diabetes mellitus [Pacher et al., 2005; Lenzen, 2008b]. 
Quite similar is the case with acinar cells, mainly involved in the secretion and 
synthesis of digestive enzymes. There are numerous indications that ROS/RNS play a 
significant role in chronic and acute pancreatitis [Rau et al., 2000; Sandstrom et al., 
2005; Shimizu, 2008]. Primary injury to acinar cells results in intracellular 
trypsinogen activation and inhibition of acinar cell secretion followed by ROS 
production leading to damage of biomolecules, membranes and activation of 
inflammatory cells which produce more ROS/RNS, responsible for acinar necrosis 
and amplification of the inflammation in pancreas. Furthermore, zymogen granules. 
the most abundant organelle in acinar cells lack full set of scavenger characteristics of 
intact cells [Niederau et al., 1996] hence are liable to oxidative damage. The structural 
and functional impairment of these granules leads to leakage of trypsin and cell 
damage enhancement. Oxidative and nitrosative stress [Ischiropoulos et al., 2003; 
Ghafourifar et al., 1999] has been documented in pancreatic tissue by detection of 
ROS generation [Urunuela et al., 2002] and accumulation of products of ROS-
mediated lipid peroxidation, protein oxidation and depletion of low molecular weight 
antioxidants [Rau et al., 2000]. 
Antioxidative and antinitrosative stress activities of caffeic acid, 
quercetin and curcumin: protection against free radicals 
Knowledge about prevention of protein oxidation is cursory. Certain approaches 
attenuate the secondary radicals and confer cytoprotection [e.g. mesalamine against 
ONOO'] but fail to affect the radical sinks [Sandoval et al., 1997]. 
Antioxidant agents of natural origin like polyphenols, flavonoids etc. have attracted 
special interest lately, because of their high efficacy and multifaceted health benefits 
[Ullah and Khan, 2008]. Several such natural components have proven to be 
beneficial in various disorders of pancreas like, curcumin against islet cell damage 
[Meghana et al, 2007; Kanitkar et al., 2008], quercetin against beta-cell damage [Kim 
et al., 2007; Coskun et al., 2005] and caffeic acid against pancreatic damage by free 
radicals [Lapidot et al., 2002]. 
Caffeic acid (3, 4-dihydroxycinnamic acid) 
Caffeic acid (CA) [Fig. 10 (C)] is a naturally occurring phenolic compound found in 
many fruits, vegetables, and herbs including coffee [Gulcin, 2006]. It has antioxidant, 
anti-ischemia reperfiision, antithrombosis, antihypertension, antifibrosis, antivirus, 
antitumor and antidiabetic activities. It is known to quench superoxide and hydroxyl 
radicals, and RNS [Gulcin, 2006; Olmos et al., 2008; Takahama et al., 2009]. 
Quercetin (3, 3', 4', 5, 7-pentahydroxyflavone) 
Quercetin [Fig. 10 (B)] is found bound to one or two glucose molecules 
(monoglycoside and diglycoside forms) as one of the most abundant dietary 
flavonoids in apples; black, green and buckwheat tea; onions; raspberries; redgrapes; 
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citrus fruits and other green leafy vegetables [Hertog and Hollman, 1996]. It has been 
shown in vitro to act as an antioxidant [Filipe et al., 2004], inhibit nitric oxide 
pathway [Mu et al., 2001], and have anti-inflammatoiy and anticancer activities 
[Wadsworth et al., 1999; Mertens-Talcott and Percival, 2005]. 
Quercetin and cafFeic acid bear structural groups, responsible for direct scavenging of 
free radicals: o-dihydroxy structure in caffeic acid and in 'B' ring of quercetin and the 
2, 3-double bond in conjugation with the 4-oxo function in the ' C ring and 3- and 5-
hydroxyl groups with 4- oxo function in the 'A' and ' C rings of quercetin [Fig. 10]. 
Curcumin (diferuloyl methane) 
Curcumin a bioflavonoid is the colouring pigment present in rhizomes of Curcuma 
longa. Curcumin has been shown to exhibit antioxidant, anti-inflammatory, antiviral, 
antibacterial, antifungal and anticancer activities and thus has a potential against 
various malignant diseases, diabetes mellitus, allergies, arthritis, Alzheimer's and 
other chronic illnesses [Sreejayan and Rao, 1997; Aggarwal et al., 2007; Dhillon et al., 
2008]. Its polyphenolic structure with two ferulic acids linked via methylene bridge at 
the C atoms of the carboxyl groups [Fig. 10 (A)], double bonds in the alkene part of 
the molecule, hydroxyl groups of the benzene ring and central p-diketone allows it to 
directly scavenge free radicals like nitric oxide, ROS etc. [Sreejayan and Rao, 1997]. 
1.13 DRUG-PROTEIN INTERACTION: EFFECT OF PANCREATITIS 
CAUSING AND ANTIDIABETIC AGENTS 
The binding and interaction of drugs with plasma and tissue proteins strongly affects 
their distribution, metabolism as well as pharmacodynamics and toxic properties. 
Accumulation of drug molecules at certain sites in the body causing a localized high 
concentration, adverse drug reactions [Wen and Ye, 1993] and ligand induced protein 
structure conformational changes [Takeda et al., 1988] are major problems 
complicating drug medical therapy. Therefore, studies analyzing the binding 
mechanism between proteins and drugs and the structure of resulting complexes are of 
particular interest. These works enable to elucidate how ligand affinity is regulated 
and how the protein conformation is altered upon complexation. Acute pancreatitis, 
an autodigestive disorder, typically presents as an acute inflammation of the pancreas. 
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Fig. 10 Chemical structures of A) Curcumin B) Quercetin C) Caffeic 
acid 
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Gallstones and heavy alcohol are major causes of this condition besides 
hypertriglyceridemia, hyperparathyroidism, pancreatic tumors and surgery 
[Greenberger and Toskes, 2006]. Many frequently prescribed drugs are suspected to 
cause acute pancreatitis (AP), referred to as drug induced pancreatits (DIP), 
accounting for atleast 2-5% of reported cases of AP. Drugs commonly associated with 
pancreatitis belong to several classes, like antimicrobials, anti-inflammatory, 
antineoplastic, immunomodulating and cardiovascular agents and antiepileptic dmgs 
(valproic acid, marketed generally as its sodium salt, sodium valproate) [Trivedi and 
Pitchumoni, 2005]. The mechanism of DIP is not clear. However, it may be caused by 
direct toxicity of drugs or by drug induced indirect mechanisms like ischemia, 
intravascular thrombosis and increased viscosity of pancreatic juices. One hallmark of 
AP is cathepsin B mediated trypsinogen activation [Halangk and Lerch, 2000] and 
oxidative/nitrosative stress [Shimizu, 2008]. Valproic acid has been categorised as 
class I medications associated with AP [Trivedi and Pitchumoni, 2005]. 
Valproic acid 
Valproic acid (VPA, 2-propylpentanoic acid/ Sodium 2-propyl pentanoate), an 8-
carbon branched chain fatty acid [Fig. 11 (A)] is an established drug for the treatment 
of epileptic seizures and mania in bipolar disorder [Bowden and Singh, 2005]. VPA is 
an emerging anticancer drug too [Kostrouchova et al., 2007]. However, it is one of 
most incriminate drugs causing AP besides being classified as teratogen [Norgaard et 
al, 2006; Gerstner et al., 2007; Werlin and Fish, 2006]. Other side effects of VPA 
include fatal hepatotoxicity, hyperammonemic encephalopathy and coagulation 
disorders [Gerstner et al., 2007]. No relationship between the occurrence of 
pancreatitis and duration of VPA therapy, dosage and serum level has been 
documented [Werlin and Fish, 2006]. Research indicates that VPA's cytotoxic 
activity is the result of generation of hydrogen peroxide and production of highly 
reactive hydroxyl radicals [Graf et al., 1998; Kawai and Arinze, 2006]. 
Anitdiabetic drugs may be subdivided into six groups, insulin, sulfonylureas, 
alphaglucosidase inhibitors, biguanides, meglitinides and thiazolidinediones. Diabetes 
is characterized by insufficiency in insulin secretion and/or action. Increased 
production of ROS/RNS is also observed in diabetes [Lenzen, 2008a; 2008b]. Since 
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Fig. 11 Chemical structures of A) Valporic acid B) Metformin 
hydrochloride C) Glimepiride 
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(C) Glimepiride 
the introduction of insulin in the 1920s as a treatment for diabetes [Banting and Best, 
1990], it is considered to be the most effective treatment. 
Metformin hydrochloride 
Metformin hydrochloride [N, N'-dimethylimidodicarbonimidic diamide 
hydrochloride. Fig. 11 B] is the only member of biguanide class of 
antihyperglycemics prescribed with increasing frequency for treatment of Type 2 
diabetes. Its overdosage and chronic use is related to incidences of lactic acidosis. 
Glimepiride 
Glimepiride [Fig. 11 C] is a hypoglycemic agent of sulfonylurea class. It acts by 
increasing insulin secretion from pancreas and insulin sensitivity in peripheral cells. 
Sulfonylureas (glimepiride) cause P-cell apoptosis, produce ROS and their prolonged 
exposure causes disturbances in islet cell fimction [Sawada et al., 2008; Del Guerra et 
al., 2005]. 
1.14 SCOPE OF THE THESIS 
Intracellular protein degradation occurs in two major cellular systems: lysosomal and 
non-lysosomal ubiquitin-proteasome systems. In the lysosomal pathway, protein 
degradation is a result of combined random and limited action of cathepsins. Recently, 
a host of functions are annexed to cathepsins, like antigen processing and presentation, 
bone remodelling, apoptosis mediation, etc. [Turk and Turk, 2008]. Potentially highly 
destructive activity of cathepsins can be regulated by their endogenous protein 
inhibitors, members of cystatin superfamily. A balance between proteolytic activity 
and proteinase inhibition is imperative to the appropriate functioning of many 
biological processes. Also, TPIs have been accredited with a multitude of roles and 
their non- or dys- functional states have been incriminated in various pathological 
conditions. This has stipulated the purification and characterization of members of 
cystatin superfamily from varied sources, since the first report of such an inhibitor 
from chicken egg white [Fossum and Whitaker, 1968]. Pancreas is one of the most 
complex tissue of the mammalian body and also capital of proteolytic power. It 
fijnctions to maintain the glucose homeostasis of the body and participates in 
digestion. However, regulation of pancreatic cathepsins by proteinaceous inhibitors 
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remains a less ventured area. 
Keeping this in view, the specific objectives of the planned research included: 
Chapter 1 
Realizing the role of cathepsins in pancreas the importance of thiol proteinase 
inhibitors (TPI) in their regulation was envisaged. Isolation and partial purification of 
TPI from pancreas of goat was performed by gel filtration chromatography. Its 
detailed biochemical characterization was undertaken, which included elucidation of 
its molecular weight, hydrodynamic properties, pH and thermal stability, partial 
amino acid sequence. Its interaction with model cysteine proteinase, papain was 
worked out to determine its kinetic properties. 
Chapter 2 
To assess the conformational stability of the isolated inhibitor, equilibrium 
denaturation studies were conducted with classical denaturants, guanidine 
hydrochloride and urea employing fluorescence and CD spectroscopy. 
Chapter 3 
Cystatins are predisposed to form amyloids. Certain pancreatic proteins are also 
known to undergo fibrillation (e.g. amylin). Thus, experiments were conducted to 
judge the propensity of isolated TPI for fibrillation under various conditions (pH 
variance, presence of organic solvent, trifluoroethanol, TFE) employing Transmission 
electron microscopy and Thioflavin T fluorescence assay. The possibility of 
disintegration of preformed fibrils and inhibition of de novo fibrillation of the isolated 
inhibitor by divalent metal cations, Zn^ ^ and Cu^^ was also studied. 
Chapter 4 
Proteins are most liable to free radical damage because of their abundance. Pancreas 
also has high proclivity of oxidative and nitrosative stress build up because of its 
feeble antioxidant defence. Furthermore, ROS and RNS are recognized as major 
culprits in pancreatitis, P-cell damage in diabetes and pancreatic stellate cell fibrosis. 
Thus affect of various reactive species (a) ROS (b) 'NO (c) H2O2 (d) HOCl, was 
determined on activity and structure of the isolated inhibitor by fluorescence 
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spectroscopy and PAGE. Natural polyphenols and flavonoids, cafFeic acid, curcumin 
and quercetin, offering inexpensive and non-toxic modes of anti-free radical therapy 
were analyzed to ascertain their efficacy and efficiency in preventing ROS/ nitric 
oxide and hypochlorous acid induced damaged to the isolated inhibitor. 
Chapter 5 
Drug-protein interactions are determining factors in the therapeutic, 
pharmacodynamic and toxicological drug properties. Experiments were conducted to 
find out the effects of pancreatitis causing sodium valproate and antidiabetic agents 
(insulin, metformin, glimepiride) on structure and function of the purified inhibitor 
employing UV, Fluorescence and CD spectroscopy and PAGE. 
The results of the present studies showed the presence of a 44 kDa thiol proteinase 
inhibitor in goat pancreas subsequently named as PTPI. It was found to be highly 
specific and efficient inhibitor of CPs. Its physical, kinetic and biochemical properties 
commensurate with the cystatin superfamily signatures. The likelihood of its being 
amyloidogenic was proved by transmission electron microscopy (TEM) and ThT 
fluorescence. PTPI was found vulnerable to ROS, nitric oxide and hypochlorous acid. 
However, curcumin, quercetin and cafFeic acid protected the free radical inflicted 
structural and functional alterations. Complexation with drugs caused significant 
conformational and functional changes in PTPI. Conclusively, these results forestall 
the significance of PTPI in vivo, in pancreatic (patho) physiology. 
51 

[II] MATERIALS AND METHODS 
[A] MATERIALS 
All chemicals used were of the finest quality commercially available and their sources 
are indicated against them. 
Sisco Research Lab (SRL, India) 
Acetic acid, Acrylamide, Ascorbic acid, n-Butanol, Casein, Coommassie brilliant 
blue-R250, Copper sulphate, L-cysteine, 5, 5'-Dithio-bis 2-nitrobenzoic acid 
(DTNB), Folin ciocaUeau's phenol reagent. Glycine, Glucose, Glutathione reduced, 
Hydrogen peroxide, Mannitol, Methanol, N N' methylene bisacrylamide. Phenol, 
Potassium iodide, Sodium acetate. Sodium azide. Sodium benzoate, Sodium 
carbonate. Sodium chloride. Sodium hydroxide. Sodium potassium tartarate. Urea, 
Uric acid. 
Qualigens, India 
Ammonium persulphate. Ammonium sulphate, Bromophenol blue, Disodium 
hydrogen phosphate, Ethanol, Ethylene diamine tetra-acetic acid (EDTA), 
Formaldehyde, Glycerol, Isopropanol, Monosodium dihydrogen phosphate, Silver 
nitrate. Sodium thiosulphate. Sodium dodecyl sulphate. Sulphuric acid, TEMED, 
Trichloroacetic acid (TCA), Tris-(Hydroxymethyl) aminomethane. Zinc chloride. 
Sigma Chemical Co., USA 
Agarose, l-Anilinonaphthalene-8- sulphonic acid (ANS), Anti-rabbit alkaline 
phosphatase (conjugate). Blue dextran. Bovine serum albumin. Bromelain, Caffeic 
acid, Catalase, Chelex medium, Chymotrypsin, Curcumin, Ficin, Griess reagent, 
Guanidine HCl (GdnHCl), Hypochlorous acid, 2-mercaptoethanol, Ovalbumin, 
Papain, Pepsin, p-nitro phenyl phosphate, PVDF membrane, Quercetin, Riboflavin, 
Sephacryl S 100-HR, Sodium nitrite. Sodium nitroprusside, Thioflavin T, 
Trifluoroethanol (TFE), Trypsin. 
Genei Pvt. Ltd., Bangalore, India 
Freund's complete and incomplete adjuvant. Molecular weight markers-PMW-M. 
Others Sodium Valproate (Microlabs Ltd., TN, India), Glimepiride (Aventis Pharma 
Ltd., Goa, India), Huminsulin R (Eli Lilly & Co. (India) Pvt. Ltd. Gurgaon, Haryana), 
Glycomet- 850 (Metformin hydrochloride) (USV Ltd., Solan, HP, India), 
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[B] METHODS 
2.1 PURIFICATION OF THIOL PROTEINASE INHIBITOR 
FROM GOAT (CAPRA HIRCUS) PANCREAS 
Fresh pancreatic tissue (100 g) (obtained from local slaughter house) was 
homogenized in 50 mM sodium phosphate buffer (200 ml, pH 7.5) containing 0.15 M 
sodium chloride (NaCl), 3 mM EDTA and 2% n-butanol. After centrifugation at 5000 
rpm for 15 min at 4°C in a Beckman J-21 cooling centrifuge, pellet having cell debris 
was discarded and the supernatant was further processed. 
Alkaline treatment 
The supernatant was adjusted to pH 11.0 by 3 M sodium hydroxide and incubated for 
30 min at 4°C. The pH was then brought back to 7.5 with glacial acetic acid. The 
precipitated proteins were removed by centrifligation at 8000 rpm for 30 min at 4 C. 
Acetone Fractionation 
The supernatant was fractionated with equal volume acetone at 4 C with stirring, over 
a period of 10 min. The precipitate was removed by centrifizgation (at 8000 rpm for 
20 min at 4'C) and discarded. A further portion of acetone equal in volume to the first 
was added to the supernatant as before. The precipitate was collected by 
centrifugation at 11,000 rpm for 30 min at 4 C and the supernatant discarded. 
Ammonium Sulphate Fractionation 
The precipitate dissolved in minimum amount of 50 mM sodium phosphate buffer 
(pH 7.5) was fractionated between 20 and 80% ammonium sulphate saturation. The 
precipitated protein was procured by centrifugation at 11000 rpm for 30 min at 4 C. 
The precipitate was dissolved in 50 mM sodium phosphate buffer pH 7.5 and dialyzed 
thrice against 100 ml volumes of the same buffer containing 0.15 M NaCl. 
Gel Filtration Chromatography 
A Sephacryl S 100-HR column (60 x 1.7 cm) was prepared as recommended by 
Peterson and Sober [1962]. Preswollen gel suspended in ethanol was soaked in 
sufficient amount of double distilled water and washed atleast thrice. The gel fines 
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were removed by suspending the gel in two to four fold excess of 50 mM sodium 
phosphate buffer, pH 7.5 and gel was allowed to settle down. The remaining gel in the 
supernatant was rapidly removed by suction. A glass column mounted on a sturdy 
vertical support was filled to one third of its length with operating buffer in order to 
check leaks and flush air bubbles from the dead space. The deaerated gel slurry was 
poured with the help of glass rod in to the column with care. The column was left 
standing overnight. Flow rate was increased gradually and after accomplishing a 
constant flow rate higher than that required for final elution, the column was adjusted 
to the required flow rate. The packed column was thoroughly washed with two bed 
volumes of operating buffer (50 mM sodium phosphate buffer, pH 7.5). In order to 
check uniform packing and to determine void volume of the column, 2% (w/v) 
solution of blue dextran in 50 mM sodium phosphate buffer (pH 7.5) was passed 
through the column. The volume of the blue dextran and protein solution applied was 
not more than 2-3% of the total bed volume. The dialyzed sample was subjected to gel 
filtration chromatography on Sephacryl S-100 HR column (60 x 1.7 cm) equilibrated 
with 50 mM sodium phosphate buffer pH 7.5. The flow rate of the column was 15 
ml/h. Fractions (5 ml) were collected and assayed for protein and thiol proteinase 
inhibitor (TPI) activity. Homogeneity was analyzed by 7.5% PAGE. 
2.2 COLORIMETRIC ANALYSIS 
Determination of Protein Concentration 
Protein concentration was estimated by the method of Lowry et al. [1951]. Aliquots of 
protein solution were taken and final volume was made up to 1 ml with distilled 
water. 5 ml of alkaline copper reagent (containing one part of 1 % (w/v) copper 
sulphate and 2 % (w/v) sodium potassium tartarate in 1 % (w/v) sodium hydroxide 
and sodium carbonate) was added and after 10 min of incubation at room temperature 
(RT), 0.5 ml of 1 N Folin Ciocalteau's phenol reagent was added. The tubes were 
instantly vortexed. The colour developed was read at 660 nm after 30 min in 
Shimadzu UV mini-vis spectrophotometer UV-1700 against a reagent blank. A 
standard curve was prepared using BSA. 
Carbohydrate Estimation 
The procedure described by Dubois [1956] was followed. 2 ml aliquots containing 
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10-70 ng of protein was pipetted in to a set of test tubes and 0.05 ml of 80% phenol 
was added. This was followed by the addition of concentrated sulphuric acid. The 
tubes were allowed to stand for 10 min at 30°C. The colour intensity was measured at 
490 nm for the quantification of hexose content. Glucose was used as standard. 
Thiol Group Estimation 
The procedure described by Ellman [1959] was followed for estimating the thiol 
groups of isolated inhibitor. SDS and P-mercaptoethanol induced appearance of free 
thiol group in TPI was followed by titration with DTNB reagent. Appropriate aliquots 
of 0.2 ml native, SDS and P-mercaptoethanol treated inhibitor were mixed with 0.1 ml 
of DTNB reagent (prepared by dissolving 40 mg DTNB in 100 ml of 0.05M Tris-
EDTA buffer, pH 8.0) in a total volume of 3.1 ml. The absorbance was read after 15 
min at 412 nm. Free thiol concentration was calculated from the absorbance using 
molar extinction coefficient (s) of 13,600 M'' cm'' for the released thpjitpeb^ffioitj^^. 
acid. A standard plot was prepared using L-cysteine. ••' > 
Assay of Thiol Proteinase Inhibitory (Cystatin) Activity % . -^  ^  
Inhibitory assay of TPI was performed as described by Kunitz [1947]. Puri^'ea'^\¥l-' 
was examined for its ability to prevent thiol proteinases from digesting casein. For 
determination of inhibitory activity, papain was activated in presence of 0.14 M L-
cysteine and 0.045 M EDTA for 10 min prior to incubation of papain-PTPI complex 
for 30 min at 37°C in 50 mM sodium phosphate buffer, pH 7.5. The enzyme inhibitor 
complex was fiirther incubated with casein for 30 min at 37 C and the reaction was 
stopped by addition of 10% TCA. Acid insoluble material was removed by 
centrifligation at 2500 rpm for 20 min. The supernatant was analysed for acid soluble 
peptides with Folin's phenol reagent as described by Lowry et al. [1951]. Ficin 
inhibition was also assayed by similar method. 
Assay of Caseinolytic activity of Bromelain 
The proteolytic activity of bromelain was measured according to the method of 
Murachi and Neurath [I960]. The enzyme was activated at 37°C for 10 min in the 
presence of 0.14 M L-cysteine. Then the volume was made up to 1 ml by 50 mM 
sodium phosphate buffer pH 7.5. 1 ml of 0.5% casein was added and incubated for 30 
min at 37°C. The reaction was stopped by addition of 1 ml of 10 % TCA. Acid 
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insoluble material was removed by centrifugation at 2500 rpm for 15 min. The 
supernatant was analysed for acid soluble peptides by Folin's phenol reagent by the 
method of Lowry et al. [1951]. 
Thermal stability 
Fifty micrograms of the inhibitor was incubated in 50 mM sodium phosphate buffer 
(pH 7.5) at various temperatures for 30 min. These samples were rapidly cooled in ice 
cold water bath and checked for residual activity against fifty micrograms of papain. 
Fifty micrograms of the inhibitor at 90°C was also incubated for different time 
intervals rapidly cooled and residual inhibitory activity measured against papain. 
pH stability 
Fifty micrograms of the inhibitor was incubated with buffers of different pH values 
like 50 mM sodium phosphate buffer (pH 7.0, 8.0), 50 mM sodium acetate buffer (pH 
3.0-6.0) and Tris HCl buffer (pH 9 and 10) for 30 min at 37°C. Aliquots of this 
mixture was used for determination of remaining % inhibitory activity as described in 
the section of assay of proteinase inhibitory activity. 
2.3 SLAB GEL ELECTROPHORESIS 
Polyacrylamide Gel Electrophoresis (PAGE) 
Electrophoresis was performed by the method of Laemmli [1970] using the slab gel 
apparatus manufactured by Biotech, India. Concentrated stock solution of 30% 
acrylamide containing 0.8% N'N' methylene bis-acrylamide and 1.5 M Tris, pH 8.8, 
were mixed in appropriate portion to give the desired concentration of gel. It was 
then poured in to the mould formed by glass plates (8.5x10 cm) separated by 1.5 
mm thick spacers. Bubbles and leak were avoided. A comb providing template for 
seven wells was inserted into the stacking gel solution before the polymerization 
began Polymerization was complete in about 30 min after which the comb was 
removed and wells overlaid with running buffer. Routinely 7.5% and 12.5% gels 
were used. Samples containing 40-60 ^g of protein were mixed with one fourth 
volume of sample buffer (62.5 mM Tris HCl pH 6.8, 10% (v/v) glycerol and 0.001% 
bromophenol blue). Electrophoresis was performed at 100 V in the electrophoresis 
buffer containingl92 mM glycine and 25 mM Tris-HCl (pH 6.8) until the tracking 
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dye reached the bottom of the gel. 
SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis was performed by the 
Tris-glycine system of Laemmli [1970] using slab gel electrophoresis apparatus. 
Concentrated stock solution of 30% acrylamide containing 0.8% N N' methylene 
bisacrylamide and 1.5 M Tris, pH 8.8 were mixed in appropriate proportions to give 
desired percentage of gel. Protein samples were prepared in solution containing 62.5 
mM Tris-HCl pH 6.8, 10% (v/v) glycerol, 2% (w/v) SDS, 5% (v/v) 2-
mercaptoethanol and 0.001% (w/v) bromophenol blue. The samples were incubated 
at 100°C for 5 min. Electrophoresis was performed at 100 V till the tracking dye 
reached the bottom of the gel. Running buffer used during electrophoresis contained 
1% SDS in addition to 192 mM glycine and 25 mM Tris-HCl (pH 6.8). 
Staining of the Gel 
Coommassie Brilliant Blue Staining 
After electrophoresis was complete the protein bands were visualized by staining the 
gel with five gel volumes of 0.25% coommassie brilliant blue R-250 in 50% 
methanol and 10% acetic acid for atleast 4 h. For destaining the gels were incubated 
in 5% methanol and 7.5% acetic acid at RT with shaking. 
Silver Staining 
The gel after electrophoresis was silver stained by Blum's silver stain method 
[Nesterenko, 1994]. The staining was initiated by fixation for 10 min in 50% 
acetone, 1% trichloroacetic acid and 0.015% formaldehyde with subsequent 
washings. After a second fixation in 50%) acetone only, the gel was pretreated with 
10%) sodium thiosulphate and then impregnated with 20%) silver nitrate, 37% 
formaldehyde and 10% sodium thiosulphate for 30 s to 1 min the reaction was 
stopped by 1% glacial acetic acid and incubated for 15 min in 1% glycerol after 
rinsing with distilled water. 
2.4 MOLECULAR WEIGHT DETERMINATION 
The molecular weight of purified goat pancreatic thiol proteinase inhibitor (PTPI) 
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was determined under native and denaturing (reducing and non-reducing) conditions 
by gel filtration chromatography and SDS-PAGE, respectively. 
Molecular weight determination by Gel Filtration Chromatography 
The molecular weight of native PTPI was computed from its elution volume on a 
Sephacryl S 100-HR column (60 x 1.7 cm). The column was calibrated by 
determining the elution volume of some marker proteins- Trypsin (23 kDa), Pepsin 
(35 kDa), Ovalbumin (43 kDa) and BSA (66 kDa). This data was analyzed 
according to the theoretical treatment by the method of Andrews [1964]. The linear 
plot between VeA^ o and log M was used for calculating the molecular weight of 
PTPI where Veis the elution volume of the protein and Vo is the void volume of the 
column determined using blue dextran. 
Molecular weight determination by SDS-PAGE 
Molecular weight of PTPI under denaturing conditions was calculated by the 
procedure of Weber and Osbom [1969] using SDS-PAGE. The mobilities of marker 
proteins determined under identical conditions were plotted against the logarithms of 
molecular weight. The standard proteins used were Phosphorylase b (97.4 kDa), 
Bovine serum albumin (68 kDa), Ovalbumin (43 kDa), Carbonic anhydrase (29.1 
kDa), Soyabean trypsin inhibitor (20.1 kDa) and Lysozyme (14 kDa). The analysis 
of data indicated a linear relationship between log M and relative mobility (RM) and 
the plot was used for calculating the molecular weight of PTPI. 
2.5 IMMUNOLOGICAL PROCEDURES 
Production of Antiserum 
Antibodies against PTPI were raised by injecting 300 ^g of the purified inhibitor in 
Freund's complete adjuvant subcutaneously into healthy male albino rabbits. The 
injection was repeated every week in Freund's incomplete adjuvant and the rabbit 
o 
was bled every second week. The blood collected was allowed to coagulate at 22 C 
for 3 h. The antisera decomplimented at 57°C for 30 min and was stored at -20 C. 
Immunodiffusion 
Immunodiffusion was performed by the method of Ouchterlony [1962]. 1% agarose 
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in normal saline containing 2% sodium azide was poured in glass petridish and 
allowed to solidify at RT. Required number of wells was cut. 15 |il of suitably 
diluted antiserum and required amount of antigen (60 ^g) were added in different 
wells. The reaction was allowed to proceed for 12-24 h in a moist chamber at RT. 
Direct binding ELISA 
The generation of antigen specific antibody was measured in the sera of PTPI 
immunized rabbits by the technique of direct binding ELISA (enzyme linked 
immunosorbent assay) as given by Voller et al. [1976]. Ninety six wells of micro-
titre plate (immulon 2 HB, Dynex, USA) were coated overnight with 100 |al of 
antigen at 4°C. The plate was washed thrice with TBS-T buffer (Tris buffered saline 
Tween 20, pH 7.4, 20 mM Tris, 14.3 mM sodium chloride, 200 mg potassium 
chloride and 5 ml Tween 20 dissolved in 1 1 of distilled water and pH adjusted to 
7.4 by 1 N HCl). The unoccupied sites were saturated by incubation with 150 
iag/200 ml of 1.5% milk in TBS (Tris buffered saline, pH 7.4, 20 mM tris, 150 mM 
sodium chloride) for 5-6 h at RT. Plates were washed twice with TBS-T. The test 
and control wells were then loaded with 100 i^l of serially diluted serum. The plate 
was incubated for 2 h at RT and then overnight at 4°C. 100 1^ of appropriate 
conjugate of anti-rabbit alkaline phosphatase (1:3000) was coated in each well and 
kept for 2 h at RT. After regular washing with TBS-T and distilled water, the 
substrate p-nitro phenyl phosphate (5 ng/100 ml of 50 mM bicarbonate buffer, pH 
9.5, containing 0.02% sodium azide) was added in each well and incubated for 30-
45 min. The reaction was stopped by addition of 100 |al of 3 M NaOH in each well. 
The absorbance of each well was monitored at 405 nm on a qualigens ELISA reader. 
2.6 KINETICS OF INHIBITION 
Stoichiometry of Proteinase Inhibition 
Papain was used for the titration of PTPI. The inhibitory activity of TPI was assessed 
by its ability to inhibit caseinolytic activity of papain by the method of Kunitz [1947] 
The concentration of papain was varied from 0.01-0.0 jiM whereas the inhibitor 
concentration was fixed at 0.06 ^M. Identical experiments were carried out for PTPI 
with other proteinases, ficin and bromelain using casein as substrate [Kunitz, 1947; 
Murachi and Neurath, I960]. 
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Inhibition constant (Ki) determination 
Ki determinations were carried out by lowering the enzymes and inhibitor 
concentrations to obtain a non-linearity of dose-response curves. Papain, ficin and 
bromelain were used at a concentration of 0.06 [oM to react with inhibitor in varying 
concentrations from 0.01 to 0.24 |JM. Residual activity was measured by the method 
of Kunitz [1947] using casein as a substrate. Four different substrate concentrations 
were used 0.5 Km, 1 Km, 2 Km and 3 Km and with Km = 2.4 mM. The results were 
analyzed by the procedure of Krupka and Laidler [1959]. The linear equation given by 
Henderson [1972], is presented as follows, 
[I]„ / 1 - (Vi A^o) = Ki [l+[S]o / Km] Vi A „^ + [E]o 
Where, [I]o, [E]o and [S]o are the initial concentrations of Inhibitor, Enzyme and 
Substrate, respectively. Vo is the velocity in absence of inhibitor and Vi is the velocity 
in presence of inhibitor. The plot of [I]o / 1- (Vi /Vo) against Vo /Viis a straight line, 
the slope of which gives, 
Ki(app) = Ki[l+[S]„/Km] 
True Ki was obtained from a replot of Ki (app) against [S]o. 
Determination of dissociation rate constant (KLi) 
For the dissociation rate constant, the conditions for maximal association between 
proteinase and inhibitor were achieved before the reaction was shifted towards 
dissociation by adding excess substrate which binds the entire free enzyme. 
Dissociation of EI complex obeys first order kinetics. Thus, integrated form of the 
dissociation rate equation is given by: 
In ([EI]/ [EI]o) = Ki t 
From which half life of the complexes may be calculated by rearranging as follows: 
tK = 0.693/Ki 
Determination of association rate constant (K+i) 
Using the values of dissociation constant and inhibition constant derived as explained 
above, association rate constant, K+i, was determined using the relation 
K+i = K i / Ki [Abrahamson et al., 1986] 
60 
2.7 N-TERMINAL ANALYSIS 
The sequencing of 24 amino acid residues from N-terminal of larger subunit of PTPI 
was carried out on Shimadzu ppsq-21 Sequencer which employs Edman degradation 
to sequentially cleave and identify amino acids starting from amino terminus of the 
protein [Edman and Begg, 1967]. The highly purified protein was transferred to the 
PVDF membrane by western blotting before amino acid analysis. 
Western Blotting 
a. Buffers used: CAPS buffer- 10 x stock (100 mM, pH 11): 22.13 g of 3-
[cyclohexylamino] l-propane-sulphonic acid was dissolved in 980 ml of 
deionized water and titrated with 2 M NaOH (15 ml) to pH 11. Deionized water 
was added to make final volume to 1 1 and the buffer was chilled at 4°C before 
use. Transfer buffer- 2 1 of buffer was prepared by mixing 200 ml of 10 x stock 
buffer, 200 ml of methanol and 1600 ml of deionized water. 
b. Procedure: The PVDF membrane and the filter paper were cut according to the 
gel dimensions. The PVDF membrane was made wet in 100% methanol for 30 s, 
then soaked in distilled water for 5 min and then placed in a dish containing 
blotting buffer for 15 min. The gel, filter paper and fiber pads are allowed to 
equilibrate in transfer buffer for 15 min to 1 h depending on the gel thickness. 
The transblotting sandwitch is assembled as filter pad, filter paper, PVDF, gel, 
filter paper and then again pad. After firmly closing the cassette it was locked 
properly taking care not to move the transblotting sandwitch. The cassette was 
placed in tank filled with transfer buffer completely. The lid was put and power 
supply plugged in. The blot was run at 30 V overnight. Upon completion of the 
run, the transblotting sandwitch was disassembled to remove the PVDF 
membrane for development. The membrane was rinsed with distilled water and 
then stained with 0.1 % coommassie blue R-250 in 10% acetic acid and 50 % 
methanol for the minimum time necessary to visualize the band of interest. The 
PVDF membrane was destained for atleast 2 h in 10% acetic acid. After 
destaining the PVDF membrane was rinsed in 100% methanol and then soaked 
in distilled water for 15 min to remove the excess acetic acid and methanol. 
Finally the PVDF membrane was air dried and placed in a new sterile container 
til! used for sequencing. 
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Hydropathy plot 
The hydropathy profiles were calculated using the mean segment approach, i.e. 
determining the average hydropathy within a segment length of four residues, the 
segment being advanced one residue at a time from the sequence of N-terminal 24 
residues [Kyte and Doolittle, 1982]. 
2.8 SPECTRAL ANALYSES 
Absorption Difference Spectra 
Ultraviolet (UV) absorption difference spectra was measured for PTPI (2.66 i^M) 
along with activated papain with a molar ratio of 1:1 at 25°C. Spectra were recorded 
by measuring the absorption between 200-350 nm on Cintra-10 spectrophotometer in 
a cuvette of 1 cm path length. Appropriate controls of the solvent buffer were run and 
corrections were made wherever necessary. 
Fluorescence spectroscopy 
Fluorescence measurements for papain, PTPI and PTPI-papain complex were 
performed on Shimadzu spectrofluorimeter model RF-540 equipped with data 
recorder DR-3. The excitation wavelength was 280 nm and the slits were set at 5 nm 
for excitation and 10 nm for emission. The path length was 1 cm and the emission 
wavelength range was 300-400 nm. The protein concentration used in the 
fluorescence measurements was 2 ^M. Each spectrum was the average of at least 
three scans. Appropriate controls were run and corrections made wherever necessary. 
Circular Dichroism (CD) Spectroscopy 
Circular dichroism measurements were carried out on a Jasco Spectropolarimeter 
model J-720 using a SEKONIC-XY plotter (model SPL-430 A) with thermostatically 
controlled cell holder attached to a NESLAB water bath model RTE 110 with an 
accuracy of ± 0.10°C. The instrument was calibrated with d-10-Camphorsulphonic 
acid. The concentration of inhibitor for far UV-CD analysis was (1.73-1.70 |iM). The 
path length used was 0.1cm. The spectra were recorded with a scan speed of 20 nm 
min"^  and with a response time of 4 s. The concentration of the inhibitor and papain 
for far UV-CD spectral analysis was 0.2 mg/ml and pathlength was 0.1 cm. Each 
spectrum was recorded as an average of 5 scans. The emission wavelength range was 
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200-250 nm. Change in secondary stmcture of PTPI on interaction with activated 
papain (activated with 0.14 M cysteine and 0.045 M EDTA) at a molar ratio of 1:1 
was monitored. The a helical content of PTPI was calculated from the MRE value at 
222 nm using the following equation [Chen et al., 1972] 
% helix = [(MRE222- 2340)/ 30300] x 100 
2.9 DENATURING ACTION OF GUANIDINE HYDROCHLORIDE 
AND UREA TOWARDS PANCREATIC THIOL PROTEINASE 
INHIBITOR 
Assay of inhibitory activity of PTPI in the presence of GdnHCl/ urea 
The inhibitory activity of PTPI under native conditions was assessed by its ability to 
inhibit caseinolytic activity of papain by the method of [Kunitz, 1947]. The purified 
inhibitor (1 ^M) was incubated with increasing concentrations of GdnHCl (0.5-6 M) 
and urea (0.5-9 M) at 25°C for 2 h before the activity was measured. Activity of 
untreated PTPI was taken as 100 %. 
Intrinsic fluorescence studies of PTPI in the presence of denaturants 
(GdnHCl and Urea) 
The fluorescence was recorded in the wavelength range of 300-400 nm after exciting 
the protein solution at 280 nm for total protein fluorescence. The slits were set at 5 nm 
for excitation and emission. The path length of the sample used was 1 cm. The protein 
concentration was taken as 1 ^M. PTPI was incubated with increasing concentration 
of GdnHCl (0.5-6 M) and urea (0.5-9 M) for 2 h at RT before the spectra were 
recorded. Appropriate controls were run and corrections were made wherever 
necessary. Each spectrum was an average of three scans. 
Refolding was also studied by fluorescence spectroscopic and activity measurements 
The refolding reaction was induced by rapidly diluting (1.50 fold) aliquots of PTPI 
denatured at desired GdnHCl/urea concentrations in the same buffer containing 
appropriate concentrations of GdnHCl/urea vigorously vortexing the solution at the 
same time. The spectra and activity were determined at regular time intervals till 24 h. 
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Extrinsic/ANS fluorescence studies of PTPI in the presence of 
denaturants (GdnHCI and Urea) 
The binding of ANS (l-anilinonapthalene-8-sulphonic acid) to PTPI in the absence 
and presence of increasing concentration of GdnHCI (0.5-6 M) and urea (0.5-9 M) 
was studied by exciting the dye at 380 nm and the emission spectra were recorded 
from 400-600 nm wavelength range. The molar ratio of protein to ANS was 
Far UV-CD measurements of PTPI in presence of GdnHCI and Urea 
Secondary structural changes of PTPI on incubation with varying concentrations of 
GdnHCI (0.5-6 M) and urea (0.5-9 M) were measured at 25°C. The concentration of 
PTPI was 1.73-1.70 ^M and the path length was 0.1 cm. Each spectrum was recorded 
as an average of five scans. The spectra obtained were normalized by subtracting the 
baseline recorded for the buffer having the same concentration of denaturants under 
similar conditions. Data were expressed in terms of fraction denatured (/d), calculated 
from the equation [Tanford, 1968], 
/d = (Y-Y„)/(Yd-Y„) 
Where Y is the observed variable parameter and Yn and Yd are the values of the 
variable characterstics of the folded and unfolded conformations. A linear 
extrapolation of the baselines in the pre- and posttransitional regions was used to 
determine the fraction of unfolded protein within the transition region by assuming a 
two state mechanism of unfolding. 
2.10 IN VITRO STUDY OF FIBRILLATION OF PTPI 
Acid Denaturation Study 
PTPI was allowed to undergo acid denaturation by subjecting it to buffers of varying 
pH range from pH 7.0 to pH 2.0. The buffers used were 50 mM solution of 
glycine/HCl (pH 2.0), sodium acetate (pH 3.0-5.0) and sodium phosphate (pH 6.0-
7.0). pH measurements were carried on a Metzer Optical Instruments (Pvt. Ltd., 
India), pH meter model 603M with a least count of 0.01 pH unit. PTPI was incubated 
with the respective buffer of desired pH at 25°C and allowed to equilibrate for 4 h 
before any spectrophotometric measurements were taken. 
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Spectrophotometric measurements 
The fluorescence was recorded in the wavelength range of 300-400 nm after exciting 
the protein solution at 280 nm for total protein fluorescence. The slits were set at 5 nm 
for excitation and emission. The path length of the sample used in the fluorescence 
measurements was 1 cm. The protein concentration was taken as 1 ^M. ANS binding 
to PTPI at varying pH was studied by exciting the dye at 380 nm and the emission 
spectra were recorded fi"om 400-600 nm wavelength range with a 5 nm slit width for 
excitation and emission. ANS to protein molar ratio of 1:50 was used for each 
respective measurement. Each spectrum was an average of three scans. Far UV CD 
spectra of PTPI at varying pH range were also measured. The concentration of PTPI 
used was 1.70 ^M. Rest conditions were same as those described in section 2.9. 
Effect of trifluoroethanol (TFE) on acid induced state of PTPI 
PTPI (1 ^M) was incubated in different concentrations of TFE (0-20% v/v) in 50 mM 
sodium acetate buffer (pH 3.0) for 2 h before the measurements. The intrinsic and 
extrinsic fluorescence studies were conducted in a manner similar to that given for 
acid denaturation studies. Far UV-CD spectra of TFE treated PTPI were also recorded 
in the wavelength region of 200-250 nm. The concentration of the inhibitor used was 
1.70 i^M and pathlength was 0.1 cm. Each spectrum was recorded as an average of 
five scans. The spectra obtained were normalized by subtracting the baseline recorded 
for the buffer having the same concentration of TFE under similar conditions. 
Binding of ANS to PTPI under above conditions was studied by exciting the dye at 
380 nm and recording emission spectra from 400-600 nm. Excitation and emission 
slits were 5 nm. Since ANS shows emission in TFE all spectra were corrected for 
blanks. Similar experiments were conducted for PTPI at pH 2.0 and at 1.0. 
Induction of PTPI Fibril Formation 
50 \xM PTPI was incubated with buffers of pH 1.0, 2.0 and 3.0 containing 0.15 M 
sodium chloride, 0.05% sodium azide in presence or absence of 10% TFE. Before 
incubation, each sample was passed through a 0.2 ^m filter to remove traces of 
aggregated material. Fibril growth was followed in six samples: (1) PTPI at pH 1.0, 
(2) PTPI at pH 1.0 with 10% TFE, (3) PTPI at pH 2.0, (4) PTPI at pH 2.0 with 10% 
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TFE, (5) PTPI at pH 3.0, (6) PTPI at pH 3.0 with 10% TFE. 50 ^M PTPI at pH 7.5 
served as control. 
Fibril Formation in the Presence of Divalent Metal Ions, Cu and Zn 
To study the effects of copper and zinc on fibrillation of PTPI 
Prior to induction of fibril formation, either 50 \iM Cu^^ or 10 ^M Zn^^ was added to 
the mixture (50 \iM PTPI incubated with buffer of pH 3.0 containing 0.15 M sodium 
chloride, 0.05% sodium azide, 10% TFE). Chelating buffers were prepared using 
chelex medium. The protein solutions were exchanged with chelating buffer of pH 7.0 
prior to fibrillation assays. Either 50 |aM CuS04 or 10 |iM ZnCb dissolved in water 
was added to the buffers. After mixing the solutions, it gave PTPI to Cu^^ ratio of 1:1 
and PTPI to Zn^^ ratio of 5:1. 
Either Cu^" (10-150 jiM) or Zn^^ (2-50 i^M) was added to preformed fibrils at pH 3.0. 
Thioflavin T Fluorescence Measurements 
The Shimadzu spectrofluorimeter model RF-540 equipped with data recorder DR-3 
was used for measuring the fluorescence spectra. Excitation was at 440 nm and 
spectra were recorded from 455 to 600 nm. Excitation and emission slits were set at 5 
nm and 10 nm, respectively. Five ^1 of the protein solution in which fibrils were 
growing were dissolved in 600 ^1 of the ThT buffer (pH7.5, 25 mM phosphate buffer, 
0.15 M NaCl, 20 ^M ThT) just before the measurements. At regular time intervals 
aliquots of the protein samples were withdrawn to perform ThT assay. 
Electron Microscopy 
A 3 ^1 sample of protein solution was placed and dried for 5 min on formwar coated 
carbon grids. After excess fluids were micropipetted from the grid surface, the grid 
was washed with water and stained with 0.3% aqueous uranyl acetate. Excess stain 
was removed and the samples were dried at RT. The samples were analyzed at 10 kV 
in a JEM 1010 transmission electron microscope. Images were captured with an AMT 
digital camera system (AMT, Chazy, NY). 
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2.11 MODIFICATION OF PANCREATIC THIOL PROTEINASE 
INHIBITOR BY REACTIVE SPECIES 
REACTION OF PHOTOSENSITIZED RIBOFLAVIN WITH PTPI 
PTPI (1 )uM) was photoilluminated with increasing concentration of riboflavin (5-50 
i^M) in a final volume of 1000 |il at RT for 30 min. Riboflavin was freshly prepared at 
2 mM concentration in 50 mM sodium phosphate buffer (pH 7.5). PTPI (1 ^M) was 
also photoilluminated for different time intervals (0-60 min) with 40 |uM riboflavin in 
a final reaction volume of 1000 [il at RT. For light incubations tubes were set at a 
distance of 1 cm fi-om 40-watt cool fluorescent lamp. The light intensity was 0.768 
milliwatt at a distance of 1 cm measured by a Model 351 A-Powermeter. The treated 
protein samples were subjected fluorescence measurements, assay of thiol proteinase 
inhibitory activity and PAGE (as described later). 
Effect of scavengers and natural antioxidants on riboflavin induced 
modifications of PTPI 
To validate the type of fi'ee radical involved in riboflavin induced PTPI modification 
different scavengers were used. PTPI (1 |iM) was photoilluminated in presence of 40 
|iM riboflavin for 60 min, in presence of 25 mM sodium azide, potassium iodide, 
thiourea, mannitol, uric acid and 100 mM ascorbic acid. Protective effect of natural 
antioxidants against riboflavin induced damage to PTPI was also studied. PTPI (1 
^M) was photoilluminated with 40 \iM riboflavin in presence of curcumin (100 pM), 
caffeic acid (350 |iM) and quercetin (350 fxM) for 30 min in a final reaction volume 
of 1000 III. The treated protein samples were subjected to fluorescence measurements, 
assay of thiol proteinase inhibitory activity and PAGE (as described later). 
The stock solution of curcumin and quercetin were prepared in acetone and 
dimethylsluphoxide, respectively. Caffeic acid was dissolved in distilled water. 
Preliminary experiments were conducted with a range of concentrations of curcumin, 
quercetin and caffeic acid against various radicals studied. Only the most effective 
concentration is reported in each case. 
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REACTION OF HYDROGEN PEROXIDE (H2O2) WITH PTPI 
The concentration of H2O2 was estimated prior to experiments by the absorbance at 
230 nm and e = 0.081 mM"' cm"^  [Andreae, 1955]. 
Treatment of PTPI with H2O2 
PTPI (1 |iM) was incubated with (ImM -500 mM) H2O2 in 50 mM sodium phosphate 
buffer (pH 7.5) in a final reaction volume of 1000 nl at RT for 30 min. PTPI (1 jiM) 
was also incubated with 250 mM H2O2 for varying time intervals (0-120 min) in a 
final reaction volume of 1000 x^l at RT. The treated protein samples were subjected to 
fluorescence measurements, assay of thiol proteinase inhibitory activity and PAGE 
(as described later). 
Effect of scavengers and natural antioxidants on H2O2 induced 
modifications of PTPI 
1 |iM PTPI was incubated with 250 mM H2O2 in presence of 25 mM mannitol, 
thiourea, sodium benzoate, sodium azide, glucose, 100 mM ascorbic acid, 100 ng/ml 
catalase, 50 |iM quercetin, 100 |iM curcumin and 60 ^M cafifeic acid in a final 
reaction volume of 1000 |il for 30 min. The treated protein samples were subjected to 
fluorescence measurements, assay of thiol proteinase inhibitory activity and PAGE. 
REACTION OF HYPCHLOROUS ACID (HOCL) WITH PTPI 
HOCl concentration was quantified immediately before use spectrophotometrically at 
290 nm (pH 12, £ = 350 M"' cm'^) [Morris, 1966]. HOCl was diluted in ice-cold water 
[Whiteman et al., 2003] to make a stock solution of 10 mM and stored no longer than 
1 min. After this time, solution was discarded and fi-esh HOCl (10 mM) was made. 
The pH values were adjusted where necessary to pH 7.4 using 1.0 M HCl or NaOH. 
Treatment of PTPI with HOCl 
PTPI (1 ^M) was incubated with HOCl (1-50 jiM) for 30 min or with 5 ^M HOCl for 
varying time intervals (0-30 min) in 50 mM sodium phosphate buffer (pH 7.5) in a 
final reaction volume of 1000 nl at RT. At the end of incubation, HOCl was quenched 
with 100 ^M reduced glutathione. The treated protein samples were subjected to 
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fluorescence measurements, assay of thiol proteinase inhibitory activity and PAGE 
(as described later). 
Effect of scavengers and natural antioxidants on HOCl induced 
modifications of PTPI 
PTPI (1 \iM) was incubated with 5 \iM HOCl in presence of 25 mM sodium benzoate, 
mannitol, glucose, 100 mM ascorbic acid, 100 |iM each of quercetin, curcumin and 
caffeic acid, in a final reaction volume of 1000 \x\. The treated protein samples were 
subjected to fluorescence measurements, assay of thiol proteinase inhibitory activity 
and PAGE (as described later). 
REACTION OF PTPI WITH NITRIC OXIDE (NO) 
Nitric oxide production from sodium nitroprusside 
Sodium nitroprusside (SNP) was used as nitric oxide donor. *N0 generated from SNP 
was measured by Griess Reagent (GR) as described by Green et al. [1982] and 
Marcocci et al. [1994a]. 100 mM of SNP was prepared by dissolving the powder in 
phosphate buffer saline (PBS) pH 7.4. The reaction mixture (2 ml) containing 100 
mM SNP (0.2 ml, final concentration 10 mM) and PBS (1.8 ml) was incubated at 
25°C for 180 min. At 30 min intervals 1 ml aliquots were withdrawn from the 
incubation and diluted with 1 ml of GR. The Griess reaction relies on a 
diazotization. The GR consists of 1% sulphanilamide and 0.1% naphthylenediamine 
dihydrochloride in 2% H3PO4. Nitrite present reacts with sulphanilamide under acidic 
conditions. The resulting compound reacts with naphthylenediamine dihydrochloride 
to form an azo compound which is read at 540 nm [Marcocci et al., 1994a]. The plot 
between the concentration of nitrite and incubation time exhibited the best incubation 
time for nitrite production from SNP. 
Treatment of PTPI with SNP ('NO) 
PTPI (1 ^M) was incubated with 0.05 mM, 1 mM and 10 mM SNP for 30 min or with 
0.05 mM SNP for varying time intervals (0-180 min) in 50 mM sodium phosphate 
buffer (pH 7.5) in a final reaction volume of 1000 1^ at RT. Following the incubation 
samples were subjected to fluorescence spectroscopy, assay of antiproteolytic activity 
and PAGE. 
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Effect of natural antioxidants on SNP induced modification of PTPI 
1 \xM PTPI was incubated with 1 mM SNP for 30 min in presence of 20 pM 
curcumin, 80 [iM quercetin and cafFeic acid, in 50 mM sodium phosphate buffer (pH 
7.5), in a final reaction volume of 1000 1^ at RT. After the incubation samples were 
subjected to fluorescence spectroscopy, assay of antiproteolytic activity and PAGE. 
FLUORESCENCE SPECTROSCOPY 
Intrinsic fluorescence measurements were carried out on a Shimadzu 
spectrofluorimeter model RF-540 equipped with data recorder DR-3 at 25 ± 0.1 C. 
The fluorescence was recorded in the wavelength range 300-400 nm after exciting the 
protein solution at 280 nm for total protein fluorescence. The slits were set at 5 nm for 
excitation and emission. The pathlength of the sample was 1 cm. Appropriate controls 
containing the oxidants used for the treatment were run and correction made wherever 
necessary. Each spectrum was the average of three scans. 
POLYACRYLAMIDE GEL ELECTROPHORESIS 
Samples of native and oxidized PTPI were examined by non-denaturing PAGE 
performed in 12.5% gels as described by Laemmli [1970], using tris-glycine buffer 
pH 8.3. Twenty |ig of protein sample was loaded in a 12.5% gel and electrophoresed. 
After running the gels were silver stained by the method of Nesterenko [1994], 
Atleast three gels of each experiment were performed. 
ANTIPROTEOLYTIC ACTIVITY OF PTPI 
Functional PTPI was assessed on the basis of its ability to inhibit the caseinolytic 
activity of papain as described by Kunitz [1947]. Riboflavin, H2O2, HOCl and SNP at 
the maximum concentration used in these studies did not show any effect on PTPI 
activity assay. 
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2.12 DRUG-PTPI INTERACTION: EFFECT OF PANCREATITIS 
CAUSING AND ANTIDIABETIC AGENTS 
Effect of sodium valproate (pancreatitis inducing drug) on PTPI 
PTPI (2 ^M) was incubated with increasing concentration of sodium valproate (2-20 
\iM) in 50 mM sodium phosphate buffer (pH 7.5), in a final reaction volume of 1000 
nl at RT for 30 min. Sodium valproate solutions were prepared in the same buffer. 
Following the incubation period, samples were subjected to spectroscopic analyses, 
assay of antiproteolytic activity and PAGE. 
EFFECT OF ANTIDIABETIC DRUGS ON PTPI 
Interaction with Glimepiride 
PTPI (2 |iM) was treated with increasing concentration of glimepiride (2-40 ^M) in 
50 mM sodium phosphate buffer (pH 7.5), in a final reaction volume of 1000 |il at RT 
for 30 min. Glimepiride solutions were prepared in same buffer. Following the 
incubation period, samples were subjected to spectroscopic analyses, assay of 
antiproteolytic activity and PAGE. 
Interaction with Metformin hydrochloride 
PTPI (2 \iM) was treated with increasing concentration of metformin hydrochloride 
(2-12 ^M) in 50 mM sodium phosphate buffer (pH 7.5), in a final reaction volume of 
1000 ^1 at RT for 30 min. Metformin hydrochloride solutions were prepared in double 
distilled water. Following the incubation period, samples were subjected to 
spectroscopic analyses, assay of antiproteolytic activity and PAGE. 
Interaction with Huminsulin R 
PTPI (2 ^M) was incubated with varying concentrations of Huminsulin R (0.05-2 
|uM) in 50 mM sodium phosphate buffer (pH 7.5), in a final reaction volume of 1000 
fil at RT, for 30 min. Following the incubation period, samples were subjected to 
spectroscopic analyses. 
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SPECTROSCOPIC ANALYSES 
UV-visible spectroscopy 
The UV vis absorption spectra were recorded on a double beam Shimadzu UV-vis 
spectrophotometer UV-1700 using a cuvette of 1 cm path length, in wavelength range 
of 190-300 nm. Each spectrum was the average of three scans. 
Fluorescence Spectroscopy 
The method followed for obtaining the fluorescence spectra of drug-PTPI compexes 
was similar to that given in section 2.11. 
CD Spectroscopy 
Far UV-CD measurements of PTPI with and without huminsulin R were conducted 
following the method similar to that reported in section 2.9. 
ANTIPROTEOLYTIC ACTIVITY 
Papain inhibitory activity of drug treated PTPI was assessed in a manner similar to 
that reported in section 2.11. 
POLYACRYLAMIDE GEL ELECTROPHORESIS 
Samples of native and drug treated PTPI were examined by non-denaturing PAGE 
performed in 7.5% gels (and 15% gels for huminsulin) as described by Laemmli 
[1970], using tris-glycine buffer pH 8.3. Twenty fig of protein sample was loaded in a 
gel and electrophoresed. After running the gels were silver stained by the method of 
Nesterenko [1994]. Atleast three gels of each experiment were performed. 
2.13 STATISTICAL ANALYSES 
Unless specified, all experiments were repeated at least four or five times to document 
reproducibility. Wherever applicable data are expressed as Mean ± SEM. Significance 
of difference in mean values were evaluated using one-way analysis of variance 
(ANOVA). A probability level of p < 0.05 was selected as indicating statistical 
significance. 
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3.1 RESULTS 
3.1.1 PURIFICATION OF THE INHIBITOR 
In the present work, pancreatic thiol proteinase inhibitor (PTPI) has been purified 
from goat pancreas by the method of Priyadarshini and Bano [2009]. As detailed in 
the methods section, the procedure involved four steps after homogenisation, alkaline 
treatment (pH 11.0), acetone fractionation, ammonium sulphate precipitation (20-
80%) and gel filtration chromatography on Sephacryl S 100 HR column. The 
progress of typical purification is summarized in Table 6. The initial homogenate 
contained free cathepsins, so presumably the inhibitors were entirely complexed. The 
alkali treatment destroyed the lysosomal cysteine proteinases liberating the inhibitors 
in assayable form. A large amount of inactive proteins was precipitated during the 
readjustment to pH 7.5, and could be removed by centrifugation. Fractionation of the 
soluble material with acetone decreased the total amount of protein providing a fold 
purification of 18.84 and a percent yield of 58.8. 
3.1.2 GEL FILTRATION 
The protein precipitate obtained after ammonium sulphate fractionation was dissolved 
in minimum amount of 50 mM sodium phosphate buffer (pH 7.5) and was dialyzed 
against several changes of the same buffer (also containing 0.15 M NaCl). The 
dialyzed protein was filtered on Whatman paper and chromatographed on Sephacryl 
S-IOOHR column (60x1.7 cm) equilibrated with 50 mM sodium phosphate buffer, pH 
7.5. A single peak giving significant papain inhibition was obtained [Fig, 12]. The 
fractions corresponding to the peak were pooled and were used for further analyses. 
The procedure provided a fold purification of 498.84 (-500) and percent yield of 20.4. 
3.1.3 HOMOGENEITY OF THE PURIFIED INHIBITOR 
As observed in Fig. 12, the inhibitor eluted as a single symmetric peak with constant 
specific activity suggesting a homogenous preparation. In addition, the preparation 
did not inhibit bovine trypsin, chymotrypsin or pepsin. Physical evidence for 
homogeneity was further provided by gel electrophoresis under non-denaturing 
conditions. The electrophoretic pattern of PTPI is shown in Fig. 13, lane e. The 
inhibitor moved as a single band. 
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Fig. 12 Gel filtration chromatography on Sephacryl S-100 HR 
The precipitate obtained from 20 to 80% ammonium sulphate saturation 
(after acetone fractionation) was dissolved and dialyzed against several 
changes of 50 mM sodium phosphate buffer, pH 7.5 containing 0.15 M 
NaCl. The sample was applied on Sephacryl S-100 HR column (60 x 1.7 
cm) and fractions were eluted with the same buffer at a flow rate of 15 ml 
h'\ Fractions of 5 ml were collected and monitored by inhibition of 
caseinolytic activity of papain. Fractions 7, 8, 9 were pooled for further 
studies. 
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Fig. 13 Gel electrophoresis of PTPI during various stages of 
purification 
Electrophoresis was performed on 7.5% acrylamide gel as described in 
methods section. Lane a contained 60 |ig pancreas homogenate, lane b 
contained 60 ng homogenate after alkaline treatment, lane c is 60 jig 
fraction obtained after acetone treatment, lane d is 60 (ig dialyzed fraction 
after ammonium sulphate fractionation, lane e is 60 \ig pancreatic thiol 
proteinase inhibitor after Sephacryl S-100 gel filtration. 
76 

3.1.4 REDUCING AND NON-REDUCING PAGE 
Purified PTPI was analyzed by SDS-PAGE under non-reducing (in the absence of P-
mercaptoethanol) or reducing conditions (in the presence of P-mercaptoethanol). PTPI 
migrated as two bands with different mobilities, suggesting a double subunit structure 
with subunits held together by non-covalent forces [Fig. 14]. 
3.1.5 PROPERTIES OF THE PURIFIED PANCREA^^IC .THIOL 
PROTEINASE INHIBITOR 
Molecular weight determination \ \ ^ ^ ^^^f^ 
The molecular weight of pancreatic thiol proteinase inhibitor was determined Otfd'er 
native as well as denaturing conditions. The molecular weight of native PTPI was 
determined using gel filtration chromatography on Sephacryl S 100 HR. The marker 
proteins-Trypsin (23 kDa), Pepsin (35 kDa), Ovalbumin (43 kDa) and BSA (66 
kDa) were chromatographed on the Sephacryl S 100 HR column (60 x 1.7 cm) 
equilibrated with 50 mM sodium phosphate buffer, pH 7.5 and their elution volume 
was determined. Analysis of the data indicated linear relationship between Ve/Vo 
and log M by the method of Andrews [1964] [Fig. 15], where Ve is the elution 
volume of the protein and Vo is the void volume of the column. The Ve/Vo of the 
native cystatin corresponds to molecular weight of 43650 (-44000) [Fig. 15]. 
The molecular weight of PTPI under denaturing conditions was calculated from its 
mobility in SDS-PAGE [Fig. 16a] by the procedure of Weber and Osbom [1969]. 
The mobilities of marker proteins were plotted against the logarithm of their 
molecular weights [Fig. 16b]. The least square analysis of the data indicated a linear 
relationship between log M and relative mobility (Rm). The molecular weight 
obtained was 43940 (-44000) (positions of two subunits corresponded to 23980 and 
19960, without reduction). In the presence of pME the molecular weight was found 
to be 47194 (positions of two subunits corresponded to 25860 and 21334) [Fig. 16b] 
Stokes radius 
Stokes radius of a protein correlates well with its elution behaviour from gel 
fihration column. The stokes radius of PTPI was determined by its elution volume 
from a calibrated Sephacryl S 100 HR column (60 x 1.7 cm) equilibrated with 50 
mM sodium phosphate buffer, pH7.5 using marker proteins. The column was 
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Fig. 14 SDS Polyacrylamide gel electrophoresis of purified PTPI 
Electrophoresis was performed on 12.5% gels as described in methods 
section. SDS PAGE was performed under non reducing and reducing 
conditions, lane a: non reducing condition (in the absence of P-
mercaptoethanol), lane b: reducing conditions (in the presence of P-
mercaptoethanol). Lanes a and b each contained 40^g of the inhibitor, 
respectively. 
Fig. 15 Molecular weight estimation of purified PTPI using Sephacryl 
S-100 HR gel filtration chromatography 
Purified PTPI was applied on a column of Sephacryl S-100 HR (60 x 1.7 
cm) and eluted with 50 mM sodium phosphate buffer, pH 7.5 at a flow rate 
of 15 ml h''. The molecular weight markers used were, A trypsin (23 
kDa); B pepsin (35 IcDa); C ovalbumin (45 kDa); D bovine serum albumin 
(66 kDa). Arrow shows the position of PTPI elution. 
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Fig. 16 Molecular weight determination of PTPI by SDS-PAGE 
electrophoresis 
(A) Electrophoresis was performed on 12.5% polyacrylamide gel. The middle 
gel lane contained the molecular mass standards: A, phosphorylase b (97.4 
kDa); B, bovine serum albumin (68 kDa); C, ovalbumin (45 kDa); D, 
carbonic anhydrase (29.1 kDa); E, soyabean trypsin inhibitor (20 kDa); F, 
lysozyme (14.3 kDa). Lane a contained 40 y.g PTPI without P-
mercaptoethanol and lane b contained 40 ng of P-mercaptoethanol treated 
purified inhibitor. 
(B) Plot of log M vs relative mobility (Rm) using least square analysis. The 
line indicates the positions of Subunit I and Subunit II of PTPI. 
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calibrated by determining the elution volume of several globular proteins with 
known stokes radii, such as Trypsin (20.2 A), BSA (35.6 A), ovalbumin (27.3 A). 
The data was analyzed according to the equation, 
K _ Ve — Vo av 
Vt-V„ 
Where, Ve= elution volume, Vo= void volume and Vt = total volume. Kav is the 
1/2 
partition coefficient. The linear plot between known stokes radius and [-log Kav] 
of the marker proteins was used for the calculation of PTPFs stokes radius [Laurent 
and Killander, 1964]. As depicted in Fig. 17, the value was found to be 27.3 A for 
the purified inhibitor. 
Diffusion coefficient 
DifRjsion coefficient (D) of PTPI was found to be 7.87 x 10"'' cm^ s\ computed 
from the value of its stokes radius by using the equation, 
kT kT 
/ 6mir 
Where k = 1.38 x lO'^ *^  erg/deg is Boltzmann's constant, T is the absolute temperature 
and x] is the coefficient of viscosity of the medium (O.Olg/cm-sec for water and dilute 
aqueous salt solutions at 20°C). The sedimentation coefficient is given by the formula 
^ M(1-V2P) M(1-V2P) 
Nof No6mir 
Where M is the mass of the protein molecule in Da, No is the Avogadro's number, 
6.023 X 10^ ,^ V2 is the partial specific volume of the protein (0.73 g/cm^), and p is the 
density of the solvent (1.0 g/cm for water). The ratio of Smax/S can be used to 
interpret the shape of the protein. In the hydrodynamic parameter Smax/S, Smax is the 
maximum possible sedimentation coefficient for a protein of the given mass, 
corresponding to a sphere of the minimum diameter, to contain mass of protein, with 
no water of hydration. The ratio of Smax/S is the same as///min, where/is the actual 
frictional coefficient of the hydrated protein and /min is the frictional coefficient ot 
unhydrated minimal sphere [Tanford, 1961]. The sedimentation coefficient of PTPI 
was found to be 3.83 s. The Smax/S ratio of PTPI is 1.2. 
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Fig. 17 Determination of Stokes radius of PTPI by plot of Laurent and 
Killander [(log Kav)^^ vs r] 
Marker proteins and the purified cystatin were subjected to gel filtration on 
Sephacryl S-100 HR (60 x 1.7 cm). The Kav values were computed from 
the elution volume of marker proteins. Stokes radii of the marker proteins 
were: A trypsin (20.2 A); B ovalbumin (27.3A); C bovine serum albumin 
(35.6 A). Arrow shows the stokes radius of purified inhibitor. The 
experimental conditions were same as in Fig. 1. 
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Carbohydrate content 
Type 1 and type 2 cystatins, generally, lack carbohydrate content. Dissimilar to this 
PTPI was found to possess 2.32% carbohydrate content. 
Sulphydryl group content 
The sulphydryl groups in PTPI were titrated against DTNB. Colourless solution 
obtained indicated that no free sulphydryl groups are present in the purified inhibitor. 
Effect of pH on activity of PTPI 
Effect of pH on the thiol proteinase inhibitory activity of pancreatic thiol proteinase 
inhibitor was examined at various pH values. Fig. 18 shows that the inhibitor is stable 
in the pH range 3.0-10.0 and has maximum activity at pH 7.5. 
Effect of temperature on activity of PTPI 
Stability of PTPI was investigated as a fianction of temperature between 30 and 90°C 
in 50 mM sodium phosphate buffer pH 7.5, by means of inhibitory activity assay. 
PTPI remained maximally active within temperature range of 30-70°C [Fig. 19]. 
Temperature stability of PTPI 
Goat PTPI was exposed to 90°C for varying time intervals, rapidly cooled and 
inhibitory activity determined by method of Kunitz [1947]. As illustrated in Fig. 20, 
PTPI retained approximately 40% of its activity till 120 min. The inhibitor was thus 
stable for 120 min at 90°C. 
3.1.6 IMMUNOLOGICAL PROPERTIES 
Antibody titre 
The PTPI caused good immune response and the resulting antiserum had a titre of 
25,118.86 as determined by direct binding ELISA in rabbit serum [Fig. 21]. 
Cross-reactivity 
PTPI was immunogenic and induced antibody formation in rabbits. The antiserum 
raised against purified inhibitor showed cross reactivity with the inhibitor (indicated 
by single precipitin line on immunodiffusion plate) exhibiting immunogenic purity 
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Fig. 18 Effect of pH on activity of PTPI 
50 ng of the inhibitor was incubated in 50 mM sodium acetate buffer, pH 
3.0-6.0, sodium phosphate buffer, pH 7.0-8.0, tris-HCl buffer, pH 9.0, for 
30 min at 37°C. After the incubation the pH of the mixture was neutralized 
and then 50 ^g of activated papain was added and the mixture was further 
incubated for 60 min at 37°C. The following procedure was same as 
described in methods section for assaying the inhibitor using casein as 
substrate. 
Fig. 19 Effect of temperature on PTPI 
50 i^g of the inhibitor was incubated in 50 mM sodium phosphate buffer, 
pH 7.5, at various temperatures for 30 min and then rapidly cooled. 50 \ig 
of activated papain was added and kept for 60 min at 37°C. the remaining 
procedure for determining thiol proteinase inhibitory activity was same as 
described in methods section using casein as substrate. 
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Fig. 20 Thermal stability of PTPI 
50 ng of the inhibitor was incubated in 50 mM sodium phosphate buffer, 
pH 7.5, at 90°C for different time intervals, rapidly cooled. 50 jig of 
activated papain was added and incubated for 60 min at 37°C. Rest of the 
procedure was same as described in methods. 
Fig. 21 Direct binding ELISA 
Serially diluted antiserum and pre-immune serum were incubated with 0.5 
Hg/100 i^l antigen. The procedure has been described in methods. The curve 
with hollow circles is for post-immunized sera, whereas the curve with solid 
circles is for pre-immunized sera. 
84 
1 
20 
-r 
40 
T — « — I — > — I — « — I — « — I — • — I — ' — r 
60 80 100 120 140 160 180 200 
Time (min) 
e s: 
in 
o 
-^ 
CJ 
u 
e CQ 
JSi 
u 
o IX 
Xi 
< 
1.6^ 
1.4-
1.2-
1.0-
0.8-
0.6-
0.4-
0.2-
0.0-
C 
. 
\ 
\ 
\ 
I 
\ 
\ 
V, 
w \ 
\ V 
CJ 
\ \ \ 
CL 
• - ^ \ S 3 
) 1 2 3 4 5 
-Log serum dilution 
6 
and homogeneity of the inhibitor preparation [Fig. 22]. It exhibited no immunogenic 
identity with goat lung and brain cystatins isolated in our laboratory. 
3.1.7 KINETIC PROPERTIES OF PTPI 
Stoichiometry of Inhibition 
The inhibition of proteinases was studied by varying their molar concentration at a 
fixed molar concentration of PTPI. The remaining activity of proteinase showed that 
as its concentration is increased from 0.01-0.06 pM it is progressively inhibited by 
0.06 pM PTPI giving a stoichiometric ratio of 1:1, thus one molecule of PTPI inhibits 
one molecule of active proteinase. Same result was obtained for ficin and bromelain. 
Inhibition of different proteinases 
The inhibitory activity of PTPI towards thiol proteinases, papain, ficin and bromelain 
and serine proteinases, trypsin and chymotrypsin was examined using casein as 
substrate. PTPI inactivated papain and ficin very efficiently and bromelain to a 
slightly lesser extent. The order of inhibition was papain > ficin > bromelain. 
However it failed to inhibit bovine trypsin and chymotrypsin [Fig. 23]. 
Ki determination 
Dissociation equilibrium constants (measured as Ki), for the binding of PTPI to plant 
cysteine proteinases papain, ficin and bromelain, were determined by monitoring 
the loss of enzyme activity and after lowering the respective inhibitor and proteinase 
concentration, which favour the dissociation of the complex. Ki values were 
determined using the steady state equation derived by Krupka and Laidler [1959], 
''^^ =KI 
1-(V,/VJ 
l + [S]o 
Km vVoy 
+ [E], 
The increasing values of Ki (app) with an increase in the substrate concentration 
suggested a competitive mechanism of inhibition. The true Ki values were obtained 
from the replot of Ki (app) versus substrate concentration. The Ki values obtained for 
papain, ficin and bromelain are 5.88, 9.02 and 22.28 nM, respectively, implying the 
highest affinity of inhibitor for papain [Fig. 24-26: inset]. 
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Fig. 22 Ouchterlony immunodiffusion 
Anti-PTPI antiserum was raised in rabbits. For the immunodiffusion study, 
the antiserum was allowed to react with inhibitor (60 ^g) on agarose plates 
as described in methods section. The central well contained the antiserum, 
whereas the surrounding three well contained purified PTPI. 
Fig. 23 Inhibitory activity of PTPI with different proteinases 
50 ng of thiol proteinases papain, ficin, bromelain and serine proteinases, 
trypsin and chymotrypsin were incubated with varying concentrations of 
PTPI (0-30 ng) for 30 min. The inhibitory activity of PTPI towards these 
proteinases was measured by using 2% casein as substrate. 
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Fig. 24 Determination of inhibition constant with (Ki) papain 
Papain was used at final concentration of 0.06 ^M with increasing amounts 
of PTPI (0.06-0.24 i^M) and measurements of residual activity were made 
as described in methods using casein as substrate. Four different substrate 
concentrations were used, i.e. 0.5 Km, 1 Km, 2 Km and 3 Km with Km = 
2.4 mM. For the sake of clarity only the result obtained for [S] = 0.5 Km 
are shown. The inset shows the replot of experimental Ki (app) values 
versus [S]. Intercept on the ordinate give the true Ki. 
Fig. 25 Determination of inhibition constant (Ki) with ficin 
Ficin was used at final concentration of 0.06 ^M with increasing amounts 
of PTPI (0.06-0.24 ^M) and measurements of residual activity were made 
as described in methods using casein as substrate. Four different substrate 
concentrations were used, i.e. 0.5 Km, 1 Km, 2 Km and 3 Km with Km = 
2.4 mM. For the sake of clarity only the result obtained for [S] = 0.5 Km 
are shown. The inset shows the replot of experimental Ki (app) values 
versus [S]. Intercept on the ordinate give the true Ki. 
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Fig. 26 Determination of inhibition constant (Ki) with bromelain 
Bromelain was used at final concentration of 0.06 ^M with increasing 
amounts of PTPI (0.06-0.24 ^M) and measurements of residual activity 
were made as described in methods using casein as substrate. Four 
different substrate concentrations were used, i.e. 0.5 Km, 1 Km, 2 Km and 
3 Km with Km = 2.4 mM. For the sake of clarity only the resuh obtained 
for [S] = 0.5 Km are shown. The inset shows the replot of experimental Ki 
(app) values versus [S]. Intercept on the ordinate give the true Ki. 
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IC50 value 
IC50 value is the concentration of the inhibitor at which 50% of the enzyme is 
inhibited. The IC50 values obtained with various thiol proteinases are summarized in 
table 7, The values obtained for the three proteinases, papain, ficin and bromelain, are 
0.08, 0.078 and 0.154 ^M, respectively, again suggesting greater affmity of the 
inhibitor for papaya proteinase. 
Dissociation rate constant (K.i) 
The conditions for the dissociation were taken such that the enzyme-inhibitor 
complex obeys first order kinetics during the initial part of the reaction. In this case 
the integrated form of the equation is given by. 
In 
^[EI] ^ 
UEI] = K_,t oj 
l o s M ^ =K,t/2.303 
Figures 27, 28 and 29 show the respective plots for papain, ficin and bromelain. The 
K.1 values obtained for papain, ficin and bromelain are 8.76 x lO"', 3.35 x 10"* and 
1.32 x 10''' s', respectively. 
Association rate constant (K+i) 
Association rate constants calculated fi^om measured dissociation rate and dissociation 
equilibrium constants by the relation. 
K+,= 
Ki 
and hence the affinity of the inhibitor for proteinases is in the following order: papain 
(1.49 X lO'' M-^ s-') > ficin (1.39 x 10'^  M'^ s"^ ) > bromelain (5.94 x 10^  M-'s"'). 
Half life of the complex 
The half life values of enzyme-inhibitor complexes were calculated using K.i values 
by the equation, 
t . = - 0 ^ 
The calculated half-life values of papain-PTPI complex was 7.91 x 10^  s, for 
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TABLE 7: KINETIC CONSTANTS OBTAINED ON INTERACTION OF 
PTPI WITH PROTEINASES - PAPAIN, FICIN AND 
BROMELAIN 
Proteinase 
Ki (nM) 
K+i (M'^  s'b 
K-i(s'S 
Half life value (s) 
IC50 (fiM) 
Papain 
5.88±0.06 
1.49±0.03xl0'' 
8.76±0.01xl0"' 
7.91x10^ 
0.08 
Ficin 
9.02±0.08 
1.39±0.02xl0'^ 
3.35±0.02xl0"^ 
5.51x10^ 
0.078 
Bromelain 
22.28±0.11 
5.94±0.02xl0^ 
1.32±0.02xl0'^ 
5.23x10^ 
0.154 
Results represent the mean ± SEM calculated from three independent experiments. 
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Fig. 27 Determination of dissociation rate constant (K.i) with papain 
Papain-PTPI complex (l^M) was preincubated for 30 min at 37°C before 
excess substrate was added to the mixture. Appearance of papain activity 
was recorded as a function of time. Inset shows plot of the data as 
described in methods. 
Fig. 28 Determination of dissociation rate constant (K_i) with ficin 
Ficin-PTPI complex (l^M) was preincubated for 30 min at 37°C before 
excess substrate was added to the mixture. Appearance of papain activity 
was recorded as a function of time. Inset shows plot of the data as 
described in methods. 
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Fig. 29 Determination of dissociation rate constant (KLi) with 
bromelain 
Bromelain-PTPI complex (1^M) was preincubated for 30 min at 37°C 
before excess substrate was added to the mixture. Appearance of papain 
activity was recorded as a function of time. Inset shows plot of the data as 
described in methods. 
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ficin-PTPI complex was 5.51 x 10'' s and 5.23 x 10^  s for bromelain-PTPI complex. 
3.1.8 N-TERMINAL ANALYSIS 
The N-terminal 24 amino acid residues of the heavier subunit (23.98 kDa) of PTPI 
were sequenced by the automated Edman degradation method. Table 8 shows the 
amino-terminal sequence of goat pancreatic thiol proteinase inhibitor and its sequence 
homology with other known mammalian cystatins. As in other cystatins, PTPI was 
found to possess a conserved glycine residue at 11* position. Maximum sequence 
homology was observed with bovine skin cystatin C as compared to other cystatins 
like bovine parotid cystatin C, bovine colostrum cystatin C, human cystatin C, human 
stefm A & B, human placental cystatin and cystatin E. 
HYDROPATHY PLOT 
Using the sequence obtained from N-terminal analysis of PTPI, a hydropathy plot was 
made using the respective hydropathy indices [Kyte and Doolittle, 1982]. Among 24 
residues sequenced, the stretch of 3-7, 7-11 and 15-19 residues has maximum 
hydropathy index suggesting that these residues might be present inside the 
hydrophobic core of the protein [Fig. 30]. 
3.L9 SPECTRAL ANALYSES 
Absorption spectrum 
PTPI gave typical protein absorption with a maximum at 278 nm and a minimum at 
250 nm. The ratio of the absorbance at 280/260 nm is 1.3 [Layne, 1957]. The 
millimolar absorption coefficient at 280 nm of PTPI is found to be 22.1 mM"'cm'' by 
taking molecular weight value of 44,000. The interaction of inhibitor and papain at its 
stoichiometric ratio was studied at pH 7.5. Absorption difference spectrum of papain-
PTPI complex showed peaks in the region of 245-255 nm, at 280 nm, negative peaks 
at around 290 nm and a shoulder at 260 nm [Fig. 31]. 
Fluorescence emission spectrum 
After excitation at 280 nm, where phenol and indole groups absorb, the PTPI exhibits 
an emission spectrum with a maximum (k max) at 335 ± 1 nm which points to the non-
polar tr>'ptophyl side chains in the protein [Burstein et al., 1973]. 
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Fig. 30 Hydropathy plot of the N-terminal residues of heavy subunit of 
PTPI 
The hydropathy calculation was made according to the method of Kyte and 
Doolittle [1982] using already known hydropathy index of the 24 amino 
acid residues. A window size of 4 was selected for plot formation. The 
upper part of the graph shows the hydrophobic, and lower part hydrophilic 
regions. 
95 
2 5 -
20-
X 15-
a 
-a 0 10-
>» 
•S 5 -
93 
O. 
2 0-
X3 
>> 
X -5-
-10-
1 c 
-13 
] 
-^— 
1 5 10 15 
Sequence Number 
• • 
20 
w^ 
IS 
o .s 
a 
o 
•a >>> 
a 
o 
rs J3 
a o 
•a 
>> 
H 
The binding of PTPI to papain was accompanied by appreciable changes in 
fluorescence emission [Fig. 32]. There was a shift of fluorescence maximum to longer 
wavelength (from 335 to 345 nm) with considerable enhancement (+21.62%) of 
fluorescence intensity at X, max. 
Circular dichroism spectra of native PTPI and its complex with papain 
The far-UV CD spectra of PTPI revealed a-helical structure of 17.18% [Fig. 33] 
[calculated using equation described by Chen et al., 1972]. Complexation of PTPI 
with papain resulted in complete loss of negative peaks and a strong positive peak is 
observed [Fig. 34]. Complex formation with papain abolished the native secondary 
structure and resulted in shifting of absorption maximum. 
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Fig. 31 UV-Absorption difference spectra measured for PTPI-papain 
complex 
PTPI (2.66 \xM) was incubated with activated papain for 30 min and an 
absorbance difference spectrum was calculated between 240 nm to 320 nm. 
PTPI and papain were in a molar ratio of 1:1. 
Fig. 32 Fluorescence spectra of PTPI alone and PTPI in complex with 
papain 
Fluorescence spectra of the inhibitor alone PTPI, papain and papain-PTPI 
complex was measured at excitation wavelength (Xex) of 280 nm and 
emission wavelength (Xem) of 300-400 nm.The concentration of PTPI was 2 
\iM. The fluorescence of complex of PTPI with papain was measured at a 
molar ratio of l.i. The slit width was 5 nm for excitation and 10 nm for 
emission beams. 
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Fig. 33 Far UV-CD spectra of native PTPI 
The concentration of PTPI was 1.7 nM. Cells of 1mm path length were 
used. The buffer used was 50 mM sodium phosphate buffer, pH 7.5. Cells 
of 1 mm path length were used. The unit on the ordinate is mean residue 
ellipticity. 
Fig. 34 Far UV-CD Spectra of PTPI in complex with papain 
Far UV-CD spectra of native PTPI alone and papain-PTPI complex. The 
concentration of PTPI was 1.73 |JM and PTPI and papain molar ratio was 
1:1. The complex was obtained after incubation at 37°C for 30 minutes in 
50 mM sodium phosphate buffer, pH 7.5. Cells of 1 mm path length were 
used. The unit on the ordinate is mean residue ellipticity. 
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DISCUSSION 
Most of the evidences indicate that the proteolytic activity of both endogenous and 
exogenous cysteine proteinases is primarily regulated by a group of proteinase 
inhibitors belonging to the cystatin superfamily. These cysteine proteinase inhibitors 
(cystatins) are ubiquitous in organisms, ranging from bacteria to mammals. Cystatins 
are classified into three distinct families based on their sequence homology, presence 
of disulphide bonds and molecular mass [Abrahamson et al., 2003]. These inhibitors 
are of physiological importance because inhibition is achieved at physiological 
concentration of the inhibitor in a sufficiently short time with negligible dissociation 
of the complex [Beith, 1980]. TPIs (cystatins) are known to play important function in 
various pathophysiologic conditions [Turk et al., 2008; Shah and Bano, 2009] 
implying that cystatin functioning is pivotal for proper health maintenance. 
Cystatins have been purified and characterized extensively from various mammalian 
sources like goat lung [Khan and Bano, 2009a], brain [Sumbul and Bano, 2006], 
human placenta [Rashid, et al. 2006a], goat kidney [Zehra et al., 2005], goat sheep 
plasma [Baba et al., 2005], human liver [Green et al., 1984] and human spleen 
[Jarvinen and Rinnie, 1982]. The presence of a thiol proteinase inhibitor in pancreas 
has been shown earlier [Ni et al., 1997] however; its isolation and physico-chemical 
characterization remained unattempted. Role of cathepsins in mediating exocrine and 
endocrine functions of pancreas has already been established (e.g. cathepsin B-
conversion of trypsinogen to trypsin [Otto & Riesenkonig, 1975; Teich et al., 2002; 
Thrower et al., 2006], involvement of cathepsin B and H in the formation of insulin 
from proinsulin [Ansorge et al., 1977]). Recent literature implicates the role of 
calpains in insulin secretion and action [Sreenan et al., 2001; Kalbe et al., 2005]. 
Altered cysteine proteinase activity in pancreas is often correlated to deleterious 
consequences like onset or enhanced severity of pancreatitis [van Acker et al., 2002; 
Shikimi et al., 1987], diabetes [Weber et al., 2002; Sreenan et al.,2001] and tumors 
[Lorenzo et al., 2000]. However information about the regulation of cysteine 
proteinase activity by their proteinaceous inhibitors in pancreas is scarce. 
In the present work, a thiol proteinase inhibitor (PTPI) was purified from goat 
pancreas by the method of Priyadarshini and Bano [2009]. The four step procedure 
involved alkaline treatment, acetone fractionation, ammonium sulphate fractionation 
and gel filtration chromatography. The procedure used provided a percent yield of 
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20.4 and fold purification of 500 [Table 6]. Purification of TPIs fi-om other sources 
has been reported using affinity chromatography, chromatofocusing, gel filtration and 
ion exchange chromatography [Anastasi et al., 1983; Evans and Barrett, 1987; Khan 
and Bano, 2009a]. The purified inhibitor was found to be homogenous on the basis of 
charge and molecular weight as shown by native PAGE [Fig. 13]. In SDS-PAGE, 
both under reducing as well as non reducing conditions, PTPI gave two bands 
suggestive of presence two subunits [Fig. 14] held together by non covalent bonds. 
The molecular weight of the isolated inhibitor ascertained fi'om gel filtration 
chromatography on Sephacryl S 100 HR column [Fig. 15] was 43650 (-44000). Quite 
similar result was obtained in denaturing PAGE [Fig. 16b]. A slightly higher 
molecular weight obtained under reducing conditions (47194 compared to 43940 
under non reducing conditions) is however, anomalous. The estimation of molecular 
weight on dodecyl sulphate gels is based on the hypothesis that all proteins bind fairly 
equal amount of detergents and that the complexes formed by protein and detergent 
adopt the same shape and conformation such that the electrophoretic mobility is 
function of the molecular weight and pore size of the gel. If a protein does not show 
such behaviour the molecular weight determination by this method becomes 
erroneous. Known examples of such proteins include polypeptide with unusual charge 
[Tung and Knight, 1971; Panyim and Chalkev, 1971], conformation [Bjork et al., 
1972] or with unreduced disulphide bonds [Trayer et al., 1971] and glycoproteins 
[Mitchell et al., 1973]. The ambiguity of this method in case of PTPI could be that it 
deviates from the general behaviour of proteins in dodecyl sulphate solution. The 
SDS-PAGE was repeated thrice and same result was obtained. 
Cystatins type 1 and type 2 have been classified on the basis of molecular weight and 
presence of disulphide bonds [Abrahamson et al., 2003]. Cystatins from tissues are 
usually small single subunit proteins with low molecular masses. Molecular masses of 
11.4 IcDa and 12 kDa have been reported for cysteine proteinase inhibitors isolated 
from human spleen [Jarvinen and Rinnie, 1982], 14 kDa-14.3 kDa for cystatins fi'om 
bovine muscle [Zabari et al., 1993]. The molecular mass of PTPI is higher than those 
of stefins and cystatins (-11 kDa and 13 kDa, respectively) but lower than those of 
kininogens [-50 kDa-100 kDa] [Turk and Bode, 1991]. Low molecular mass of tissue 
cystatins is now contrasted with reports on high molecular mass. Ylonen et al. [1999] 
isolated and purified high molecular mass thiol proteinase inhibitors (of 43 kDa and 
-52 kDa) from the skin of Atlantic salmon, Cystatins isolated from goat kidney were 
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reported to have a molecular mass of 67 IcDa [Zehra et al., 2005]. A high molecular 
mass cystatin (of 70.8 kDa) has also been isolated from goat brain [Sumbul and Bano, 
2006], Recently, the work from our lab, has reported the purification of high 
molecular mass cystatins from goat lung [Khan and Bano, 2009a]. 
The purified inhibitor was characterized for its various hydrodynamic properties. 
Stokes radius of PTPI as deduced from its gel filtration behaviour was 27.3 A. 
Diffusion coefficient of PTPI was found to be 7.87 x 10"' cm^ s'^ The sedimentation 
coefficient of PTPI was calculated to be 3.83 s. The values of stokes radius and Smax/S 
ratio can be used to predict the shape of the protein molecule [Schurmann et al., 2001] 
Globular proteins typically have Smax/S ratio of 1.2-1.3 (for example catalase and 
serum albumin have Smax/S of 1.20 and 1.29), and the ratio increases to 1.6-2,0 or 
more for elongated proteins [Erickson, 1982]. For PTPI Smax/S ratio was calculated to 
be 1.2. The values of stokes radius and Smax/S ratio for PTPI are in close agreement 
with those of ovalbumin, suggesting that PTPI is a globular in shape. 
Generally, cystatins type 1 and type 2 isolated from tissues lack carbohydrates [Bode 
et al., 1988] whereas the presence of carbohydrates is a distinguishing property of 
type 3 cystatins, the kininogens [Ohkubo et al., 1984]. However, presence of 
carbohydrate has been reported in some tissue thiol proteinase inhibitors like cystatins 
E, F, M and those isolated from goat kidney and brain [Ni et al., 1997; 1998; 
Sotiropoulou et al., 1997; Zehra et al., 2005; Sumbul and Bano, 2006]. PTPI contains 
2.32% carbohydrates and has no thiol group. Analysis of the influence of pH on 
activity of PTPI reveals that the inhibitor remains fairly active in the pH range of 3.0-
10.0 [Fig. 18]. PTPI also exhibited stability in a wide temperature range of 30-70°C 
[Fig. 19] and remained active upto 120 min when heated to 90°C [Fig. 20]. High 
stability of the purified inhibitor in broad temperature and pH ranges is consistently 
found in other cystatins like goat lung cystatins [Khan and Bano, 2009a], goat brain 
cystatins [Sumbul and Bano, 2006], human placental cystatin [Rashid et al., 2006a], 
goat kidney cystatins [Zehra et al., 2005], stefin A and B [Zerovnik et al., 1997], etc. 
The PTPI or pancreatic cystatin gave a good immune response with an antibody titre 
of 25,118.86 as determined by direct binding ELISA in rabbit serum [Fig. 21]. The 
antibodies raised against purified inhibitor gave a reaction of identity with the 
inhibitor as indicated by a single precipitin line on immunodiffusion suggesting that 
the isolated PTPI is pure. Experiments also showed that the antiserum had no 
immunogenic identity with goat brain and lung cystatins purified in our lab. This 
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indicates that the epitopes of goat pancreatic thiol proteinase inhibitor are different 
from goat brain and lung thiol proteinase inhibitors. The purified inhibitor was found 
to be specific for cysteine proteinases since no activity against aspartic (pepsin) and 
serine proteinases (trypsin and chymotrypsin) was detected. This has been reported 
for many other cystatins along with the thiol proteinase inhibitor isoforms purified 
from human spleen [Jarvinen and Rinnie, 1982], and other goat cystatins [Khan and 
Bano, 2009a; Sumbul and Bano, 2006; Zehra et al., 2005]. The stoichiometry of 
binding of purified cystatin to papain, ficin and bromelain was 1:1. This value shows 
that PTPI is a tight binding inhibitor of these proteinases and essentially all enzyme 
molecules are able to bind to the inhibitor. Anastasi et al. [1983] have also reported 
equimolar complexes of cystatin with cysteine proteinase. Abrahamson et al. [1987b] 
also reported the rapid formation of 1:1 complex between cystatin C and papain. 
There are other reports also demonstrating similar binding of thiol proteinase 
inhibitors with papain like that of the recombinant human cystatin C [Bjork et al., 
1994], recombinant bovine cystatin C [Olsson et al., 1999], recombinant stefin A 
[Nicklin and Barrett, 1984]. Members of cystatin superfamily also show different 
binding stoichiometries with papain. The high molecular weight kininogens from 
human and sheep plasma as well as low molecular weight kininogens from the latter 
show 1:2 stoichiometry of interaction with papain [Baba et al., 2005; Turk et al., 
1996b]. 
The IC50 values of the PTPI obtained for papain, ficin and bromelain were 0.08, 
0.078 and 0.154 ^M, respectively [Table 7]. Lower IC50 value suggests a greater 
affinity of the inhibitor towards the enzyme. The values obtained for PTPI indicate its 
greater affinity towards papain then for ficin and bromelain. Katunuma and 
Kominami [1985] have found IC50 value for the inhibitor isolated from rat liver as 
0.16 lag for papain, 0.46 ng for ficin, 4.2 [ig and 0.14 \ig for cathepsin B and H, 
respectively. 
Accurate Ki values were determined by working at lower enzyme concentrations and 
using equations derived by Krupka and Laidler [1959] and Henderson [1972]. Ki 
values were calculated from the slope of the curve obtained for the inhibition of 
caseinolytic activity of papain, ficin and bromelain. PTPI is a strong inhibitor of thiol 
proteinases as indicated by their Ki values. The data shows that PTPI inhibited papain, 
ficin and bromelain with Ki values of 5.88, 9.02 and 22.28 nM, respectively, under 
conditions of routine assay system [Table 7, Fig. 24-26]. Thus, of the enzymes studied. 
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PTPI binds most tightly to papain. These values are in good comparison with other 
thiol proteinase inhibitors. Sumbul and Bano [2006] obtained Ki values of 1.87 x 10'^  
M and 3.125 x 10"^  M, for inhibition of papain by goat brain cystatins. Quite similar 
values were obtained for goat kidney cystatins [Zehra et al., 2005]. Human placental 
cystatin also gave a Ki value of 5.5 x 10"* M for papain as reported by Rashid et al. 
[2006a]. Ki values of nanomolar range have been documented for cathepsin B, H and 
L with cystatin A [Barrett et al., 1984], cystatin C [Machleidt et al., 1986], cystatin D 
[Balbin et al., 1994]. Studies of the kinetics of binding of chicken cystatin to several 
cysteine proteinases have shown that these reactions are best described by the simple 
reversible bimolecular mechanism: 
K 
+1 
P + I j — • PI 
K 
-1 Where P is the proteinase, I represents inhibitor and PI their complex [Bjork and 
Ylinenjarvi, 1990; Henderson, 1972]. The same conclusion is strongly indicated by 
studies with PTPI in this work. The linear increase in the observed pseudo-first order 
rate constant for cysteine proteinases studied with PTPI concentration is consistent 
with a simple reversible bimolecular reaction mechanism [Nicklin and Barrett, 1984]. 
Moreover, the increasing value of Ki with an increase in substrate concentration 
suggests the inhibition to be competitive as reported earlier by Li et al., [2000] and by 
Nicklin and Barrett [1984] for inhibition of human cathepsin B by chicken cystatin. 
Latter obtained Ki (app) values of 1.85 and 3.68 nM with the substrate concentration 
of 0.05 and 0.39 mM, respectively. Possibly, all cystatins of family II, and perhaps 
also those of other families, interact with the target enzymes in same general manner. 
Association constant obtained for papain-PTPI interaction was 1.49 x 10 M' s' . In 
general, proteinases having low Ki also have high K+i and low K.i values suggesting 
the stability of the enzyme inhibitor complex and rapidity of its formation. Our data is 
in accordance with this, thereby suggesting that the interaction of PTPI with papain is 
rapid and stable. The association rate constants obtained for ficin and bromelain were 
1.39 x 10"* M"'s"' and 5.94 x 10'' M"'s"\ respectively. Thus, reiterating the order of 
affinity as, papain > ficin > bromelain. The Ki and rate constants for association of 
the inhibitor with papain and ficin are also comparable with the values measured for 
chicken cystatin [Bjork et al, 1989], human cystatin C and bovine cystatin C [Bjork 
et al, 1994] and cystafin D [Balbin et al, 1994] for their interactions with various 
cysteine proteinases (papain, ficin and cathepsins B, H and L). 
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The dissociation constant (K-i) values for the enzyme-inhibitor complex was 
determined by displacement procedure, in which the inhibitor released from the 
complex was trapped by excess substrate (casein) with increase in time. The amount 
of enzyme released from the complex was monitored by continuous measurement of 
enzyme activity. The respective K.i values obtained for papain, ficin and bromelain 
are 8.76 x 10"^ 3.35 x 10"^  and 1.32 x lO""* s\ respectively [Fig. 27-29, Table 7]. The 
values of K.i obtained in the present work are comparable to K.i values obtained for 
chicken cystatin, 5 xlO'' s"^  with papain [Nicklin and Barrett, 1984]. The published 
data on rate constants for other goat cystatins [Khan and Bano, 2009a; Sumbul and 
Bano, 2006; Zehra et al., 2005] is in similitude with our resuhs. This resemblance in 
inhibitory mechanism of cystatins isolated from goat earlier reflects the species 
similarities. The above data gives comprehensive information about the kinetics of 
inhibition of purified thiol proteinase inhibitor with papain, ficin and bromelain and 
the overall comparison showed that PTPI inhibits papain more effectively compared 
to other two proteinases. 
The N-terminal 24 amino acid residues of the heavier subunit (23.98 kDa) were 
sequenced, and some interesting resuhs were obtained. As in other cystatins [Table 8], 
PTPI possesses a conserved glycine residue at 11^ position rather than the conserved 
position 9 in various species [Brzin et al., 1984]. Maximum sequence homology was 
observed with bovine skin cystatin C (20%) [Cimerman et al., 1996]. Fair sequence 
homology of PTPI was also observed with bovine parotid cystatin C (12.5%), bovine 
colostrum cystatin C (11.8%), and human cystatin C (12.5%) [Cimerman et al., 1996], 
sheep plasma LMW Kl [Baba et al., 2005], placental cystatin [Rashid et al., 2006a] 
and cystatin E [Ni et al., 1997]. Using sequence of these N-terminal amino acid 
residues, a hydropathy plot was made using the respective hydropathy indices [Kyte 
and Doolittle, 1982]. Among 24 residues sequenced, the stretch of 3-7, 7-11 and 15-
19 residues has maximum hydropathy index suggesting that these residues might be 
present inside the hydrophobic core of the protein [Fig. 30]. 
The absence of disulphide bonds is a unique character of type 1 cystatin family 
members. Molecular masses of type 1 and 2 cystatin families range in 11 kDa to 13 
kDa [Turk and Bode, 1991]. Presence of carbohydrates is however limited only to 
kininogens, with few exceptions found for members of type 2 cystatin family. PTPI is 
devoid of any disulphide linkage, has high molecular mass (44 kDa) and bears 
sequence similarities to both stefins and cystatins [Table 8]. Studies on kinetics of 
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inhibition as well as on biophysical interaction of PTPI with thiol proteinases shows 
that it bears resemblances with other members of type 2 cystatin family. Based on this 
the purified inhibitor can be regarded as a variant of type 1 and type 2 cystatin 
families. This is not unusual as there is growing list of proteins possessing some 
structural and functional motifs of cystatin superfamily, but bearing substantial 
differences causing them to be classified as variants of cystatin superfamily. 
The interaction between papain and PTPI was studied using various spectroscopic 
techniques. The complex spectroscopic changes (observed in UV-difference spectrum 
of PTPI-papain complex) [Fig. 31] accompanying the binding of PTPI with papain 
indicate that the environment of several aromatic residues in the proteins has been 
perturbed upon interaction. Peak at 280 nm is indicative of changes around tyrosine 
residues [Donovan, 1969; 1973a; 1973b]. The shoulder around 260 nm may be partly 
due to phenylalanine and may also contain contribution from aromatic residues 
[Donovan, 1973a]. The changes at 290 nm suggest that aromatic amino acid residues 
are involved in binding with papain, like tryptophan. Such results are consistent with 
earlier reported results for interaction of low and high molecular weight kininogens, 
human placental cystatin, goat brain cystatin and rat cystatin with papain [Baba et al, 
2005; Rashid et al., 2004; Sumbul & Bano, 2006; Takeda et al., 1983]. 
Fluorescence studies showed that complexation of PTPI with papain resuhed in 
changes in intensity and shape of the emission spectrum. The maxima of cystatin 
shifted from 335 nm to 345 nm for the PTPI-papain complex which was accompanied 
by an increase in the fluorescence intensity. The largest increase of intensity was 
observed between 330-345 nm [Fig. 32] indicating that these changes arise 
predominantly from perturbations around tryptophan residues, either by exposure of 
tryptophan residues to the solvent or may originate fi"om local interactions affecting 
chromophoric groups of the two proteins. 
A CD spectrum in the far UV region depicts the contributions of the secondary 
structure of the protein [Jirgensons, 1970]. The a-helical structure of the protein in the 
far UV region is characterized by negative peaks at 208-210 nm, at 222 nm and a 
positive peak between 190-192 nm [Jirgensons, 1970; Chen et al., 1972]. PTPI has an 
a-helical content of 17.18%. The a helical content was calculated from the ellipticity 
values at 222 nm using equation given by Chen et al. [1972]. The CD spectra of PTPI 
(a helical content 17.18%) resembled that of cystatin A (with a low a helical content 
-15%) [Stubbs et al., 1990; Pol et al., 1995]. This type of structure has also been 
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reported for chicken cystatin which has an a helical content of about 20% [Schwabe 
et al, 1984]. 
The goat pancreatic cystatin loses its native structure on formation of complex with 
papain [Fig. 34]. Far UV-CD spectra of the inhibitor-papain complex showed intense 
positive peak and complete loss of any negative peaks, characteristic of random coil 
structure [Ramasarma et al., 1994]. However, earlier studies for the interaction of 
chicken cystatin, human cystatin C and cystatin A with several proteinases reported 
no appreciable conformational adaptation of either protein [Pol et al., 1995; Lindahl et 
al,, 1992; Takeda et al., 1983]. The positive ellipticity of PTPI-papain complex 
observed in the present case is in similitude with reports of Rashid et al., [2004] and 
Baba et al., [2005]. This feature of PTPI-papain interaction is comparable to that of 
serine proteinase inhibitors with target enzymes involving conformational change 
[Luthy et al, 1973; Quast et al., 1974; Olson and Shore, 1982]. 
The results indicate that the UV absorption, fluorescence emission and far UV CD 
changes are more due to conformational changes in proteins rather than any local 
interaction affecting the chromophoric groups of the two constituent proteins of the 
complex. The positive ellipticity observed for PI (proteinase-inhibitor) complex in far 
UV CD region further confirms that cystatin and papain both lose their native 
structures on formation of complex. The conformation of this complex resembles 
neither of the constituent proteins, rather indicates attainment of random coil structure 
due to this interaction. The kinetic studies also suggest formation of tight complex on 
interaction of inhibitor with papain. 
PTPI is a good partner of other reported goat tissue cystatins in terms of its physical 
properties. Also, the pH and heat stability, interaction with papain, affinities towards 
other proteinases and N-terminal sequence analysis of the purified PTPI are quite 
similar to other cystatins; but differences in terms of its molecular mass, subunit 
structure, sulphydryl groups, and carbohydrate content from other tissue cystatins 
imply different routes of biosynthesis, different in vivo distribution and suggest a 
variety of physiological functions. It is interesting to speculate on the physiological 
role of this endogenous proteinase inhibitor. It seems likely that this endogenous 
inhibitor would at least serve a protective function against inappropriate proteolysis 
both with in the cell and outside the cell. 
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3.2 RESULTS 
The possibility of measuring the conformational stability of proteins with precision is 
important to resolve the protein folding problem, to define the structural 
characteristics of the proteins for studying their structure and function through 
mutational analysis and to applied research. 
With this view, a systematic investigation on the effect of increasing concentration of 
guanidine hydrochloride (GdnHCl) and urea on the functional and structural 
parameters of pancreatic thiol proteinase inhibitor (PTPI) was performed using the 
following methods: 
(1) Enzyme catalytic activity, to indicate the disruption of active site regions. 
(2) Red shift of wavelength of the maximum fluorescence emission (Xmax), to 
monitor global structural changes induced by the denaturant. 
(3) EUipticity at 222 nm in the CD spectrum, to detect the secondary structural 
changes induced by GdnHCl and urea. 
(4) ANS- binding to detect the appearance of hydrophobic patches in the enzyme 
molecule during unfolding. 
Time dependent changes in the structural parameters and enzymatic activity of PTPI 
at increasing GdnHCl and urea concentrations were monitored to standardize the 
incubation time required for achieving equilibrium under these conditions. Under all 
of the conditions studied, the changes occurred within maximum of 2 h with no 
further alteration upto 12 h (data not shown). These observations demonstrated that an 
incubation time of 2 h is sufficient for achieving equilibrium under any condition of 
denaturant studied. 
3.2.1 CHANGES IN MOLECULAR PROPERTIES OF PTPI 
ASSOCIATED WITH GdnHCl INDUCED UNFOLDING 
Effect of GdnHCl on papain inhibitory activity of PTPI 
Enzyme activity can be regarded as the most sensitive probe for studying protein 
unfolding and refolding as it reflects subtle readjustments at the active site, allowing 
very small conformational variations of an enzyme structure to be detected. Fig. 35 
shows the effect of increasing concentration of GdnHCl on the papain inhibitory 
activity of PTPI. The inhibitor was incubated with increasing GdnHCl concentration 
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Fig. 35 Effect of increasing GdnHCl concentration on the activity of 
PTPI 
Native PTPI (1 pM) was incubated with increasing concentration of 
GdnHCl (0-6 M) for 2 h at room temperature. PTPI was assayed for loss of 
antiproteinase activity by caseinolytic assay of Kunitz [1947]. Values are 
Mean ± SEM of four independent determinations. 
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in 50 mM sodium phosphate buffer, pH 7.5 and its thiol proteinase inhibitory activity 
was monitored by the method of Kunitz [1947]. The activity of native PTPI was taken 
as 100. A sigmoidal dependence of enzymatic activity on GdnHCl concentration was 
observed. No significant effect of the denaturant on enzymatic activity of native PTPI 
was observed upto 1 M GdnHCl. Approximately, 20% loss of the papain inhibitory 
activity of PTPI occurred at 2 M GdnHCl. At 4 M GdnHCl concentration only 35% of 
the native enzyme activity was left. PTPI was found to be almost completely 
inactivated beyond 4 M GdnHCl. 
Effect on spectroscopic properties of PTPI in the presence of GdnHCl 
Optical spectroscopic studies on PTPI in the presence of increasing GdnHCl 
concentrations were performed to study the effect of denaturant on its structural 
properties. 
Fluorescence spectra of PTPI in the presence of GdnHCl 
The spectral parameters of fluorescence emission spectra such as position, shape and 
intensity are dependent on the electronic and dynamic properties of the chromophore 
environment; hence steady-state fluorescence has been extensively used to obtain 
information on the structural and dynamic properties of protein [Prajapati et al., 1998]. 
Fluorescence measurements were performed by using a 280 nm excitation wavelength 
in order to detect the contribution of both tryptophan and tyrosine residues. This 
choice is advantageous in having fluorescence signals that reflect the global 
conformational changes of the tertiary structure, rather than local modifications. 
The modification of the microenvironment of aromatic residues of PTPI due to 
denaturant has been monitored by studying changes in the intensity and wavelength of 
emission maxima (Xmax) as a fiinction of denaturant concentration. Fig. 36 illustrates 
changes in fluorescence emission intensity and Xmax (inset) of PTPI with increasing 
GdnHCl concentration (0-6 M). The wavelength of maximum emission (Amax) is a 
robust signal for measuring the unfolding of proteins. The fluorescence emission 
spectrum of native PTPI shows a maximum of 335 nm that shifts to 350 nm in 6 M 
GdnHCl [Fig. 36 inset]. Prominent but a gradual red shift was observable only at 
concentrations beyond 3 M GdnHCl. There was little or no effect on the fluorescence 
intensity till 1 M GdnHCl. 2-4 M GdnHCl caused an increase in the emission 
intensity. Further, increment of denaturant concentration to 5 and 6 M, quenched the 
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Fig. 36 Intrinsic fluorescence analysis of PTPI on interaction with 
various concentrations of GdnHCl 
The concentration of PTPI was 1 \\M. PTPI was preincubated for 2 h at 
25°C in 50 mM sodium phosphate buffer (pH 7.5) containing the 
increasing concentration of GdnHCl (0-6 M). Fluorescence was measured 
at an excitation wavelength of 280 nm and emission range of 300-400 nm 
with slitwidth of 5 nm. The inset shows changes in wavelength of 
maximum emission with increasing concentration of GdnHCl. 
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fluorescence intensity below native. This effect has also been documented for 
GdnHCl mediated alteration in fluorescence emission of other multimeric proteins 
like alcohol dehydrogenase [Sacchetta et al, 2001], glutamate dehydrogenase [Ruiz et 
al, 2003], p-nerve growth factor [Timm & Neet, 1992]. It is well known that 
fluorescence spectra of proteins with maxima around 335 nm are characteristic of 
tryptophan residues well buried in the hydrophobic core, whereas fluorescence spectra 
with maximum around 350 nm are characteristic of tryptophan residues exposed to 
the aqueous solvent [Lakowicz, 1983]. Thus, treatment of PTPI with higher 
concentrations of GdnHCl results in exposure of the buried tryptophan moieties 
present in native inhibitor to the solvent. Also, decrease in emission intensity at high 
denaturant concentration may result from quenching of the tryptophan fluorescence 
by aqueous solvent. Such a situation can happen only when the denaturant induces 
unfolding of PTPI. 
Secondary structure of PTPI in GdnHCl solutions 
Far UV-CD studies on GdnHCl induced unfolding of PTPI were carried out to study 
the effect of GdnHCl on the secondary structure of the inhibitor. The CD observed 
below 230 nm is due to the peptide amide chromophore [Johnson, 1985] and can be 
used to estimate the content of secondary structure. In the far UV region, the CD 
spectrum of native PTPI shows the presence of fair amount of a-helical conformation 
[Priyadarshini and Bano, 2009]. It was found to possess 17.2% of a-helical content 
determined by the method of Chen et al. [1972]. Fig. 37 summarizes the effect of 
GdnHCl on secondary structure of PTPI. Upto 1 M GdnHCl, in similitude to activity 
and fluorescence results, minute effects are seen on mean residue ellipticity (MRE) at 
222 nm. Beyond 4 M GdnHCl a complete loss of signal was observed. These 
observations suggest that treatment of PTPI with higher GdnHCl concentration results 
in complete unfolding of the inhibitor. 
Midpoint of denaturation transition (Cm) in the presence of GdnHCl 
The midpoint of chemical denaturation transition of proteins, abbreviated as Cm, can 
be defined as the concentration of the denaturant, at which 50% of the transition is 
complete, that is where /a = /n, fraction of denatured protein molecules is equal to 
fraction of native species. 
Transition curves were constructed from various parameters determined in GdnHCl 
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Fig. 37 Secondary structure analysis of PTPI in the presence of GdnHCl 
The figure shows changes in far UV CD spectra of PTPI denatured in 
increasing concentrations of GdnHCl (0-6 M). The conditions were same as 
for figure 3 except that the concentration of PTPI was 1.73 \iM. The inset 
shows changes in MRE at 222 nm with increasing concentration of GdnHCl. 
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denaturation of PTPI. The results are depicted in Fig. 38. Cm determined from the 
equilibrium transition curve derived from activity data [Fig. 38a] was 3.2 M GdnHCl. 
Cm is a function of protein concentration in dimer coupled systems [Timm & Neet, 
1992]. To analyze if the dissociation of dimeric PTPI and inactivation are coupled 
denaturation curves were constructed over a range in PTPI concentration (0.1, 1 and 
10 ^M). A concentration dependent shift in the midpoint of transition was observed, 
consistent with two-state model of denaturation [Fig. 38a]. Fig. 38b shows the 
normalized transition curve of changes in X^ ax of PTPI as a function of GdnHCl 
concentration. The midpoint of transition (Cm) was again determined to be 3.2 M. Cm 
deduced from the normalized transition curve of MRE 222nm [Fig. 38c] was also 3.2 M. 
Changes in the molecular properties of PTPI such as enzymatic activity, MRE222 nm, 
Xnax with increasing GdnHCl concentration reveal a monophasic sigmoidal 
dependence, with coincidental profiles [Fig. 38d], characteristic of cooperative 
unfolding, suggesting a two state model for denaturation of the inhibitor. 
3.2.2 CHANGES IN MOLECULAR PROPERTIES OF PTPI 
ASSOCIATED WITH UREA INDUCED UNFOLDING 
Although urea and GdnHCl are believed to have similar modes of action [Nandi & 
Robinson, 1984], GdnHCl is a monovalent salt that has both ionic and chaotropic 
effects [Mayr and Schmid, 1993; Makhatadze et al., 1998; Myers et al., 1995], 
whereas urea has only chaotropic effects. Thus, urea is an ideal control agent for 
distinguishing between the ionic and chaotropic effects of GdnHCl. 
Urea induced changes in structural and functional properties of PTPI were studied by 
changes in papain inhibitory activity, fluorescence emission intensity and Xmax of 
emission and MRE222 nm with increasing urea concentration. 
Effect of urea on papain inhibitory activity of PTPI 
PTPI was incubated with increasing concentration of urea in 50 mM sodium 
phosphate buffer (pH 7.5). Its thiol proteinase inhibitory activity was determined at 
each concentration of the denaturant using casein as substrate, by the method of 
Kunitz [1947]. Activity of native PTPI was taken to be 100. Fig. 39 shows that urea 
concentration lower than 1 M did not substantially affect the activity. 20% of activity 
was lost at 2 M urea concentration. At 4 M urea concentration 40% loss of 
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Fig. 38 Changes in functional and structural properties of PTPI in the 
presence of GdnHCl 
The figure shows normalized transition curves for GdnHCl induced 
unfolding of PTPI as obtained from 
(a) enzymatic activity 
(b) wavelength of maximum emission 
(c) MRE at 222 nm 
(d) shows the coincidence of transition curves, (a), (b) and (c). 
Panel (a) also shows the protein concentration dependence of PTPI 
denaturation. Inhibitory activity of PTPI was monitored at different 
concentrations, 0.1 ^M -o-, 1 ^M -n-, 10 ^ M - ^ of the native protein each 
incubated with increasing concentrations of GdnHCl. Fraction of unfolded 
protein was calculated at each concentration as explained in methods 
section. 
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Fig. 39 Effect of increasing urea concentration on activity of PTPI 
Native PTPI (1 |JM) was incubated with increasing concentration of urea 
(0-9 M) for 2 h at room temperature. PTPI was assayed for loss of 
antiproteinase activity by caseinolytic assay of Kunitz [1947]. Values are 
Mean ± SEM of four independent determinations. 
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activity was obtained and only 18% of native PTPI papain inhibitory activity was 
observed at 6 M urea. Beyond this concentration the inhibitor was barely active. 
Effect of urea on spectroscopic properties of PTPI 
Fluorescence spectra of PTPI in the presence of urea 
Intrinsic fluorescence emission spectra of native and unfolded proteins in the presence 
of increasing urea concentration are shown in Fig. 40. An increase in fluorescence 
emission of native PTPI without any shift in emission X a^xWas observed till 2 M urea. 
Fluorescence emission enhancement was again noticed at 6 M urea, preceded by a 
plateau (at 4 and 5 M urea). A sharp increase in emission intensity was observed 
beyond 8 M urea with a marked red shift of Xmaxto 350 nm which indicates that 
treatment of PTPI with high concentrations of urea leads to unfolding of the inhibitor. 
The maximum value of X^ ax obtained for both denaturants was same. 
Secondary structure of PTPI in urea solutions 
Far UV-CD spectroscopy was used to monitor changes in secondary structure of PTPI 
upon urea induced unfolding. Incubation of PTPI in urea solutions results both in 
changes the shape of CD spectra and in urea-concentration dependent loss in 
ellipticity [Fig. 41]. Upon denaturation the negative CD below 230 nm diminishes 
significantly, consistent with the loss of ordered secondary structure that should 
accompany protein unfolding. At urea concentrations above 5 M, there is complete 
loss of negative peaks. A sigmoidal dependence of decrease in MRE222 nm with 
increasing urea concentrations was observed with no change in the value observed for 
the native inhibitor upto 1 M urea. 
Midpoint of denaturation transition (Cm) in presence of urea 
As in GdnHCl-denaturation, Cm (the concentration at which 50% of the protein 
molecules exist in the unfolded state) was determined for urea denaturation also from 
the data derived on various parameters studied. Fig. 42a depicts the normalized 
transition curve for the loss of enzymatic activity in response to urea. The Cm value 
deduced from the curve was 3.6 M. No dependence of Cm on protein concentration 
was detected. It may be that inactivation and dimer dissociation in case of 
urea denaturation of PTPI are not coupled or as has been explained in the case of 
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Fig. 40 Intrinsic fluorescence analysis of PTPI on interaction with 
various concentrations of urea 
The concentration of PTPI was 1 ^M. PTPI was preincubated for 2 h at 
25°C in 50 mM sodium phosphate buffer (pH 7.5) containing the 
increasing concentration of urea (0-9 M). Fluorescence was measured at an 
excitation wavelength of 280 nm and emission range of 300-400 nm with 
slit width of 5 nm. The inset shows changes in wavelength of maximum 
emission with increasing concentration of urea. 
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Fig. 41 Secondary structure analysis of PTPI in the presence of urea 
The figure shows changes in far UV CD spectra of PTPI denatured in 
increasing concentrations of urea (0-9 M). The conditions were same as for 
figure 3 except that the concentration of PTPI was 1.73 i^M. The inset 
shows changes in MRE at 222 nm with increasing concentration of urea. 
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Fig. 42 Changes in functional and structural properties of PTPI in 
presence of urea 
The figure shows normalized transition curves for urea induced unfolding 
of PTPI as obtained from 
(a) enzymatic activity 
(b) wavelength of maximum emission 
(c) MRE at 222 nm 
(d) shows the coincidence of transition curves, (a), (b) and (c). 
Fraction of unfolded protein was calculated at each concentration as 
explained in methods section. 
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denaturation of the dimeric myosin rod, the equilibrium constants are Hkely to be very 
sensitive to denaturant concentration such that the effect of protein concentration is 
overshadowed [Nozais and Bechet, 1993]. The midpoint of Xmax transition curve was 
determined to be 4 M [Fig. 42b]. The Cm value deduced from MRE222 nm transition 
curve was 3.6 M urea [Fig. 42c]. 
The urea denaturation profiles of PTPI as studied by monitoring the changes in 
inhibitory activity, fluorescence emission maximum and MRE222 nm at increasing urea 
concentrations are non-coincident [Fig. 42d]. The inactivation of the inhibitor and loss 
of secondary structure can be seen as concomitant events. However, the modification 
(or substantial loss) in tertiary structure seems to occur at higher urea concentration 
since the midpoint of X^ ax transition curve is located around 4 M [Fig. 42c]. 
3.2.3 ANS FLUORESCENCE 
ANS has been widely used as a sensitive reporter of apolar regions in proteins and as 
a probe for protein non-native, partially unfolded conformations [Semisotnov et al., 
1991; Stryer, 1965; Ptitsyn, 1995]. Such intermediates are characterized by the 
presence of solvent exposed hydrophobic clusters. The binding of ANS to apolar 
region of proteins results in a significant enhancement of ANS fluorescence intensity 
and in a pronounced blue-shift of Xmax [Semisotnov et al., 1991]. For ANS in the 
presence of native PTPI, significant fluorescence intensity with emission X^ ax at 505 
nm was observed indicating the hydrophobic interaction between ANS and native 
PTPI that may be present due to the presence of some exposed hydrophobic patches in 
native PTPI. Reports with native proteins interacting considerably with ANS are 
present. Bovine liver catalase binds to ANS in native state [Prakash et al., 2002] so 
does cytoplasmic creatine kinase [Couthon et al, 1995]. 
To check if any non-native intermediate is present in unfolding of PTPI by GdnHCl 
and urea, ANS binding to denatured PTPI at increasing concentrations of the 
denaturants was analyzed. Denatured protein samples were incubated with 50 molar 
excess of ANS and fluorescence was monitored. In GdnHCl denaturation there was 
absence of any notable binding of ANS to GdnHCl-treated PTPI. ANS emission 
intensity slightly decreased during urea denaturation indicating disruption of native 
PTPI structure. Also no appreciable changes were detected in ANS emission X^ ax in 
both the cases, suggestive of no increase in apolar surface exposure during the process 
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[Fig. 43]. Similar results have been reported for creatine kinase. ANS binding 
fluorescence data for creatine kinase denaturation in 6 M urea and 3 M GdnHCl 
showed no hydrophobic surface exposure [Huang et al., 2001]. 
3.2.4 RENATURATION OF PTPI AFTER GdnHCl- AND UREA-
INDUCED DENATURATION 
For studying the renaturation of GdnHCl- and urea- treated PTPI, refolding studies 
were performed. PTPI was incubated with increasing concentrations of GdnHCl (0-6 
M) or urea (0-9 M) for 2 h. For performing refolding studies, these samples were then 
diluted to 50-fold in 50 mM sodium phosphate buffer (pH 7.5). The extent of 
renaturation was monitored by the recovery of inhibitory activity and fluorescence 
properties; at regular intervals till 24 h. Table 9 depicts the properties of refolded 
PTPI. Regain of inhibitory activity of PTPI was taken to be the main criterion for 
refolding as the fiilly active enzyme under these conditions is the manifestation of 
active site being present in proper (native) conformation. The inhibitor did not regain 
its papain inhibitory activity on urea denaturation. In case of GdnHCl induced 
denaturation only 10% of the native activity was observed even at low denaturant 
concentrations. Also, as seen in table 9 at all time intervals, both in urea and GdnHCl 
mediated denaturation (at all denaturant concentrations) the inhibitor refolded to a 
species having significantly different spectroscopic properties, Xmax of which was 
within the range of 325-330 nm, instead of 335 nm (for native PTPI). Upon 
incubation with ANS, the refolded species obtained both in case of urea and GdnHCl, 
did not aher the emission spectra of the dye, in intensity or in Xmax-
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Fig. 43 ANS fluorescence of PTPI at various concentrations of GdnHCI 
and urea 
The figure shows dependence of fluorescence emission of ANS bound to 
PTPI on the denaturant concentration. No significant change in the 
fluorescence intensity (at 505 nm) is observed at any concentration of 
GdnHCI. In presence of urea, fluorescence intensity continuously 
decreases. 
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TABLE 9: FLUORESCENCE EMISSION MAXIMA AND PAPAIN 
INHIBITORY ACTIVITY DURING REFOLDING OF 
PTPI AT VARIOUS TIME INTERVALS AFTER 50 FOLD 
DILUTION OF DENATURED SAMPLES 
Denaturant 
GdnHCl 
GdnHCl 
Urea 
Papain inhibitory activity (%)' 
2 h 
10 
4 h 
11 
8 h 
ND 
24 h 
ND 
Fluorescence emission maximum (nm) 
2 h 
325 
325 
4h 
330 
332 
8 h 
330 
328 
24 h 
320 
327 
^ Activity of the refolded PTPI was determined by the method of Kunitz [1947]. The 
activity is expressed as percent of native PTPI activity which was taken to be 100%, 
ND: None Detected. 
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DISCUSSION 
The altered levels (or activities) of cysteine proteinases (cathepsins) has been 
established as a cause for rheumatoid arthritis, osteoarthritis and osteoporosis 
[Vasiljeva et al, 2007], neurological disorders [Nakanishi, 2003], pancreatitis [van 
Acker et al., 2002], cancer [Gocheva & Joyce, 2007], etc. This fact prompted an 
increase in the interest in the enzymes that regulate CP activity, in vivo. Such 
proteinaceous inhibitors of CPs, ubiquitously distributed in organisms as well as 
tissues, primarily belong to the cystatin superfamily. Modified expression or function 
of the members of cystatin superfamily marks predisposition to diverse pathological 
states [Turk et al., 2008]. Studies that delve into the structural and functional 
properties of these inhibitors in response to various externally imposed conditions 
thus intend to provide a good approximation of the conformational stabilities of these 
inhibitors. 
An interplay of various physicochemical forces- like hydrophobic interactions, ionic 
interactions, disulfide bonds and other local as well as non-local interactions maintain 
the three dimensional structure of proteins. The conformational stability of the native 
protein is a flinction of external variables, such as, temperature, pH, ionic strength and 
solvent composition and can be measured by equilibrium unfolding studies using urea 
and guanidine hydrochloride (GdnHCl) [Pace, 1986]. CD measurements in the far-UV 
region, detecting changes in the secondary structure and steady-state fluorescence 
measurements, detecting changes in the tertiary structure, are complementary tools to 
investigate the conformational stability of globular proteins. 
Equilibrium denaturation studies usually focus primarily on monomeric globular 
proteins. However, muhidomain and oligomeric proteins remain relatively little 
explored [Jeanicke, 1991]. 
A number of investigations on unfolding have already been conducted for various 
members of cystatin superfamily [Khan & Bano, 2009; Rashid et al., 2005; 
Jankowska et al., 2004; Zerovnik et al., 1992; etc.]. On these lines, equilibrium 
denaturation of the purified cystatin, PTPI, was undertaken. 
The unfolding of PTPI in GdnHCl and urea suggests different unfolding pathways. 
The two possible pathways in urea and GdnHCl are represented schematically in Fig. 
44. In the figure dotted arrow in case of GdnHCl denaturation represents partial 
reversibility of the process, whereas in case of urea denaturation it represents the 
124 
uncertainty in presence and placement of intermediate states. Analysis of PTPI 
denaturation by fluorescence emission )wmax, MRE222 nm, and enzymatic activity 
measurements reveals a coincident transition, with Cm value of 3,2 M for GdnHCI 
denaturation. These results are consistent with two-state transition involving a folded 
dimer and unfolded monomer. 
Native PTPI-^  6 M GdnHCI ^ Unfolded Monomer 
Urea Urea 
Native PTPI ^ I^ntermediate • Unfolded Monomer 
Fig, 44 Schematic diagram of GdnHCI- and urea- induced unfolding of PTPI 
Equilibrium denaturation studies of the small dimeric globular proteins, fl gene V 
protein [Liang & Terwilliger, 1991], P22 Arc repressor [Bowie and Sauer, 1989a], 
mouse-P-nerve growth factor [Timm & Neet, 1992], revealed that stable intermediates 
are not detected at equilibrium. The experimental data were consistent with a two-
state model involving only the native dimer and denatured monomer. However, 
recent reports catalogue the presence of intermediates in denaturant induced unfolding 
of multimeric or large proteins [Garrido et al., 2005; Akhtar et al., 2002; Guo et al., 
2004b; etc]. Two-state denaturation of dimeric proteins by GdnHCI has also been 
reported earlier [Timm & Neet, 1992]. 
Inactivation and loss of secondary structure appear to be concomitant events in urea 
denaturation [Fig. 42]. The midpoint of transition curves for ellipticity and 
inactivation by urea was 3.6 M. The midpoint value of the X^ ax transition curve is 
shifted to a slightly higher concentration of urea (4 M). The non-coincidence of 
transition curves, as measured by probes that are sensitive to different levels of 
protein structure are consistent with a mechanism involving intermediate states [Kim 
& Baldwin, 1982]. The non-coincidence of the Xmax transition curve with those 
monitoring the changes in enzymic activity and ellipticity suggests the existence of 
intermediate states during urea denaturation. It may illustrate the unfolding of portions 
enclosing tryptophan residues. However, the intermediates are not clearly observed. 
As for example, no compact intermediate state possessing hydrophobic areas have 
been detected through ANS fluorescence. Intermediates in urea-induced unfolding of 
oligomeric enzymes have been documented for cytoplasmic creatine kinase [Couthon 
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et al., 1995], bovine liver catalase [Prakash et al., 2002], glucose dehydrogenase 
[Mendoza-Hernandez et al., 2000]. Creatine kinase denaturation by urea revealed 
presence of intermediate states adjudged by non-coincidence of the ellipticity curve 
with the curves presenting changes in enzymic activity, tertiary structure and 
molecular dimensions. However, intermediates were clearly observed in case of 
GdnHCl mediated creatine kinase unfolding [Couthon et al, 1995]. Presence of 
intermediate states in urea denaturation has also been documented for glucose 
dehydrogenase monitored easily by CD and fluorescence spectroscopy. Contrary to 
this, glucose oxidase was found to denture following a two-state model for urea 
[Akhtar et al., 2002]. 
Although monomeric, but high molecular mass goat lung cystatin are also known to 
denature in the presence of urea by following a muUistep process [Khan and Bano, 
2009b], suggesting the presence of aggregated/non-native intermediates in urea 
unfolding of high molecular mass proteins. 
Refolding and reactivation of the denatured PTPI (both for urea- and GdnHCl-
denaturation) was incomplete. The partially refolded PTPI gave maximum emission 
in range of 325-330 nm. Although close to the native enzyme and suggestive of a 
compact structure, its specific tertiary structure is quite different from the native PTPI, 
as no ANS binding was observed. This points to a disrupted native from. Activity gain 
was only 10% in case of GdnHCl, while in case of urea it remained undetected. This 
agrees with the generally recognised opinion that conformational integrity is 
important for maintaining the enzyme activity and the slight changes at the active site 
can lead to complete enzyme inactivation. In case of urea, it may point to large kinetic 
barrier for the unfolded monomer to reassociate into an active dimer. Or under in vivo 
conditions assisted folding might be taking place. Conditions for 100% recovery of 
active enzyme thus require optimization, in case of GdnHCl. 
The data derived from these studies indicate that unfolding pathways in GdnHCl and 
urea are different. This is not surprising since the two denaturants interact with 
proteins in a different way. Apart from their hydrogen bond breaking effect, urea also 
acts on hydrophobic bonds [Kamoun, 1988] and ions arising from GdnHCl are known 
to modulate electrostatic interactions [Hagihara et al., 1994]. Urea is generally known 
to be about half as effective in protein unfolding and dissociation as GdnHCl [Pace, 
1986]. This is suggestive of a '2-fold rule' [Mayers et al., 1995; Smith & Schohz, 
1996]. Multimeric proteins have higher ratio of [Cm (urea)/ Cm (GdnHCl)] [Akhtar et 
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al., 2002], which suggests that multimeric proteins are more susceptible to GdnHCl 
denaturation. Although, for proteins with non-two state transitions (as seen for urea 
induced denaturation in the present case) the Cm value may not be an accurate 
measure of the stability to the chaotrope, it does provide some indications for the 
differences in the interactions of the denaturant with different classes of proteins. The 
results of the present study show that PTPI is an exception to the '2-fold rule' of urea 
and GdnHCl denaturation. Fig. 38 and Fig. 42 present the results of denaturation of 
PTPI as monitored by the change in enzyme activity, MRE222 nm, and X^ ax of 
fluorescence emission. The midpoint of transition for urea unfolding was 3.6 M (4 M 
from the X^ ax curve), and that for GdnHCl was 3.2 M. Violation of '2-fold rule' for 
urea and GdnHCl denaturation has also been reported for the dimeric enzyme glucose 
oxidase [Akhtar et al., 2002]. This further points to significant contributions of both 
electrostatic and hydrophobic interactions in maintaining the active site and /or 
dimeric nature of the PTPI. 
The resuhs obtained in this study give an idea about the stability of PTPI and can be 
extrapolated to physiological conditions. Studying the behaviour and stability of 
proteins under denaturing conditions allows one to understand and quantify the forces 
that contribute to the conformational stability of protein in their aqueous environment 
[Pace, 1986]. Further the data on the stability of proteins can be used in algorithms to 
predict the structure or docking of proteins and to design new proteins with better 
activities and stabilising changes. 
127 
(gJ M 
^koM&y' 3 
3^n vitre fibrillation of 
pancreatic thiol proteinase 
inhibitor 
& 
3.3 RESULTS 
Amyloid fibril formation is generally the result of the alteration of native 
conformation of proteins. The partially folded conformations are favoured by 
mutations or changes in pH and ionic strength [Pedersen et al., 2004]. Members of 
cystatin superfamily show predisposition for fibrillization. A number of reports are 
available on in vitro fibrillation of cystatins under experimentally exposed mild 
denaturational conditions, besides, cystatin C and stefin B fibrillation been 
incriminated in human cystatin C amyloid angiopathy (HCCAA) and progressive 
myoclonus epilepsy (EPMl), respectively [Turk et al., 2008]. 
The ability for rational design of conditions promoting amyloid formation with a 
wider range of proteins (than those so far identified in specific diseases) provides an 
opportunity to investigate in detail the mechanism of the underlying processes (in 
vivo) and hence to explore the factors that predispose individual sequences to form 
ordered aggregates under particular conditions. This could be an important factor in 
the development of strategies to combat amyloid formation/deposition. 
On these footings, present study was designed to investigate the conditions under 
which the purified goat pancreatic thiol proteinase inhibitor fibrillates and to probe the 
inhibition or deaggregation of fibrils in the presence of divalent metal ions. 
3.3.1 ACID DENATURATION OF PTPI 
It has been well established that fibril formation requires appropriate physicochemical 
conditions, among which pH exerts a significant influence on the whole process of 
fibrillogenesis [Lai et al., 1996]. pH engendered deformation of proteins is common 
in biology. A number of proteins have been reported to exist as partially folded 
intermediates or as molten globules under acidic conditions [Rashid et al, 2006b; 
Kuwajima, 1989; Zerovnik et al, 1992; Ahmad and Khan, 2006; Brahma et al, 2005], 
a condition already emphasized as an important start point for amyloid aggregation, 
Thus to explore the existence of any non-native, partially unfolded intermediate under 
acidic conditions, PTPI was subjected to denaturation over a pH range of 1.0-7.0. 
Fluorescence spectra of PTPI in the presence of varying pH 
Acid induced unfolding of PTPI was followed by intrinsic fluorescence properties of 
the protein. PTPI incubated in buffers of different pH was excited at 280 nm to assess 
global conformational changes inflicted by pH. In its native state PTPI is 
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characterized by a peak at 335 nm (at pH 7.5) [Priyadarshini and Bano, 2009], Till pH 
5,0, no change is observed in X^ ax of emission [Fig. 45a]. However, a 10 nm blue shift 
is observed at pH 3.0. Lowering the pH to 2.0 caused a red shift of 2 nm (compared to 
the state at pH 3.0) fiirther followed by a red shift of 3 nm, at pH 1.0. On the other 
hand, as the pH is lowered fi-om 7.0 to 1.0, fluorescence intensity is quenched [Fig. 
45a]. This decrease in fluorescence intensity and a blue shift of 10 nm at pH 3,0 is 
indicative of burial of aromatic residues in the hydrophobic core of the protein and 
formation of a more compact structure. Red shift observed at pH 2.0 and 1.0 can be 
ascribed to slight unfolding of the structure. 
Effect of pH on ANS spectrum of PTPI 
In order to study the exposure of hydrophobic clusters of the PTPI during acid 
induced unfolding, effect of pH was followed by ANS fluorescence at 505 nm after 
exciting the ANS-protein complex at 380 nm [Fig. 45b]. Till pH 4.0, there was no 
appreciable increase in ANS binding. A sharp increase is noticeable at pH 3,0, 
reaching maximum at pH 1.0. Further, there was a shift in Xmax of ANS emission at 
pH 3.0, the XtnaxOf ANS-protein complex was blue shifted to 490 nm with no further 
change with pH reduction. These results show that at pH 3.0, small amount of 
hydrophobic clusters are present which bind ANS and also suggest the presence of 
large number of solvent accessible non-polar clusters in protein molecule at pH 1.0. 
Perturbation of secondary structure of PTPI by pH 
Tlie effect of acid induced unfolding on secondary structure of PTPI was 
monitored by ellipticity measurements at 222 nm. The results are shown in Fig. 46, 
The ellipticity at 222 nm decreased markedly below pH 7.0, to a minimum value at 
around pH 3.0. A fiirther decrease in pH below 3.0 resulted in a second transition 
corresponding to the formation of secondary structure which became maximum at pH 
1.0. At pH 3.0, -40% of secondary structure is lost. At pH 1.0, -34% of secondary 
structure is regained and it is marked by the presence of 82% secondary structure. 
Thus it may be concluded that PTPI at pH 3.0 exists as a partially unfolded 
intermediate which has -60% of residual secondary structure, but almost completely 
altered tertiary structure. PTPI at pH 1.0 exhibits more of molten globule like features 
with native like secondary structure contents, enhanced ability to bind ANS, however 
with tertiary contacts quite similar to native PTPI [Fig. 45a]. 
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Fig. 45 pH dependence of intrinsic and ANS fluorescence properties of 
PTPI 
(a) Figure shows variation in intrinsic fluorescence intensity at 335 nm and 
Xroax of emission of PTPI with pH. PTPI (1 \M) was incubated in 50 mM 
solutions of glycine/HCl (pH 2,0), sodium acetate (pH 3.0-5.0), sodium 
phosphate (pH 6.0-7.0) at room temperature for 4 h. The excitation 
wavelength was 280 nm and emission was recorded in range of 300-400 
nm with a slit width of 5 nm. 
(b) Figure shows variation in ANS fluorescence intensity at 505 nm and X a^xof 
emission of ANS-PTPI complex with pH. The samples were prepared as 
described above. The ANS to protein molar ratio was 1:50. ANS 
fluorescence was measured at an excitation wavelength of 380 nm in the 
emission range of 400-600 nm with a slit width of 5 nm. 
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Fig. 46 pH dependence of mean residue ellipticity (MRE) of PTPI at 
222 nm 
For far UV CD, 1.73 |iM of PTPI was incubated in 50 mM solutions of 
glycine/HCl (pH 2.0), sodium acetate (pH 3.0-5.0), sodium phosphate (pH 
6.0-7.0) at room temperature for 4 h. Cells of 1 mm pathlength were used. 
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3.3.2 EFFECT OF 2, 2,2-TRIFLUOROETHANOL (TFE) ON ACIDIC 
pH INDUCED STATE OF PTPI 
TFE has been used widely with other proteins to induce amyloid fibril formation 
[Zerovnik et al., 2007]. TFE has a double edged effect on proteins and peptides, on 
one hand, it can destroy the tertiary structure of proteins on the other hand, it can 
increase the a-helical structure of proteins and peptides via strengthening of the 
hydrogen bonds [Luo and Baldwin, 1998; 1997]. Effect of TFE on pH 3.0 state of 
PTPI was studied by means of intrinsic and extrinsic fluorescence and far UV CD. 
Effect of TFE on the secondary structure of PTPI at pH 3.0 
Fig. 47a shows changes in ellipticity at 222 run of pH 3.0 state as a function of TFE 
concentration. As shown earlier approximately 40% loss in secondary structure at pH 
3.0 occurred as compared to the native state at pH 7.5. Increase in concentration of 
TFE leads to increase in MRE 222 nm value. It is interesting to note that at 10% TFE the 
induced secondary structure reached almost the value for the native state. At higher 
TFE concentration denatured states vsdth very high a-helical content were formed. 
Native PTPI was also titrated with various concentrations of TFE. At all TFE 
concentrations accumulation of secondary structure was noticed with native PTPI 
transforming to an all-helical state beyond 10% TFE (data not shown). 
Effect of TFE on intrinsic fluorescence of PTPI at pH 3.0 
Since the pH 3.0 state of PTPI in presence of 10% (v/v) TFE shows native like 
secondary structure content it was of interest to study properties of pH 3.0 state in 
presence of TFE. Fig. 47b shows intrinsic emission spectra of PTPI at pH 7.5, pH 3.0 
and pH 3.0 state in the presence of 10% (v/v) TFE. The emission spectrum of PTPI 
shows >^ ax at 335 nm under native conditions. At pH 3.0, there was -31% loss in 
fluorescence intensity and a change in X^ ax to 325 nm suggesting internalization of 
tryptophan residues to a more hydrophobic environment [Haq et al., 2002]. At 10% 
(v/v) TFE concentration, there is -17% increase in fluorescence intensity with further 
blue shift in Imaxto 323 nm, suggesting further internalization of tryptophan residues 
in the hydrophobic environment and creation of a more compact structure. 
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Fig. 47 Effect of TFE on PTPI at pH 3.0 
(a) Figure shows the effect of increasing concentration of TFE (0-20%) on pH 
3.0 state of PTPI as monitored by changes in MRE value at 222 nm. Cells 
of 1 mm pathlength were used. 
(b) Intrinsic emission spectra of PTPI at pH 7.5, at pH 3.0 alone and in 
presence of 10% (v/v) TFE. The concentration of PTPI used was 1 nM, 
The excitation wavelength was 280 nm and emission was recorded in the 
range of 300-400 nm with a slit width of 5 nm. 
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Effect of TFE on ANS spectrum of PTPI at pH 3.0 
Fluorescent hydrophobic probe ANS has higher affinity for the partially unfolded 
intermediates and molten globules than for the proteins in the native or fully unfolded 
state. Fig. 48a shows that ANS binds maximally to pH 3.0 state of PTPI in presence 
of 10% (v/v) TFE compared to minimal ANS binding to native PTPI. The emission 
maximum blue shifts to 485 nm in the presence of TFE as compared to those of pH 
3.0 state (490 rmi) and at pH 7.5 (505 nm), further suggesting that the protein is 
adopting an altered structure. Titration of the pH 3.0 state with increasing 
concentration of TFE as studied by ANS binding at 490 nm [Fig. 48b] indicates slight 
disruption of compact structure at 10% (v/v) TFE. However at higher TFE 
concentrations [15 and 20% (v/v)] the pH 3.0 state gets altered as there is decrease in 
exposed hydrophobic clusters available for ANS binding. 
Similar studies were also conducted for acid induced pH 2.0 state and pH 1.0 state of 
PTPI. Unlike pH 3.0 state, no stabilized intermediates were observed. However, 10% 
(v/v) TFE was found to be predenaturational concentration in both the cases. 
3.3.3 OPTIMAL pH AND TFE CONCENTRATION TO INDUCE PTPI 
AMYLOID FIBRIL GROWTH 
Above results show that on decreasing the pH beyond 4.0 there is decrease in the 
dichroicity of PTPI at 222 nm and a blue shift of the Amax of fluorescence emission. 
With ftirther decrease in pH to 2.0 and 1.0 there are fiirther alterations in 
conformation of the protein. As reported for many other proteins acidic conditions 
prevent complete unfolding of the protein molecule [Rashid et al., 2006b; Gupta et al., 
2003; Artigues et al., 1994], and result in the formation of compact, non-native 
intermediates or molten globules. Acidic conditions render PTPI to adopt a partially 
unfolded conformation at pH 3.0 referred here as pH 3.0 state having substantial 
amount of secondary structure but devoid of native like tertiary state. At pH 1.0 more 
of a molten globule like intermediate is formed characterized by its compactness 
(compared to native state), persistence of secondary structure without well defined 
tertiary packing and a strong affinity for ANS as a consequence of the exposure of 
hydrophobic areas. TFE is known to induce a-helical states and to stabilize partially 
unfolded intermediates in proteins. PTPI at pH 3.0 gains native like secondary 
structure at 10% (v/v) TFE concentration and exhibits substantially exposed 
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Fig. 48 Fluorescence spectra of ANS bound to PTPI under different 
conditions 
(a) Figure shows fluorescence emission spectra of ANS bound to PTPI at pH 
7.5, at pH 3.0 alone and in presence of 10% (v/v) TFE. 
(b) Figure shows the effect of increasing concentration of TFE on pH 3.0 state 
as monitored by changes in ANS binding at 490 nm. 
The ANS to protein molar ratio was 1:50. ANS fluorescence was measured 
at an excitation wavelength of 380 nm in the emission range of 400-600 nm 
with a slit width of 5 nm. 
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hydrophobic patches (revealed by ANS binding). However, there is absence of native 
lilce tertiary fold. Beyond this concentration of TFE, denaturing states with very high 
a helical content were formed. 
Based on these findings PTPI for amyloid growth was incubated in acidic medium, as 
it is known that TFE accelerates amyloid growth [Zerovnik et al., 2002a], 10% (v/v) 
TFE was added. Amyloid formation was followed by two standard procedures, 
thioflavin T (ThT) assay and transmission electron microscopy (TEM) [Nilsson, 
2004], in the following six samples at regular time intervals, 
PTPI at pH 1.0, 2.0 and at pH 3.0 and at these three pH in presence of 10% (v/v) TFE. 
3.3.4 AMYLOID TYPE AGGREGATION/FIBRILLATION OF PTPI 
MONITORED BY ThT FLUORESCENCE 
The enhancement in the fluorescence intensity of ThT upon binding to ordered protein 
aggregates is a rapid and sensitive method to show presence of fibrils. Free ThT has 
emission maximum at 450 nm. However, upon binding to fibrils the emission A-max 
changes to 485 imi [Levine, 1999]. 50 ^M PTPI was incubated at pH 2.0 and at pH 
3.0, in presence of 0.15 M NaCl and 0.05% sodium azide. Changes in fluorescence 
emission of ThT were monitored at regular time intervals for both the samples. 
Results are depicted in Fig. 49a and 50a. The pH 2.0 sample, showed only ~5 fold 
enhancement in ThT fluorescence even after 55 days of incubation [Fig. 49a], 
suggesting a very lengthy lag phase. At pH 3.0 however, ~14 fold increment was 
observed within 5 days of incubation [Fig. 50a]. This indicates that at pH 3.0 the 
amyloid growth is rapid. PTPI samples incubated at neutral pH served as controls and 
showed no ThT binding. Results obtained for PTPI incubated at pH 1.0 were quite 
similar to those obtained for pH 3.0 sample. These results thus reveal that amyloid 
aggregates from PTPI form under acidic conditions and more readily at pH 3.0 and 
1.0 than at pH 2.0. 
Influence of TFE on amyloid aggregation of PTPI 
To study the effect of TFE on the formation of aggregates of PTPI, 50 jxM protein 
was incubated at pH 3.0 and at pH 2.0, with 0.15 M NaCl, 0.05 % sodium azide and 
10% (v/v) TFE. Fig. 49b and 50b show the time course of the change of ThT 
fluorescence as the protein aggregates form at pH 2.0 and pH 3.0 in presence of 10% 
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(v/v) TFE. Typical fibrillation processes involve a lag phase followed by a relatively 
rapid elongation phase, which stabilizes at a plateau level when all the protein 
molecules have been incorporated into fibrils [Harper and Lansbury, 1997]. Whereas 
at pH 2.0 aggregates develop after a long lag phase and exhibit relatively less ThT 
fluorescence enhancement [observed at SS"' day of incubation, Fig. 49a], in the 
presence of TFE the maximum ThT fluorescence is reached at 30 day of incubation 
with several fold increase in the intensity [Fig. 49b]. Similarly for the sample 
incubated at pH 3.0 in presence of TFE, amyloid aggregation started without a distinct 
lag phase with a profound fluorescent intensity enhancement [Fig. 50b]. The absence 
of lag phase suggests that amyloid aggregation of PTPI at pH 3.0 in presence of TFE, 
proceeds without a nucleation phase or the nucleus might have formed very rapidly 
(in the dead time of mixing). For PTPI incubated at pH 1.0, a rapid fibrillation was 
observed without any lag phase in presence of TFE. But ThT fluorescence intensity 
enhancement was lower to that obtained for pH 3.0. 
3.3.5 TRANSMISSION ELECTRON MICROSCOPY IMAGES 
Fibril formation was also followed by TEM. Fig. 51 shows TEM image of native 
dehydrated PTPI. No distinct fibril morphology is seen. Fig. 52 shows the TEM image 
of PTPI at pH 1.0 obtained after 15 days of incubation. Peculiar foliage like pattern is 
observed. Fig. 53 shows the TEM image obtained after one month of incubation of 
sample under similar conditions but at pH 2.0. It shows fibrils. Fig. 54 shows TEM 
image of PTPI at pH 3.0 in presence of 10% (v/v) TFE obtained after 15 days of 
incubation. Sharp fibril is observed. 
3.3.6 EFFECT OF DIVALENT METAL IONS, Cu^ ^ AND Zn^ "^  ON PTPI 
FIBRILLATION 
To date there is no potential cure to amyloidosis. Different effects of metal ions on 
amyloid aggregation have been documented. Fig. 55 shows the effect of Cu^ ^ and 
Zn on ThT fluorescence of preformed fibrils. PTPI fibrils grown at pH 3.0 in the 
presence of 10% (v/v) TFE were used in the experiment. Just before the ThT assay 
metal solutions were added to the sample. Controls of each concentration of Cu^ ^ and 
Zn were run to nullify the possibility of interaction with the dye. A concentration 
dependent decline in ThT fluorescence intensity at 485 nm was observed, about -35% 
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Fig. 49 PTPI fibrillation at pH 2.0 
(a) Fluorescence emission spectra of Thioflavin T (ThT) dye in the 
presence of PTPI at pH 2.0 
Figure shows increase of ThT fluorescence on binding to the fibrils of 
PTPI obtained after 55 days of incubation. 50 ^ iM protein was incubated at 
pH 2.0 at room temperature. 
^ly\ Time course of fibril growth of PTPI followed by ThT fluorescence at 
485 nm at pH 2.0 and in presence of 10% (v/v) TFE 
50 nM PTPI was incubated at pH 2.0 alone and in presence of 10% (v/v) 
TFE. Excitation was at 440 nm and spectra were recorded from 455 to 600 
nm with a slit width of 5 nm. For ThT assay 5 |i.M of incubated protein was 
used vidth a protein to ThT molar ratio of 1:6. The data were obtained after 
subtraction of the signal of the buffer containing ThT. 
138 
(a) 
14-
^ 12-
M 
H 
« io-
ta i-H 
S 9i 
Vi O-
lU 
u 
o S 4-
^ 
-a 2-
H 
u-
^ - s ^ 55 days 
Oh \ ^ 
' 1 ' 1 • 1 • 1 
480 510 540 570 
Wavelength (nm) 
1 
600 
(b) 
800n 
1 600-
e 
V IT) 
« ^ 400-
2 1 
o S 
s H 200-
JS 
H 
0-
r^  
/ —•—CMitrol 
/ -«-10%(v/v)TFE 
•Ml— t—• • • •—• 
0 10 20 30 40 50 60 
Time (days) 
Fig. 50 PTPI fibrillation at pH 3.0 
(a) Fluorescence emission spectra of Thioflavin T (ThT) dye in the 
presence of PTPI at pH 3.0 
Figure shows increase of ThT fluorescence on binding to the fibrils of 
PTPI obtained after 5 days of incubation. 50 |xM protein was incubated at 
pH 3.0 at room temperature. 
(b) Time course of fibril growth of PTPI followed by ThT fluorescence at 
485 nm at pH 3.0 and in presence of 10% (v/v) TFE 
50 ^M PTPI was incubated at pH 3.0 alone and in presence of 10% (v/v) 
TFE. Excitation was at 440 nm and spectra were recorded from 455 to 600 
nm with a slit width of 5 nm. For ThT assay 5 }AM of incubated protein was 
used with a protein to ThT molar ratio of 1:6. The data were obtained after 
subtraction of the signal of the buffer containing ThT. 
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Fig. 51 Electron micrograph of PTPI incubated under native 
conditions 
Figure shows image obtained for native dehydrated PTPI. 50 |xM of PTPI 
in 50 mM sodium phosphate buffer (pH 7.5) was used. 
Fig. 52 Electron micrograph showing amyloid aggregation of PTPI 
incubated at pH 1.0 
Figure shows image obtained for PTPI incubated at pH 1.0 in presence of 
10% (v/v) TFE. Sample used was obtained after 15 days of incubation. 
Experimental details are provided in methods section. 
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Fig. 53 Electron micrographs showing amyloid aggregation of PTPI 
incubated at pH 2.0 
Figure shows image obtained for PTPI (at different magnifications as 
shown by the size of bar lines) incubated at pH 2.0 (50 mM glycine/HCl) 
in presence of 10% (v/v) TFE. Sample used was obtained after 30 days of 
incubation. Experimental details are provided in methods section. 
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Fig. 54 Electron micrographs showing amyloid aggregation of PTPI 
incubated at pH 3.0 
Figure shows image obtained for PTPI (at different magnifications as 
shown by the size of bar lines) incubated at pH 3.0 (50 mM sodium acetate 
buffer) in presence of 10% (v/v) TFE. Sample used was obtained after 15 
days of incubation. Experimental details are provided in methods section. 
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decrease in intensity was observed at 10 i^M Cu ion concentration, which increased 
to -42% at 20 |iM culminating into 98% decline in ThT fluorescence at 50 |AM CU^* 
ion concentration, beyond this concentration fluorescence intensity was too 
diminished for any discernible peak to be observed at 485 nm [Fig. 55a]. Similar 
effects were observed for Zn^ "^ . Minute decline (1-2%) in ThT fluorescence was 
observed till 6 |j,M Zn ion concentration. At 10 |xM Zn ion concentration almost 
97% of the intensity was quenched. Beyond this concentration no perceivable effect 
was seen [Fig. 55b]. 
When Cu^ "^  and Zn^ ^ were added at 50 )xM and 10 )xM concentration respectively, to 
50 \iM PTPI (pH 3.0, 10% (v/v) TFE) at the start of incubation, no ThT binding was 
observed, indicative of absence of any amyloid type aggregation in the presence of 
metal ions, suggesting Cu^ ^ and Zn^ "^  help in preventing amyloid formation. 
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Fig. 55 Inhibition of fibrillation of PTPI by Cu^ ^ and Zn^ ^ as probed 
by ThT fluorescence 
2+ (a) Figure shows inhibition of fibrillation as a function of Cu concentration 
(b) Figure shows inhibition of fibrillation as a function of Zn^ ^ concentration 
For both the experiments 50 |xM PTPI was incubated at pH 3.0 in presence 
of 10% (v/v) TFE. Metal solutions were added prior to ThT assay. 
Excitation was at 440 nm and spectra were recorded from 455 to 600 nm 
with a slit width of 5 nm. For ThT assay 5 \iM of incubated protein was 
used with a protein to ThT molar ratio of 1:6. The data were obtained after 
subtraction of the signal of the buffer containing ThT. 
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DISCUSSION 
Cathepsin knockouts have demonstrated that cathepsins have specific and individual 
functions, w h^ich are very important for the normal functioning of the organism [Turk 
et al., 2001]. Among others they degrade the extracellular matrix, of importance in 
tumor progression and invasion [Gocheva and Joyce, 2007]. Accidentally escaped 
cathepsins from lysosomes are trapped by cystatins, their endogenous protein 
inhibitors. Cystatins comprise large family of thiol proteinase inhibitors. Members of 
cystatin superfamily have propensity to form fibrillar aggregates [Skerget et al., 2009]. 
Lately, various non-pathogenic proteins have been shown to form amyloid fibrils in 
vitro, such as acylphosphatase [Chiti et al., 1999], cold shock protein [Wilkins et al., 
2000], hen lysozyme [Krebs et al., 2000], SH3 domain [Zurdo et al., 2001], 
cytochrome C [Pertinhez et al., 2001] and myoglobin [Fandrich et al., 2001], etc. 
The aim of the present study was to define the requisite conditions for the in vitro 
fibrillation of pancreatic thiol proteinase inhibitor and thus test the generic ability of 
proteins to aggregate to p sheet rich fibrillar structures. The 'generic amyloid' 
hypothesis essentially states that the ability of proteins to form ordered fibrillar cross 
P-structures is inextricably linked to the nature of the protein backbone [Chiti et al., 
1999; Dobson, 1999] and is independent of the structure of the native state. Thus, 
while some proteins obviously fibrillate more readily than others, it should be 
possible to find conditions that are sufficiently destabilizing for the native state to 
allow the protein to explore alternative conformations and lock on to the stable P-
sheet aggregated state. 
Exploring conditions for PTPI fibrillation 
It is generally believed that globular proteins need to unfold, at least partially, to 
aggregate into amyloid or amyloid like fibrils [Chiti et al., 1999; Krebs et al., 2000; 
Fandrich et al., 2001; Rabzelj et al., 2005; Holm et al., 2007; Zerovnik et al., 2007]. 
Such a "conformational change hypothesis" is widely supported by a large body of 
experimental data. Proteins normally adopting a compact and well defined three-
dimensional fold have a higher propensity to aggregate under conditions that promote 
their partial unfolding such as high temperature, high pressure, low pH or moderate 
conditions of organic solvents [Konno, 2001; Rabzelj et al., 2005; Soldi et al., 2005]. 
As noted for various proteins, amyloid formation by PTPI in vitro was achieved by 
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destabilizing the native state of the protein under conditions in which non-covalent 
interactions still remain favourable. PTPI when subjected to acid denaturation yields a 
'partially unfolded intermediate', the pH 3.0 state and a molten globule like 
intermediate at pH 1.0 [Fig. 45 and 46]. From these results it can be inferred that the 
structure remaining at these low pH environments may not be residual native like 
structure that the acid unfolding has failed to disrupt, but rather newly formed 
organisations, and consequently with little resemblance to native structure [Buck et al, 
1993]. 
PTPI at pH 3.0, 2.0 and 1.0 possess significant non-native secondary structure, which 
is likely to transform to amyloid aggregates and this tendency was judged by ThT 
fluorescence assay. PTPI incubated under these three acidic conditions tested positive 
for amyoid by Tht fluorescence assay. However, there were differences in ThT 
binding [Fig. 49a and Fig. 50a]. Distinct fibrillar states under different solution 
conditions have also been reported for stefin B [Zerovnik et al., 2007] where different 
type of fibrils originate from pH 4.8-native like and pH 3.3-mohen globule like 
intermediate. Fibril growth has also been documented under (mild) acidic conditions 
for insulin [Ahmad et al., 2005], endostatin [He et al., 2006], acylphosphatase [Chiti 
et al., 1999], stefin B [Rabzelj et al, 2005] and stefin A and B [Jenko et al., 2004; 
Zerovnik et al., 2002b]. Rapid fibrillation was observed at pH 3.0 and 1.0 then at pH 
2.0; suggesting that partially folded and native like molten globule states have a 
higher propensity to form aggregates [Fig. 49a and Fig. 50a]. This is supported by 
reports on fibrillation of bovine serum albumin [Holm et al., 2007]. 
It is a well known fact that 2, 2, 2-trifluoroethanol (TFE), a hydrogen bond promoting 
solvent has an accelerating effect on amyloid fibrillation. To find out the most 
appropriate concentration of TFE, required for PTPI fibril growth, influence of 
increasing concentration of TFE on pH 3.0 state of PTPI was studied. It was observed 
that at 10% (v/v) TFE, pH 3.0 state of PTPI gained sufficient amount of non-native 
secondary structure with increased amount of exposed non polar clusters whereas at 
higher concentrations of TFE, a-helical content was profoundly enhanced with 
decreased hydrophobic effect. Binary mixtures of water with alcohols like methanol, 
ethanol, or TFE have been shown to cause conformational transition of proteins into 
new stable conformational states with high a-helical content and disrupted tertiary and 
quaternary structure resembling that of molten globule intermediate [Polverino de 
Laureto et al., 2002]. Alcohols weaken non-local hydrophobic interactions while 
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enhancing local polar interactions (i.e. hydrogen bond) of proteins [Rashid et al., 
2006b]. Alcohols induce significantly higher a-helical structures in partially or 
completely unfolded proteins as compared to those in folded proteins [Bhakuni, 1998]. 
Among various alcohols, TFE is often preferred because of its remarkable potential in 
stabilizing the a-helical structure [Gupta et al., 2003]. 10% (v/v) TFE was found to 
stabilize pH 3.0 state of PTPI drawing credence from previous reports. In this study, 
amyloid fibril growth was accelerated by addition of 10% (v/v) TFE to samples 
incubated at pH 2.0 as well as at pH 3.0 [Fig. 49b and 50b]. The lag observed initially 
for fibrillation at pH 2.0 was considerably reduced by addition of TFE and at pH 3.0 
fibrillation initiated without any lag phase in presence of TFE. Quite similar results 
were obtained for sample incubated at pH 1.0. This suggests that pH 1.0 and pH 3.0 
states of PTPI (in presence of TFE) have a higher tendency to aggregate and fibrillate. 
Enhancement of the rate of fibrillation by TFE has also been noted before. Stefin A 
and stefin B showed accelerated fibril growth in the presence of predenaturational 
TFE concentrations [Jenko et al., 2004; Rabzelj et al., 2005; Zerovnik et al., 2007]. 
This effect was also observed for fibrillation of acylphosphatase. Chiti et al. [1999] 
found that fibrillation of acylphosphatase proceeds at moderate concentration of 
trifluoroethanol. Chiti et al. [2001] reiterated similar effects of TFE, with HypF-N 
terminal domain. TFE was also found to promote fibrillation in case of endostatin [He 
et al., 2006]. 
Based on above discussion, possible mechanism of PTPI aggregation could be 
presented as, 
^, Acidic pH „„^ 
TFE (moderate concentration) 
Ni • Agg 
Fig. 56: Scheme for mechanism of PTPI aggregation, where N stands for native 
state, PFI for acid induced partially folded intermediate; Ni for TFE 
induced native like intermediate and Agg for amyloid aggregate. 
The proposed mechanism shows that the protein may form fibrils from a partially 
folded intermediate stabilized by organic solvent TFE to a more native like structure, 
NI. Thus it can be propounded that partially folded predenaturational intermediates 
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appear to be critical species in the fibrillation process. A probable explanation was 
offered by He et al. [2006] for the observation that destabilization of native fold and 
presence of non-native a-helix promotes fibrillation. They suggested that hydrophobic 
surface exposure and stability are two important factors controlling protein 
conformation. Unstable proteins with exposed hydrophobic surfaces result in 
molecular adhesion [Wodak and Janin, 2003]. In present case also PTPI at acidic pH 
[1.0, 2.0 and 3.0] was found to possess exposed non-polar clusters revealed by 
enhanced ANS binding [Fig. 45b]. In an environment that favors the conformational 
stability, a-helix would prevent the polypeptide chain from converting into fibril 
structure [Fandrich and Dobson, 2002]. Contrarily, under other conditions where 
mutagenesis or organic solvents reduce the stablitiy of the a-helical structure formed 
in proteins, the polypeptide is therefore ready to form fibrils. As for PTPI the a-
helical structure revealed by far UV CD in Fig. 47a is not in the fully structured native 
conformation but is induced by TFE. This non-native a-helical structure of PTPI 
being unstable can easily transform to amyloid like aggregates [as shown by ThT 
fluorescence and TEM [Fig. 50b and 54]. Thus, unstable a-helix induced in proteins 
can facilitate fibril formation [He et al., 2006]. 
The fibrils obtained for PTPI incubated at pH 3.0 [Fig. 54, TEM image] were similar 
to classical straight needle-form structures characteristic of bona fide fibrils. Those 
obtained for PTPI incubated at pH 2.0, also exhibited fibrillar aggregates. However, 
pecuhar foliage like pattern was obtained for PTPI incubated at pH 1.0. Distinct 
fibrillar patterns have also been shown for bovine serum albumin [Holm et al., 2007], 
endostatin [He et al., 2006], insulin [Grudzielanek et al., 2006] and P2 microglobulin 
[Hong et al., 2002]. This fiulher suggests that PTPI is able to form different type of 
fibrils. It has already been noted that fibril morphologies differ depending upon 
solvent conditions [Zerovnik et al., 2007], which in the present case refer to differing 
pH. 
Strategies against fibrillation of PTPI 
A range of human disorders is associated with the extracellular deposition of insoluble 
protein aggregates of regular arrays of P sheet rich filaments or fibres of indefinite 
length, often coiled together in higher order structures [Frokjaer and Otzen, 2005; 
Dobson, 2003], example, Alzheimer's disease, prions disease, Huntington's and 
Parkinson's disease, type 2 diabetes etc. [Sambashivan and Eisenberg, 2006; Meriini 
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and Bellotti, 2003; Engel et al., 2008]. Because of the connection of amyloid fibrils to 
conformational diseases which are hitherto incurable, various compounds (natural and 
synthetic) are under experimentation for their efficacy in destabilizing and 
disaggregating amyloid fibrils or inhibiting the basic conformational change of the 
protein responsible for fibrillation. A number of compounds like curcumin, antibiotics, 
anticancer agents, nicotine etc. have been demonstrated to inhibit formation of 
fibrillar assemblies or are under trials [Zerovnik, 2002; Findies, 2000; Riviere et al., 
2008]. 
Recent reports have shown that Cu^ * and Zn^ "^  retard the amyloid growth [Zerovnik et 
al., 2006; Raman et al., 2005]. These divalent metal ions were also used for inhibiting 
PTPI fibrillation and for disintegrating the formed fibrils. 50 |j,M Cu^ ^ and 10 |iM 
Zn^ "^ , almost completely abolished ThT fluorescence enhancement. The same 
concentration when added to the PTPI sample prior to fibril induction, fibrillation 
seemed to be arrested. In this case, Cu^ ^ and Zn^ ^ may stabilize the protein, 
preventing the aggregation. In the former case, Cu^ ^ and Zn^ ^ salts might exert 
GdnHCl like action, disintegrating the ordered structure of fibrils. 
Conclusively, these results sustain the generic hypothesis of amyloid fibrillation and 
outline the conditions necessary for PTPI fibrillization. The work also foreshadows 
the use of redox active metals like copper as therapeutic agents against amyloid 
formation. Lastly, it connects to the susceptibility of cystatin superfamily members 
for amyloid aggregation. 
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3.4 RESULTS 
Pancreatic tissue exhibits particular sensitivity to oxidative stress, contributing to 
impaired functioning characteristic of diabetes, pancreatitis and fibrosis [Lenzen, 
2008a]. Proteins offer the most potential targets of radical species and are usually 
rendered with compromised functions. 
The purified protein, pancreatic thiol proteinase inhibitor (PTPI) was presumed to be 
equally sensitive (may be with somewhat enhanced susceptibility to reactive species, 
because of its host tissue). The experiments were thus focused to examine the effects 
of various reactive species on PTPI and also to investigate the potential of 
bioflavonoids quercetin (QE), caffeic acid (CA) and curcumin (Cur) to protect its 
damage against deleterious effects of the radicals by analyzing, papain inhibitory 
activity, along with intrinsic fluorescence and polyacrylamide gel electrophoresis 
behaviour of treated PTPI. 
3.4.1A INTERACTION OF PTPI WITH PHOTOSENSITIZED 
RIBOFLAVIN 
Riboflavin upon irradiation with fluorescent light generates reactive oxygen species 
like superoxide anion (O2'"), singlet ('O2) and triplet oxygen (^62), flavin radicals and 
substantial amounts of hydrogen peroxide [Husain et al., 2006]. 
Functional inactivation of PTPI by riboflavin 
Effect of riboflavin on PTPI function was assessed by monitoring the changes in its 
antiproteolytic activity by caseinolytic assay of papain [Kunitz, 1947]. 1 ^M PTPI 
was photo illuminated with increasing concentrations of riboflavin (5-50 ^M) or with 
40 ^M riboflavin for various time intervals. The results obtained are summarized in 
Table 10. As shown in Table 10 (A) exposure of PTPI to increasing concentration of 
riboflavin, resulted in rapid decline of antiproteolytic activity (83% loss) towards 
papain, with half of the inactivation (56%) taking place at a concentration of 
riboflavin as low as 10 |iM. Similarly, increase in length of exposure (0-60 min) of 
PTPI with riboflavin caused loss of inhibitory activity towards papain (Table 10 B), 
with more than 50% inhibition taking place after 30 min of incubation. To detect the 
ROS type involved in PTPI inactivation various free radical scavengers were used. 
Fig. 57 (A) illustrates the results obtained. 
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Fig. 57 Effect of scavengers on riboflavin mediated inactivation of 
PTPI 
(A) 1 |AM PTPI was incubated with riboflavin (40 |xM) alone or in presence of 
sodium azide/potassium iodide/thiourea/mannitol/sodium benzoate/uric 
acid/glucose (final concentration, 25 mM) or ascorbic acid (final 
concentration, 100 mM) for 30 min at room temperature under fluorescent 
light and assayed for antiproteolytic activity. None of the scavengers used 
had any effect on PTPI assay. Data are expressed as Mean ± SEM for four 
experiments. * p < 0.05 compared to PTPI+riboflavin alone. 
(B) Native PTPI (1 p,M) was incubated with riboflavin (40 |xM) alone or in 
presence of curcumin (Cur • , final concentration, 100 [xM) or caffeic 
acid (CA | | )/quercetin (QE| | ) (final concentration, 350 ^M). Rest of 
the experimental conditions were same as above. Data are expressed as 
Mean ±SEM for four experiments. * p < 0.05 compared to PTPI+riboflavin 
alone. 
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Maximum suppression of PTPI inactivation was caused by potassium iodide closely 
followed by sodium azide. Sodium azide is a scavenger of singlet oxygen and 
potassium iodide scavenges flavin triplet state. Sodium benzoate, mannitol and 
thiourea eliminate hydroxyl radicals [Khan and Khan, 2004; Martinez-Cayuela, 1995]. 
These hydroxyl radical scavengers also offered some protection explicating moderate 
role of these radicals in riboflavin mediated PTPI inactivation. Biological antioxidants 
such as uric acid, glucose and ascorbic acid were analysed for suppression of PTPI 
inactivation by riboflavin. Ascorbic acid was found to be most effective. 
Structural modification of PTPI by riboflavin 
The effects of various concentrations of photoilluminated riboflavin were also 
determined on the structure of PTPI. The samples incubated at increasing riboflavin 
concentrations (5-50 |iM) were subjected to PAGE [Fig. 58]. At 5|xM riboflavin 
concentration, a lighter intensity band was observed. At concentrations above that, till 
30 ^M, diffused bands were observed. At higher concentration, 40 and 50 pM, 
aggregation was observed with concomitant loss of native bands. 
No aggregated products were observed in treated PTPI in presence of potassium 
iodide, sodium azide and ascorbic acid [Fig. 59]. Again propounding, flavin triplet 
and singlet state as main culprits for photodynamic modifications PTPI. 
Treatment of PTPI with photo illuminated riboflavin drastically altered its intrinsic 
fluorescence properties. The fluorescence emission spectra of native PTPI gave an 
emission maximum at 335 nm when excited at 280 nm [Fig. 60] [Priyadarshini and 
Bano, 2009]. 1 ^M PTPI photoilluminated with increasing concentration of riboflavin 
5-50 ^M was subjected to fluorescence spectroscopy to assess the effect on global 
conformation of protein, the samples were excited at 280 nm and emission range was 
300-400 nm. Riboflavin treatment upto 10 [iM did not induce any change in emission 
Xmax however ~ 44% decline in fluorescence intensity was precipitated. Beyond this 
concentration a blue shift of 5 nm (Xmax shifted to 330 nm compared to 335 nm for 
native) was observed with a profound decline (-75%) in fluorescence intensity [Fig. 
60]. Effect of 40 \JM riboflavin on intrinsic fluorescence of PTPI (1 [M) was also 
studied for various time periods (0-60 min). A time dependent gradual loss in 
fluorescence intensity with a similar blue shift was also observed after 20 min of 
incubation. To ascertain the effect of various scavengers in subjugating the 
detrimental consequences of the photodynamic action of riboflavin on structure of 
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Fig. 58 PAGE of native and riboflavin treated PTPI 
Native PTPI (1 |jM) was incubated with increasing riboflavin 
concentrations (5-50 |aM) for 30 min under fluorescent light and subjected 
to non denaturing PAGE. Gels were silver stained. 
Fig. 59 PAGE of PTPI exposed to riboflavin in presence of various 
scavengers 
Native PTPI (1 pM) was incubated with 40 pM riboflavin in presence of 
various scavengers, sodium azide/potassium iodide (final concentration, 25 
mM)/ascorbic acid (final concentration, 100 mM) or in presence of 
curcumin ( Cur, final concentration, 100 }JM) or caffeic acid 
(CA)/quercetin (QE) (final concentration, 350 |JM) and subjected to non 
denaturing PAGE. The experimental conditions were same as defined for 
Fig. 58. Gels were silver stained. 
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Fig. 60 Intrinsic fluorescence analysis of PTPI treated with different 
concentrations of riboflavin 
1 i^M PTPI was incubated with increasing concentrations of riboflavin (5-
50 fiM) under fluorescent light for 30 min in a final reaction volume of 1 
ml in 50 mM sodium phosphate (pH 7.5) at room temperature. The 
excitation wavelength was 280 nm and emission was recorded in range of 
300-400 nm with a slit width of 5 nm. Trace 1 is native PTPI, or PTPI + 
riboflavin 5 ^M (trace 2), 10 i^M (trace 3), 20 ^M (trace 4), 30 nM (trace 
5), 40 ^M (trace 6), 50 ^M (trace 7). 
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TABLE 11: RETENTION OF TRYPTOPHAN FLUORESCENCE IN THE 
PRESENCE OF DIFFERENT SCAVENGERS AND 
ANTIOXIDANTS 
Condition 
1 }iM PTPI + 40 ]iM Riboflavin 
-
+ Sod. Benzoate 
+ Mannitol 
+ KI 
+ Sod. Azide 
+ Glucose 
+ Ascorbic acid 
+ Cur 
+ CA 
+ QE 
% retention of tryptophan fluorescence 
27.29 
37.15 
25.00 
77.17 
77.60 
66.68 
76.35 
59.15 
75.16 
66.70 
Results are % retention of tryptophan fluorescence emission intensity (which is dependent upon but not 
synonymous with the number of tryptophan residues) measured at 280 nm excitation and 300-400 nm 
emission with a slit width of 5 nm. Experiment details are as described in methods section 
PTPI, fluorescence spectra of treated PTPI in presence of scavengers was obtained 
and percent retention of tryptophan fluorescence was determined. The results are 
summarized in Table 11. Treated PTPI retained only 27% of native tryptophan 
fluorescence. Reaffirming the involvement of flavin triplet state and singlet oxygen in 
photodynamic modification of PTPI by riboflavin, maximum retention of tryptophan 
fluorescence (-78%) was seen in presence of potassium iodide and sodium azide. 
Marmitol and sodium benzoate exhibited <50% retention, implicating only faint 
involvement of hydroxyl radicals. Among biological antioxidants, ascorbic acid again 
showed maximum protection. 
3.4.1B PROTECTIVE EFFECT OF BIOFLAVONOIDS 
Curcumin (Cur), Caffeic acid (CA) and Quercetin (QE) against 
photodynamic modifications of PTPI 
In quest of finding natural alternatives to scavengers. Cur, CA and QE were examined 
for their potency to revert/prevent any modification induced in PTPI by 
photosensitized riboflavin. Preliminary experiments were conducted to determine the 
most effective concentration of above three compounds. 350 |j.M CA and QE 
prevented loss of antiproteolytic activity of PTPI [Fig. 57B]. Aggregation of PTPI 
was also restrained by QE and CA [Fig. 59]. In presence of 350 fxM CA, -75% of 
tryptophan fluorescence was retained [Table 11]. QE afforded retention of tryptophan 
fluorescence to an extent similar to glucose. Cur (100 |iM) however exerted only 
moderate preventive influence in all the features studied. 
3.4.2A INTERACTION OF PTPI WITH HYDROGEN PEROXIDE 
(H2O2) 
Hydroperoxides such as H2O2 and lipid hydroperoxides have been implicated as 
mediators of cellular injuries in a variety of clinical conditions including pancreatitis, 
cancer, etc. [Pryor et al., 2006]. Thus, deleterious effects of H2O2 and protective 
effects of polyphenols on PTPI were assessed. 
Functional modification of PTPI by H2O2 
H2O2 caused only modest inactivation of PTPI. Even at high concentrations of H2O2 
(500 mM) only 50% of antiproteolytic activity of PTPI was compromised 
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[Table 12A]. To study the impact of H2O2 on activity of PTPI as a function of time, 1 
)iM PTPI was incubated with 250 mM H2O2 in dark for varying time periods (0-60 
min) and activity of PTPI was determined [Kunitz, 1947]. A slow and gradual decline 
in activity was observed culminating to only a 50% loss [Table 12B]. The effect of 
various scavengers on H2O2 induced PTPI inactivation was studied. Sodium benzoate 
and thiourea did not show any protection. Mannitol offered 27% enhancement of the 
papain inhibitory activity of treated PTPI. Since manntiol, sodium benzoate and 
thiourea are specific hydroxyl scavengers, this suggests only partial involvement of 
these radicals in H2O2 mediated PTPI damage [Fig. 61]. Among biological 
antioxidants 25 mM glucose offered better protection than 100 mM ascorbic acid. 
Structural modification of PTPI by H2O2 
1 \iM PTPI was exposed to (1-500 mM) H2O2 in dark for 30 min and the samples 
were analyzed by polyacrylamide gel electrophoresis. There was only a slight decline 
in band intensity as compared to the untreated PTPI, which was maximized at 500 
mM H202- In parallel to modest inactivation of the inhibitor, the gross conformational 
status of PTPI remained largely unaffected even when exposed to high H2O2 
concentration [Fig. 62]. In the presence of the scavenger mannitol and physiological 
antioxidant, glucose, the band intensity was retrieved to that of native PTPI [Fig. 63]. 
Gel results are presented for most conspicuous effects only. 
The intrinsic fluorescence spectra of samples treated with various concentrations of 
H2O2 are depicted in Fig. 64. Complex changes were observed in contrast to the 
results of inactivation and PAGE. PTPI imder native conditions gives fluorescence 
emission spectrum with maximum at 335 nm. Even at 1 mM H2O2, the emission ^ imax 
suffered a red shift of 5 rmi, with pronounced enhancement in intensity. No changes 
were noticeable till 50 mM H2O2 (spectra not shown). At higher concentrations 
fluorescence intensity decreased, reaching to that of native at 250 mM H2O2, while 
red shift to 340 mn was maintained. At 500 mM H2O2, hnax suffered another red shift 
of 5 nm, reaching a value of 350 run. When studied as a function of time, within 20 
min, 250 mM H2O2 produced a red shift of 5 nm in Amax- Within 60 min A,max shifted 
to 350 nm from 335 mn for the native. Conclusively, H2O2 causes unfolding of PTPI. 
Keeping in view the complex alterations in fluorescence intensity of PTPI in presence 
of H2O2, regain of native Xmax of emission was chosen as a criterion to judge the 
effects of various scavengers on PTPI (1 ^M) in presence of 250 mM H2O2. 
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Fig. 61 Effect of scavengers on H2O2 mediated inactivation of PTPI 
Native PTPI (1 |j,M) was incubated with H2O2 (250 mM) alone or in 
presence of mannitol/glucose (final concentration, 25 mM)/ascorbic acid 
(final concentration, 100 mM) or curcumin ( C u r Q 100 nM)/ caffeic acid 
(CA ^ 6 0 ^M Vquercetin (QE 050 |iM ) for 30 min in a final reaction 
volume of 1 ml at room temperature in dark and was assayed for its 
antiproteolytic activity. None of the scavengers used had any effect on 
PTPI assay. Data are expressed as Mean ± SEM for four experiments. * p < 
0.05 compared to PTPI+H2O2 alone. 
Fig. 62 PAGE of native and H2O2 treated PTPI 
Native PTPI (1 |JM) was incubated with increasing H2O2 concentrations (1-
500 mM) for 30 min in dark subjected to non denaturing PAGE. Gels were 
silver stained. 
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Fig. 63 PAGE of PTPI exposed to H2O2 in presence of various 
scavengers 
Native PTPI (1 ^M) was incubated with 250 mM H2O2 in presence of 
various scavengers, mannitol/glucose (final concentration, 25 mM) or in 
presence of curcumin ( Cur, final concentration, 100 ^M) or caffeic acid 
(CA)/quercetin (QE) (final concentration, 60 and 50 ^M, respectively) and 
subjected to non denaturing PAGE. The experimental conditions were 
same as defined for Fig. 61. Gels were silver stained. 
Fig. 64 Intrinsic fluorescence analysis of PTPI treated with different 
concentrations of H2O2 
1 nM PTPI was incubated with increasing concentrations of H2O2 in dark 
for 30 min in a final reaction volume of 1 ml in 50 mM sodium phosphate 
(pH 7.5) at room temperature. The excitation wavelength was 280 nm and 
emission was recorded in range of 300-400 nm with a slit width of 5 nm. 
Trace 1 is native PTPI. Trace 2 is PTPI treated with 1 mM H2O2. Trace 3 
represents PTPI treated with 100 mM H2O2. Trace 4 and 5 are PTPI treated 
with 250 mM and 500 mM H2O2. 
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Thiourea and sodium benzoate did not show any impact. Glucose and ascorbic acid 
brought back the Xmaxto 335 nm. Mannitol gave same effect however fluorescence 
intensity of the treated PTPI in its presence remained quenched below that of 
untreated PTPI. 
3.4.2B PROTECTIVE EFFECT OF BIOFLAVONOIDS 
Curcumin (Cur), caffeic acid (CA) and quercetin (QE) against H2O2 
mediated modifications of PTPI 
There is limited number of reports indicating direct subjugation of oxidative damage 
inflicted by H2O2 on proteins in vitro. Curcumin (Cur), caffeic acid (CA) and 
quercetin (QE) were probed for their suppressive effects against the adverse 
consequences of H2O2 on PTPI. 
As shown in Fig. 61, among the three bioantioxidants, most substantial increment 
(45%) in the treated PTPI's inhibitory activity was brought about by 100 pM Cur, 
followed by a 35% enhancement spawned by 60 i^M CA. QE (50 nM) showed a 
mediocre gain of 30% in activity. However, all of the three antioxidants, generated 
native like band pattern of PTPI even in the presence of 250 mM H2O2 [Fig. 63], 
Intrinsic fluorescence properties of treated PTPI were also brought back to native in 
the presence of Cur, CA and QE. 
3.4.3A INTERACTION OF PTPI WITH HYPOCHLOROUS ACID 
(HOCI) 
Myeloperoxidase released by phagocytic cells at sites of inflammation, catalyzes the 
formation of potent chlorinating/oxidising agent hypochlorous acid from H2O2 and 
chloride ions. It is a recognized DNA and protein damaging agent [Jenner et al, 2002], 
Effects of HOCI on function and structure of the purified inhibitor were analyzed. 
Functional modification of PTPI by HOCI 
The exposure of 1 i^M PTPI to varying HOCI concentrations resuhed in a dramatic 
change in its antiproteolytic potential. At concentration as low as 0.5 i^M, HOCI 
incited 34% loss in activity of PTPI. At equimolar concentrations with the inhibitor, 
60% PTPI activity was compromised. The inhibitor was barely active at 5 pM HOCI 
(-90% loss in activity). Beyond which no papain inhibitory activity was detected 
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[Table 13], Since in vivo many physiological antioxidants will be present together 
with PTPI, the protective effect of two, namely glucose and ascorbic acid was studied 
[Fig. 65]. The HOCl mediated loss in activity, was diminished in the presence of 
ascorbic acid and glucose, with ascorbic acid exerting a better protection. 
Structural modification of PTPI by HOCl 
1 ^M PTPI was incubated with increasing concentrations of HOCl. The samples were 
analyzed for impact on structural integrity of PTPI employing PAGE. As shown in 
Fig. 66, significant loss of the parent protein band was observed even at HOCl: PTPI 
ratio of 0.5; 1. There was a progressive increase in fragmentation of the inhibitor (as 
assessed by the loss of parent protein band) at higher ratios with complete loss of any 
staining material at HOCl: PTPI ratio of 10:1. Physiological antioxidants glucose and 
ascorbic acid were expected to protect PTPI fragmentation. Fig. 67 illustrates the 
resuh obtained. 25 mM glucose and 100 mM ascorbic acid afforded significant 
protection. 
The intrinsic fluorescence properties of PTPI were also adversely affected. As shown 
in Fig. 68 fluorescence intensity declined with increase in HOCl concentration. No 
fluorescence was observed beyond 5 nM HOCl. Interestingly, emission Xmax remained 
unaffected at all concentrations of HOCl. The protective effects of glucose and 
ascorbic acid were observed in retaining tryptophan fluorescence (-40% and -45%, 
respectively) even in the presence of 5 ^M HOCl. 
3.4.3B PROTECTIVE EFFECT OF BIOFLAVONOIDS 
Curcumin (Cur), caffeic acid (CA) and quercetin (QE) against HOCl 
mediated modifications of PTPI 
Flavonoids have been extensively studied for their antioxidant properties against 
various free radicals. However, their effect on hypochlorous acid mediated damage is 
less known. Thus, present work was also aimed at exploring the potential of Cur, CA 
and QE against hypochlorite inflicted damage. As depicted in Fig. 65, 100 ^M each of 
CA, Cur and QE, diminished the extent of loss of PTPI activity by several times 
causing the papain inhibitory potential of PTPI to remain close to that of native. 
Similar protection was also noticed in PAGE [Fig. 67], All three antioxidants 
subjugated structural damage of PTPI caused by HOCl. Tryptophan fluorescence, lost 
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Fig. 65 Effect of scavengers on HOCl mediated inactivation of PTPI 
Native PTPI (1 |j.M) was incubated with HOCl (5 |aM) alone or in presence 
of glucose (final concentration, 25 mM)/ascorbic acid (final concentration, 
100 mM) or curcumin (Cur I I )/ caffeic acid (CA | [ )/quercetin 
(QE [][[]) (final concentration, 100 ^M, respectively) for 30 min in a final 
reaction volume of 1 ml at room temperature and was assayed for its 
antiproteolytic activity. None of the scavengers used had any effect on 
PTPI assay. Data are expressed as mean ± SEM for four experiments. * p < 
0.05 compared to PTPI+HOCl alone. 
Fig. 66 PAGE of native and HOCl treated PTPI 
Native PTPI (1 nM) was incubated with increasing HOCl concentrations 
(0.5-10 ^M) for 30 min followed by the addition of 100 ^M GSH to 
quench residual oxidants and subjected to non denaturing PAGE. Gels 
were silver stained. 
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Fig. 67 PAGE of PTPI exposed to HOCl in presence of various 
scavengers 
Native PTPI (1 |iM) was incubated with 5 |iM HOCl in presence of 
scavengers, glucose (final concentration, 25 mM) or ascorbic acid (final 
concentration, 100 mM) or in presence of curcumin ( Cur)/caffeic acid 
(CA)/quercetin (QE) (final concentration, 100 |xM) followed by the 
addition of 100 i^M GSH to quench residual oxidants and subjected to non 
denaturing PAGE. The experimental conditions were same as defined for 
Fig. 66. Gels were silver stained. 
Fig. 68 Intrinsic fluorescence analysis of PTPI treated with different 
concentrations of HOCl 
1 pM PTPI was incubated with increasing concentrations of HOCl for 30 
min in a final reaction volume of 1 ml in 50 mM sodium phosphate (pH 
7.5) at room temperature. The reaction was stopped by adding 100 pM 
GSH. The excitation wavelength was 280 nm and emission was recorded in 
range of 300-400 nm with a slit width of 5 nm. Trace 1 is native PTPI, or 
PTPI + HOCl 0.5 pM (trace 2), 1 pM (trace 3), 3 [M (trace 4), 5 \M (trace 
5). 
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to 5 |iM HOCl was -99% retrieved [Fig. 69]. Percent retention of tryptophan 
fluorescence was -71% and -44% in presence of Cur and QE, respectively. 
3.4.4A INTERACTION OF PTPI WITH NITRIC OXIDE (NO) 
It is widely accepted that enhanced NO formation [and subsequent generation of 
complex cocktail of cytotoxic and oxidant reactive nitrogen species] contributes to 
oxidative and nitrosative stress in a variety of pancreatic and cardiovascular 
pathologies [Lenzen, 2008a; Denicola and Radi, 2005]. Thus, studies were undertaken 
to study the effects of NO on function and structure of purified pancreatic thiol 
proteinase inhibitor (PTPI). Also Cur, CA and QE were analyzed for their efficacies 
in ameliorating the detrimental effects of NO on PTPI. 
Generation of NO 
Sodium nitroprusside (SNP) was used as a selective NO donor. SNP in aqueous 
solution at physiological pH spontaneously generates NO, which interacts with 
oxygen to produce nitrite ion which can be estimated using Griess reagent. Incubation 
of solutions of SNP in phosphate buffered saline at 25 °C resuhed in linear time-
dependent nitrite production. 
Functional modification of PTPI by NO 
1 nM PTPI was incubated with increasing concentrations of SNP (0.05 to 10 mM) for 
30 min and its papain inhibitory activity was determined by caseinolytic assay of 
papain [Kunitz, 1947]. The fiinctional loss of PTPI inhibitory activity was 
proportional to SNP concentration [Table 14]. Approximately 37% loss in activity 
was incurred by 0.05 mM SNP. At 1 mM SNP, a significant decline (72%) of native 
PTPI activity was observed with complete loss at 10 mM SNP concentration. Time 
dependent loss in PTPI activity was also monitored. PTPI (1 |aM) was incubated with 
0.05 mM SNP, and activity was determined for varying time intervals (0-180 min). 
There was a gradual decrease in inhibitory activity till 45 min. A sharp decline (60%) 
was observed after 60 min of incubation, 94% at 150 min, with no activity detected 
after 180 min of incubation. 
Structural modification of PTPI by NO 
Effect of NO on structural integrity of PTPI was examined by PAGE. No major 
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Fig. 69 Intrinsic fluorescence analysis of PTPI treated with HOCl in 
presence of natural antioxidants 
1 (xM PTPI was incubated with 5 jiM HOCl in presence of curcumin 
(Cur)/cafFeic acid (CA)/quercetin (QE) (final concentration, 100 \iM) for 
30 min in a final reaction volume of 1 ml in 50 mM sodium phosphate (pH 
7.5) at room temperature. The reaction was stopped by adding 100 pM 
GSH. The excitation wavelength was 280 nm and emission was recorded in 
range of 300-400 nm with a slit width of 5 nm. 
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modifications were observed. The parent band pattern was conserved at all 
concentrations except that band intensity was slightly increased [Fig. 70]. 
The modifications of amino acid residues of PTPI consequential to NO exposure were 
analyzed by intrinsic fluorescence spectroscopy by monitoring the changes in 
intensity and Xmax- The resuhs are summarized in Fig. 71. Fluorescence intensity was 
considerably quenched at 0.05 mM SNP with a 5 nm red shift (from 335 nm for 
untreated PTPI to 340 nm). A further increase in concentration of SNP to 1 mM, 
quenched the intensity to 77.4% with another 5 nm red shifl (to 350 nm). At 10 mM 
SNP, fluorescence was completely quenched. Conclusively, NO lead to quenching of 
fluorescence coupled to 15 nm red shift in Xmax-
When analyzed as a function of time, the decrease in fluorescence intensity was 
triggered within 15 min of incubation and culminated to -71% decline at 180 min of 
incubation. The red shift of 15 nm precipitated within 60 min of incubation. 
3.4.4B PROTECTIVE EFFECT OF BIOFLAVONOIDS 
Curcumin (Cur), caffeic acid (CA) and quercetin (QE) against NO 
mediated modifications of PTPI 
A great deal of evidence has amassed pointing to reactive nitrogen species (RNS) as 
the main contributors to nitrosative stress in a variety of pathologies. Therefore, 
targeting NO (and NO congeners) either directly by scavengers or indirectly by 
inhibitors of its downstream targets are exciting therapeutic strategies. In this respect, 
plant polyphenols offer to be attractive candidates. Present study was undertaken to 
examine the anti-nitrosative efficacies of CA, QE and Cur in reclamation of the NO 
induced modifications of PTPI. 
For these studies, 1 pM PTPI was incubated with 1 mM SNP and the samples were 
analyzed by caseinolytic assay of papain [Kunitz, 1947] and fluorescence 
spectroscopy. NO mediated a decline in activity (72% loss. Table 14). 20 pM Cur 
prompted restoration of lost activity near to native [Fig. 72]. 
80 pM each of QE and CA inhibited the loss to a similar extent. These bioflavonoids 
were also analyzed for their potency to restore the structural changes induced by NO 
on PTPI. As shown in Fig. 73 all the three natural antioxidants negated the loss in 
tryptophan fluorescence and retrieved the native like fluorescence pattern in treated 
PTPI. Maximum protection was offered by CA and Cur. 
169 
Fig. 70 PAGE of native and SNP treated PTPI 
Native PTPI (1 joM) was incubated with increasing SNP concentrations 
0.05,1 and 10 mM, for 30 min and subjected to non denaturing PAGE. Gels 
were silver stained. 
Fig. 71 Intrinsic fluorescence analysis of PTPI treated with different 
concentrations of SNP 
1 nM PTPI was incubated with increasing concentrations of SNP for 30 
min in a final reaction volume of 1 ml in 50 mM sodium phosphate (pH 
7.5) at room temperature. The excitation wavelength was 280 nm and 
emission was recorded in range of 300-400 nm with a slit width of 5 nm. 
Trace 1 is native PTPI. Trace 2 is 0.05 mM, trace 3 is 1 mM and trace 4 is 
10 mM SNP treated PTPI. 
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Fig. 72 Effect of natural antioxidants on SNP mediated inactivation of 
PTPI 
Native PTPI (1 (xM) was incubated with SNP (1 mM) alone or in presence 
of curcumin (Cur | | ) / caffeic acid (CA L J )/quercetin (QE \ ]) (final 
concentration, 20 ^M for Cur and 80 jxM for CA and QE) for 30 min in a 
final reaction volume of 1 ml at room temperature and was assayed for its 
antiproteolytic activity. None of the scavengers used had any effect on 
PTPI assay. Data are expressed as Mean ± SEM for four experiments. * p < 
0.05 compared to PTPI+SNP alone. 
Fig. 73 Intrinsic fluorescence analysis of PTPI treated with SNP in 
presence of natural antioxidants 
1 ^M PTPI was incubated with 1 mM SNP in presence of curcumin 
(Cur)/caffeic acid (CA)/quercetin (QE) (final concentration, 20 |iM for 
Cur, 80 l^M for CA and QE) for 30 min in a final reaction volume of 1 ml 
in 50 mM sodium phosphate (pH 7.5) at room temperature. The excitation 
wavelength was 280 nm and emission was recorded in range of 300-400 
nm with a slit width of 5 nm. 
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DISCUSSION 
Reactive species (ROS/RNS) like superoxide anions, hydroxyl radicals, hydrogen 
peroxide, and nitric oxide are the intermediates of regular pathway of aerobic 
metabolism and processes. These reactive species generated from normal metabolism 
or exogenous insults lead to peroxidation of membrane lipids and damage to cellular 
macromolecules like DNA and proteins. Aerobic organisms synthesize enzymes 
devoted to the prevention and repair of oxidative damage and extreme genetic 
deficiency in either of these two defences can lead to inviability in aerobic 
environments. The uncontrolled oxidative stress initiates a series of harmful 
biochemical events associated with diverse pathological processes [Droge, 2002]. 
There are numerous indications that ROS/RNS play significant role in various 
pancreatic pathologies including diabetes and its secondary complications like 
retinopathy, nephropathy and neuropathy, in chronic and acute pancreatitis and in 
pancreatic stellate cell fibrosis [Chvanov et al., 2005; Pacher et al., 2005; Lenzen, 
2008a]. Interestingly, pancreas has been found to be exceptionally liable to oxidative 
and nitrosative damage as a consequence of its feeble antioxidant defence [Lenzen, 
2008a, Neuschwander-Tetri et al., 1997]. 
Pancreatic thiol proteinases, cathepsin B, H and calpains are involved in activation of 
zymogen and insulin secretion and action [Thrower et al., 2006; Sreenan et al., 2001], 
Their activity is primarily regulated by thiol proteinase inhibitors. In traumatic 
processes usually the balance between the lysosomal proteinases released by 
macrophages and neutrophils and their endogenous inhibitors is disturbed. This 
imbalance may originate from various reasons one of which may be inactivation by 
radical species viz. H2O2, HOCl, ROS, NO (and RNS). 
The present work was thus outlined to deduce the effect of exposure of purified PTPI, 
in vitro, to photoilluminated riboflavin (mimicking the biological subjection to 
oxygen radicals [Tsai et al., 1985], non-radical oxidants H2O2 and HOCl and NO 
(generated from SNP), on its function and structure. The results evinced the 
susceptibility of PTPI to aforementioned reactive species and the modifications 
induced included altered molecular weight (aggregation or fragmentation), loss of 
fluorescence and inhibitory function. 
Photosensitized riboflavin produces ROS [Husain et al., 2006] whose damaging 
effects have been documented in various proteins [Ali et al., 1991; Jazzar and Naseem, 
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1994; Husain et al, 2006; Hasan et al., 2006]. Among the various forms of ROS 
generated, singlet oxygen is of particular physiologic significance because of its 
selectively long life in aqueous solution, its ability to cross cell membrane barrier and 
high reactivity towards biomolecules [Joshi, 1998]. 
The results reveal the loss of PTPI function on exposure to photosensitized riboflavin. 
This bears similarity to sheep plasma high molecular weight kininogen (HMWK) 
[Baba et al., 2004], membrane proteins [Ali et al., 1991], BSA, invertase, lysozyme 
[Jazzar and Naseem, 1994] and trypsin [Husain et al., 2006; Hasan et al., 2006] 
damage caused by photosensitized riboflavin. Results obtained with specific ROS 
scavengers suggested that singlet oxygen and flavin triplet state were predominantly 
responsible for PTPI damage. Same resuhs are reported for sheep HMWK and 
catalase [Baba et al., 2004; Gantchev and van Lier, 1995] showing that singlet oxygen 
and radical species can participate in photosensitizer-induced inactivation of enzymes. 
Riboflavin at higher concentration (40 and 50 \JM) generated aggregate formation. 
This behaviour has also been reported earlier for sheep plasma HMWK [Baba et al., 
2004] and goat brain cystatin [Sumbul and Bano, 2008]. Owing to the absence of free 
sulphydryls in purified PTPI [Priyadarshini and Bano, 2009] these aggregates might 
have formed due to the exposed hydrophobic patches. This is supported by the ahered 
fluorescence of PTPI in presence of photoilluminated riboflavin (a 5 nm blue shift in 
Imax, firom 335 nm for native to 330 nm for the treated PTPI) and enhanced ANS 
binding to treated PTPI. 
The reactive species like H2O2 and HOCl have been recognized as hallmark of 
inflammation [Martinez-Cayuela, 1995]. Macrophages and neutrophils reduce 
molecular oxygen to superoxide anion, as a part of host defence system to neutralize 
the invading pathogens [Mamett et al., 2003]. The superoxide produced is rapidly 
dismutated to hydrogen peroxide. Activated neutrophils release the enzyme 
myeloperoxidase that reacts with H2O2 and chloride ions present to form HOCl 
[Mamett et al., 2003], a reactive oxygen metabolite, that can modify amino acid 
residues, induce conformational changes in proteins and inactivate enzyme and 
enzyme inhibitors [Shechter et al., 1975; Wasil et al., 1987; Dean et al., 1997]. HOCl, 
a strong oxidant, is known to oxidize many important biomolecules such as DNA, 
proteins, enzymes and antiproteinases [Jerlich et al., 2000; Whiteman et al., 2003; 
Khan and Khan, 2004; Szuchman-Sapir et al., 2008]. 
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The results reveal that PTPI, in the presence of HOCl lost its antiproteinase activity 
rapidly (within 30 min, 90% loss occurred at 5 i^M HOCl). Inactivation of proteins 
like of a2 M, by HOCl has been registered earlier [Khan and Khan, 2004]. Whiteman 
et al. [2003] reported a 90% loss in activity of isolated ai antiproteinase in presence of 
7 ^M HOCl. Protein inactivation by HOCl may occur through muhiple mechanisms, 
like, oxidation of critical amino acid residues e.g. cysteine [Tyagi, 1991], methionine 
[Moreno and Pryor, 1992]; modification of tyrosines [Feste and Gan, 1981] as well as 
other residues [Whiteman, 1998]. PTPI inactivation may also be consequent to 
oxidation/ modification (chlorination) of residues crucial to its activity or due to 
diminished conformational integrity changing the active site region of the inhibitor. 
H2O2 was found to be a modest inactivator of PTPI relative to HOCl (and other 
radicals studied). The treated inhibitor lost only 50% of its antiproteolytic activity 
even in presence of 500 mM H2O2 [Table 12A]. Use of scavengers reflected H2O2 as 
the damaging agent itself with only partial involvement of hydroxyl radicals. Non-
radical (molecular reactions) driven damage of proteins (e.g. lens crystallins and a2 M, 
in vitro) by H2O2 has been reported earlier [Khan and Khan, 2004; McNamara and 
Augusteyn, 1984]. The conformational status of H202-treated PTPI remained largely 
unchanged [Fig. 62]. Material with slightly higher mobility appeared at H2O2 
concentration of 100 mM and above, with a little loss in the band intensity as 
compared to the parent protein band. Protein fragmentation by H2O2 has been shown 
for BSA by Hunt et al. [1988]. Correspondingly, significantly higher mobility 
material was observed for HOCl treated PTPI. Glucose and ascorbic acid lodged 
prevention of protein fragmentation [Fig. 66 and 67]. In case of H2O2, marked red 
shift of 15 nm was observed indicating change in the microenvironment of tryptophan 
residues towards polar [Fig. 64], and the loss of native folded state of PTPI. While in 
presence of HOCl, fluorescence of PTPI was quenched completely beyond 5 ^M 
HOCl [Fig. 68] without any change in \aax- In H2O2 mediated damage, the higher 
mobility material consists of fi-agmentation products, and the unfolding might have 
facilitated the protein fragmentation [Davies and Delsignore, 1987]. 
HOCl usually causes aggregation of proteins as has been shown for fibronectin 
[Vissers and Winterboum, 1991], apolipoprotein A-I [Bergt et al., 2001], caprine a2 
M [Khan and Khan, 2004], ovalbumin [Olszowski et al., 1996], apohaemoglobin and 
apomyoglobin [Chapman et al., 2003]. Protein fi-agmentation by HOCl is 
substantiated from reports on serum albumin, Cu/Zn SOD, and glucose-6-phosphate 
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dehydrogenase [Hawkins and Davies, 1998; Ullrich et al., 1999; Auchere and 
Capeillere-Blandin, 2002]. HOCl reacts with amide groups of protein backbone and 
also with free amino groups of lysine residues of proteins yielding chloramines. These 
chloramines can than effectuate protein fragmentation. At low HOCl concentrations 
preferably lysines are modified limiting the rapid backbone fragmentation. Further, 
extent of fragmentation at low HOCl concentrations is defined by number of lysine 
residues in proteins [Hwakins and Davies, 1998]. The fluorescence profile of HOCl-
treated PTPI reveals complete loss of intensity at concentrations above 5 |iM without 
any change in X^ ax of emission. There was a HOCl concentration dependent increase 
in higher mobility material when treated PTPI was subjected to PAGE [Fig. 66] with 
complete loss of any staining material at 10 pM HOCl. Separate bands were not 
discernible at any HOCl concentration. This suggests that HOCl even at very low 
concentrations (protein:HOCl ratio of 1:0.5) causes backbone fragmentation releasing 
smaller fragments which make up for the appearance of higher mobility material in 
PAGE. Upto protein:HOCl ratio of 1:5, though fragmentation was induced [Fig. 66], 
native PTPI might have existed in significant proportions defining the unaltered Xmax 
Also, HOCl is prejudiced to modify tyrosine, phenylalanine (by chlorination), 
cysteine, methionine (by sulphoxidation and oxy-acid formation) than to oxidize 
tryptophan [Stadtman and Levine, 2003]. This might also explain the unaltered Xmax of 
PTPI mainly attributable to tryptophan. 
NO is a highly reactive free radical gas, which can participate as a cytotoxic effector 
molecule and/or pathogenic mediator when produced at high rates by inflammatory 
stimuli induced nitric oxide synthase or over stimulation of constitutive forms of 
enzyme [Radi, 2004]. In contrast to the protective action of low levels of NO, its 
excess has injurious outcomes due to exacerbated oxidative damage [Pryor, 2006]. 
NO also caused extensive loss of PTPI fiinction. Presumably NO enfeebled PTPI in 
quite a similar fashion as HOCl (by modification or damage of critical amino acid 
residues). A number of reports catalogue protein inactivation by NO through amino 
acid modification e.g. goat lung cystatin [Khan et al., 2009], catalase [Sigfrid et al., 
2003; Brunelli et al., 2001] and cytochrome P450 [Wink et al., 1993] etc. 
NO produced a red shift of 15 nm and PTPI was completely unfolded at higher 
concentration [Fig. 71]. Such effect has also been reported for goat lung cystatin 
[Khan et al., 2009]. There were no significant changes in the mobility of NO-treated 
PTPI when subjected to PAGE. However, increased band intensity was observed as 
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compared to native PTPI band. This may be due to increased reaction of NO-treated 
PTPI with silver stain reagent [Davies and Delsignore, 1987]. The drastic change in 
fluorescence profiles of NO-treated PTPI compared to unnoticeable conformational 
change on PAGE analysis can be supported to some extent by the initial association of 
oxidatively generated fragments of PTPI in a conformation similar to that of native 
protein [Dean et al., 1997]. Similar results were obtained for BSA damaged by 
hydroxyl radicals, in which initially only very small amount of molecules with 
changed size were detected [Hazell et al., 1994; Fisher and Stadtman, 1992]. 
DIETARY ANTIOXIDANTS AS STRATEGIES AGAINST FREE 
RADICAL DAMAGE 
Many antioxidant defences, enzymatic (superoxide dismutase, catalase, glutathione 
peroxidase) and non-enzymatic (ascorbic acid, uric acid, glucose, glutathione, vitamin 
E) exist to maintain the balance between reactive species production and 
neutralization. However, they fail to provide complete protection against conditions of 
severe oxidative stress [Cesaratto et al., 2004]. Also the non enzymatic oxidants are 
relatively inefficient as high concentrations are required to prevent oxidative damage. 
This inefficiency is reinforced by the observation that protein derived radicals can be 
detected in plasma treated with low concentrations of HOCl even when endogenous 
antioxidants were present [Hawkins and Davies, 1998; Dean et al., 1997]. Besides, 
many synthetic antioxidants have shown toxic and/or mutagenic effects. These 
observations shifted the attention towards naturally occurring antioxidants. 
Therefore, experiments were also designed to address these issues. Three plant 
components were chosen, whose protective effects in various pancreatic (and other 
organ) pathologies have already been registered, viz. Curcumin (Cur), Caffeic acid 
(CA) and Quercetin (QE) [Kanitkar et al., 2008; Jung et al., 2006; Kim et al, 2007]. 
These bioflavonoids are known for exerting pleiotropic heahh benefit through their 
antioxidant, anti-inflammatory, antimicrobial, anticancer, antidiabetic activities 
[Aggarwal et al., 2007; Takahama et al., 2009; Sreejayan and Rao, 1997]. 
Efficacy of these natural antioxidants against the detrimental effects of 
photosensotized riboflavin, H2O2, HOCl, and NO on PTPI, in vitro, was evaluated. 
Concentration dependent protective effect was observed for all the three, for all four 
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radical systems (results not shown). Only the most effective concentration of each, in 
every radical system is described. 
Riboflavin mediated photodynamic damage of PTPI was considerably diminished by 
QE and CA. Cur provided only partial moderation. QE and CA (350 [M each) caused 
manifold enhancement in the activity of treated PTPI [Fig. 57B]. Aggregation 
(observed at 40 ^M riboflavin) was also inhibited and tryptophan fluorescence 
retrieved back. However, Cur failed to show any preventive effects in the latter two 
cases. Major damage on PTPI by photoilluminated riboflavin was incurred by singlet 
oxygen and flavin triplet state. High concentration of phenolics has been shown to 
quench these two radical states [Cardoso et al., 2006]. Such effect was also provided 
by rutin, catechin and epigallocatechin gallate [Becker et al., 2005]. 
Direct mitigation of H2O2 toxicity in in vitro assay systems finds rare documentation. 
In the present study, PTPI inactivation (though modest), unfolding and loss in 
conformational integrity, induced by H202was alleviated by 100 pM Cur, 60 pM CA 
and 50 pM QE. This concurs with the study of Nakayama [1994] in which CA and 
QE suppressed the H2O2 induced cytotoxicity in biological assay systems. In general 
ROS scavenging on the whole has been shown by Cur [Huang et al., 1988]. 
HOCl reduced PTPI's antipapain potential, and altered its structural integrity, 
presumably causing fragmentation and modification of constituent amino acid 
residues. CA (100 pM) effectuated almost complete reversal of the HOCl damage, 
followed closely by Cur (100 pM). QE exhibited slightly diminished protection. 
Diminution of hypochlorite induced damage on human serum albumin by flavonoids 
has been reported by Firuzi et al. [2004]. 
In the three radical systems studied, physiological antioxidants like ascorbic acid, 
glucose etc. were also employed but corresponding protection was attainable at 
millimolar concentrations corroborating the potency of natural antioxidants. 
NO imposed deleterious effects on PTPI function and structure were ameliorated by 
these natural antioxidants. Cur, an established NO scavenger; completely reverted NO 
induced PTPI inactivation at 20 pM. 30-50 pM Cur was shown to be potent NO 
scavenger by Sreejayan and Rao [1997]; Onoda and Inano [2000]; Chan et al. [2005] 
and Sumanont et al. [2004]. This is also reinforced by the recent study of Khan et al. 
[2009], showing Cur to prevent NO mediated structural and functional damage of 
goat lung cystatin. Quite similar effect was shown by CA (80 pM). This is in 
conjunction with the works of Jung et al. [2006]; Gulcin [2006]; Olmos et al. [2008]; 
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Chung et al. [2006]. 80 ^M QE also protected against the NO induced damage. The 
resuhs draw support from earlier reports [Lapidot et al., 2002; Hirota et al., 2005]. 
Structural alterations engendered by NO in PTPI were also diminished markedly by 
the three natural antioxidants. 
These resuhs are important as Cur, QE and CA, 
a) come out to be potential scavengers of radical sinks viz. NO and HOCl. 
b) provide alternate therapeutic strategies against free radical damage. 
c) are effortlessly consumed by large proportion of human population and pose 
lesser or no side effects. 
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3.5 RESULTS 
The present set of experiments was devised to investigate the effects of sodium 
valproate (an antiepileptic drug causing pancreatitis), glimepiride (an antidiabetic 
drug of sulphonylurea class) and metformin hydrochloride (an antidiabetic drug, of 
biguanide class) on structure and function of PTPI. 
3.5.1 INTERACTION OF PTPI WITH SODIUM VALPROATE 
Association of valproate [Werlin and Fish, 2006] and cathepsin mediated trypsinogen 
activation with pancreatitis provoked the interest in probing the effects of valproate on 
PTPI, as thiol proteinase inhibitors (cystatins) are prime endogenous regulators of 
cathepsin activity. 
The concentration of sodium valproate (VPA) used in the experiments was well 
within the therapeutic range [Werlin and Fish, 2006]. Fig. 74 depicts the effect of 
VPA on PTPI activity. 2 \}M PTPI was incubated with increasing concentrations of 
the drug (2-20 tiM) in 50 mM sodium phosphate buffer pH 7.5 at room temperature 
for 30 min and its papain inhibitory activity was determined by caseinolytic assay 
[Kunitz, 1947]. The activity of native PTPI was taken to be 100%. As shown in the 
figure, -50% loss in PTPI activity occurred at 2 |iM VPA concentration. 67% loss 
precipitated at 4 pM and at 10 pM only 20% activity was left. Beyond 10 jiM the 
inhibitor was barely active. 
Fluorescence and UV-vis absorption spectroscopy are powerful tools for the study of 
the reactivities of chemical and biological systems since it allows non-intrusive 
measurements of substances in low concentrations under physiological conditions. 2 
yM PTPI treated with increasing concentrations of the drug (2-20 ^M) was analyzed 
spectroscopically by above mentioned techniques. The excitation wavelength was 
chosen to be 280 nm to assess changes induced in global conformation of the inhibitor 
on interaction with the drug. The emission range was from 300-500 nm. As in Fig. 75, 
only mild changes were induced on PTPI. At 2\JM drug concentration, -20% decline 
in fluorescence intensity was observed. The intensity was slightly enhanced than 
native at 4 nM VPA. In presence of 6 |aM drug, the fluorescence intensity was 
considerably increased (-40% above native). Between 8-15 [xM VPA the intensity 
was again quenched although remaining faintly higher than the native. At 20 ^M VPA 
concentration, the emission intensity increased 65% above untreated PTPI. However, 
179 
Fig. 74 Effect of Sodium valproate complexation on activity of PTPI 
Native PTPI (2 pM) was incubated with increasing concentrations of 
sodium valproate (VPA) (2-20 |xM) for 30 min at room temperature. PTPI 
was assayed for loss of antiproteinase activity by papain caseinolytic assay 
of Kunitz [1947]. Values are Mean ± SEM for four independent 
determinations. * Significantly different from native PTPI (control) at 
p< 0.05 by one way ANOVA. 
Fig. 75 Intrinsic fluorescence analysis of PTPI on interaction with 
various concentrations of Sodium valproate (VPA) 
The concentration of PTPI was 2 pM. PTPI was preincubated for 30 min at 
room temperature in 50 mM sodium phosphate buffer (pH 7.5) containing 
increasing concentration of VPA (2-20 pM). Fluorescence was measured at 
an excitation wavelength of 280 nm and emission range of 300-400 nm 
with slit width of 5 nm. 
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at all the drug concentrations, wavelength of maximum emission (Xmax) remained 
unaltered. The UV-vis absorption difference spectra were computed at all the drug 
concentrations. However, profound changes were noted only for those obtained at 2, 6 
and 20 |jM VPA [Fig. 76]. The difference spectra obtained for PTPI interacted with 2 
\JM VPA, shows two distinct positive peaks at 230 nm and 285 nm. In the difference 
spectra obtained at 6 and 20 pM VPA, broad shoulders were observed at 260 nm and 
maxima at 255 and 295 nm. Besides, intense negative peaks were noticeable at 210 
and 215 nm. On subjection to polyacrylamide gel electrophoresis, the gross 
conformation of PTPI at all VPA concentrations was found to be unaffected (results 
not shown). 
3.5.2 INTERACTION OF PTPI WITH GLIMEPIRIDE 
Glimepiride is an antidiabetic drug belonging to the sulphonylurea class. One of the 
adverse impacts of glimepiride therapy is the production of ROS in pancreatic cells 
[Sawada et al., 2008]. Thus the effect of therapeutic concentrations of glimepiride on 
PTPI activity and structure were examined. 2 pM PTPI was incubated with increasing 
concentrations of the drug (2-40 pM) in 50 mM sodium phosphate buffer pH 7.5 at 
room temperature for 30 min and its inhibitory activity was determined by 
caseinolytic assay of papain [Kunitz, 1947]. The activity of native PTPI was taken as 
100%. On interaction with 2 ^M glimepiride, 10% loss of PTPI activity was noticed 
[Fig. 77]. At 5 |JM drug concentration 50% of inhibitor's activity was compromised. 
With no significant change in activity of PTPI till 35 nM glimepiride, a drastic 
decline (85%) was noticed at 40 ^M drug concentration and the inhibitor retained 
only 15% of its original papain inhibition potential. 
Effect of glimepiride on the structure of the inhibitor was analyzed by intrinsic 
fluorescence. The spectra were obtained by exciting the protein at 280 nm and the 
emission range was 300-500 nm. As shown in Fig. 78 the tertiary structure of the 
inhibitor remained more or less uninfluenced by the drug with only a little increment 
in fluorescence till 30 (xM concentration. At 35 ^M glimepiride, the intensity was 
slightly quenched below untreated PTPI. However at 40 i^M glimepiride, pronounced 
enhancement in fluorescence intensity was observed. Similar to VPA, no change in 
Xmax was registered. When analyzed by UV-vis spectroscopy, corresponding to 
fluorescence resuhs no significant changes were observed except at 40 JJM 
glimepiride concentration. The difference spectra obtained at 40 ^M drug 
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Fig. 76 UV-Absorption difference spectra measured for PTPI-VPA 
complexes 
PTPI (2 nM) was incubated with VPA (2-20 \M) for 30 min and 
absorbance difference spectrum was calculated between 200 nm to 320 nm. 
Results are shown for complexes obtained at 2, 6 and 20 |JM VPA. 
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Fig. 77 Effect of glimepiride complexation on activity of PTPI 
Native PTPI (2 nM) was incubated with increasing concentration of 
glimepiride (2-40 yM) for 30 min at room temperature. PTPI was assayed 
for loss of antiproteinase activity by papain caseinolytic assay of Kunitz 
[1947]. Values are Mean ± SEM for four independent determinations. 
* Significantly different from native PTPI (control) at p< 0.05 by one way 
ANOVA. 
Fig. 78 Intrinsic fluorescence analysis of PTPI on interaction with 
various concentrations of glimepiride 
The concentration of PTPI was 2 |iM. PTPI was preincubated for 30 min at 
room temperature in 50 mM sodium phosphate buffer (pH 7.5) containing 
the increasing concentration of glimepiride (2-40 pM). Fluorescence was 
measured at an excitation wavelength of 280 nm and emission range of 
300-400 nm with slitwidth of 5 nm. 
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concentration is shown in Fig. 79. An intense negative peak was observed at 220 nm, 
a broad shoulder at 260 nm and a small negative peak at 280 nm. The difference 
spectra obtained at all other glimepiride concentrations showed small peaks in the 
region of 210-230 nm only. No changes were evidenced in the conformation of PTPI 
in the presence of drug in PAGE (results not shown). 
3.5.3 INTERACTION OF PTPI WITH METFORMIN 
HYDROCHLORIDE 
Another antidiabetic drug, metformin hydrochloride the only representative of the 
biguanide class, was also analyzed for its interaction with PTPI. 2 ^M PTPI was 
incubated with increasing concentrations of the drug (2-12 ^M) in 50 mM sodium 
phosphate buffer pH 7.5 at room temperature for 30 min. The effect of drug on 
antiproteolyitc potential of PTPI was determined by inhibition of caseinolytic activity 
of papain [Kunitz, 1947]. The activity of native PTPI was taken to be 100%. There 
was a gradual decline in PTPI activity with increasing drug concentration culminating 
to a 60% loss at 12 ^M metformin hydrochloride. Progressive decline of-20% each 
in activity of PTPI was observed at 2 i^M and 4 jiM concentrations of the drug, 
respectively. Further magnitude of decline was relatively smaller with increasing drug 
concentration. In contrast to sodium valproate and glimepiride, even at 12 \iM 
metformin hydrochloride the inhibitor retained 40% of its antiproteolytic potential 
[Fig. 80]. 
The impact of drug interaction on structure of PTPI was also explored by fluorescence 
and UV-vis spectroscopy. PTPI treated in similar manner as for the activity 
measurements was subjected to fluorescence spectroscopic analysis. Fig. 81 illustrates 
the results obtained. Xmax of emission remained unaltered at all drug concentrations. 
There was little increment in fluorescence intensity in comparison to untreated PTPI, 
In a similar fashion, on subjection to UV-vis spectroscopy and PAGE no significant 
changes were observed on PTPI (results not shown). 
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Fig. 79 UV-Absorption difference spectra measured for PTPI-
glimepiride complexes 
PTPI (2 ^M) was incubated with glimepiride (2-40 yM) for 30 min and 
absorbance difference spectrum was calculated between 200 nm to 320 nm. 
Results are shown for complex obtained at 40 ^M glimepiride. 
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Fig. 80 Effect of metformin hydrochloride complexation on activity of 
PTPI 
Native PTPI (2 jiM) was incubated with increasing concentration of 
metformin hydrochloride (2-12 ^M) for 30 min at room temperature. PTPI 
was assayed for loss of antiproteinase activity by caseinolytic assay of 
Kunitz [1947]. Values are Mean ± SEM for four independent 
determinations. * Significantly different from native PTPI (control) at 
p< 0.05 by one way ANOVA. 
Fig. 81 Intrinsic fluorescence analysis of PTPI on interaction with 
various concentrations of metformin hydrochloride 
The concentration of PTPI was 2 \iM. PTPI was incubated for 30 min at 
room temperature in 50 mM sodium phosphate buffer (pH 7.5) containing 
the increasing concentration of metformin (2-12 nM). Fluorescence was 
measured at an excitation wavelength of 280 nm and emission range of 
300-400 nm with slitwidth of 5 nm. 
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3.5.4 INTERACTION OF PTPI WITH INSULIN 
Insulin is released from pancreas in response to body glucose levels indirectly 
regulating protein, carbohydrate and lipid metabolism and acting as a switch between 
carbohydrate and lipid metabolism. Improper insulin production causes diabetes 
mellitus/hyperinsulinism. Since, the introduction of insulin in the 1920s as a treatment 
for diabetes [Banting and Best, 1990], it is considered to be the most effective 
treatment for Type 1 and Type 2 diabetes. 
Antihyperglycemic agent, proteinic in nature, recombinant insulin's interaction with 
PTPI was also investigated. 2 |JM PTPI was incubated with monocomponent 
Huminsulin R, in inhibitor to insulin ratios of 1:1-1:10 in 50 mM sodium phosphate 
buffer pH 7.5 at room temperature for 30 min. The treated PTPI samples were 
subjected to fluorescence, UV-vis and CD spectroscopy (in the far UV region); to 
assess changes in the structure of PTPI induced upon complexation with Huminsulin 
R. The resuhs of fluorescence are shown in Fig. 82. The insulin showed maximum 
emission at 304 nm and PTPI alone gave a Xmax of 335 nm [Priyadarshini and Bano, 
2009]. At 1:1 molar ratio of PTPI to insulin, the Kax was red shifted to 345 nm, with 
considerable enhancement in fluorescence intensity, with respect to PTPI or insulin 
alone. At a molar ratio of 1:2 of PTPI to insulin, 2 peaks were observed, one specific 
for insulin at 304 nm and other at 340 nm. At molar ratios lower than 1:1, Xmax of 345 
nm was observed. 
UV absorbance spectra of PTPI, insulin and their complexes are shown in Fig. 83, 
PTPI and insulin like other proteins showed peaks in regions of 200-210 nm and 278-
280 nm. On complexation profound changes were introduced. At 1:1 molar ratio all 
peaks were abolished with a broad plateau in the range of 200-300 nm, with 
considerably enhanced absorbance. At 1:2 ratio the peak at 275 nm of lone proteins 
was shifted to 260 nm. At ratios, 1:4 to 1:10, the peak was again red shifted to 273-
275 nm with considerable increment in absorbance. 
To examine the effect of complexation on secondary structure of PTPI, the complexes 
were subjected to CD spectroscopy in the far UV region. For CD experiments, 
following molar ratios of PTPLinsulin were used, 1:05, 1:0.25, 1:0.5, 1:1 and 1:2. The 
spectrum of PTPI alone is characterized by a minimum at 222 nm [Priyadarshini and 
Bano, 2009]. Insulin gave two negative minima at 210 and 222 nm [Fig. 84]. On 
complexation a gradual increase in ellipticity at 222 nm was observed. 
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Fig. 82 Intrinsic fluorescence analysis of PTPI on interaction with 
various concentrations of insulin 
The concentration of PTPI was 2 |iM. PTPI was incubated for 30 min at 
room temperature in 50 mM sodium phosphate buffer (pH 7.5) with insulin 
in various molar ratios of PTPI to insulin (1:1 to 1:10). Fluorescence was 
measured at an excitation wavelength of 280 nm and emission range of 
300-400 nm with slitwidth of 5 nm. 
Fig. 83 Absorption spectra of FTPI-insulin complexes 
The concentration of PTPI was 2 \M. PTPI was incubated for 30 min at 
room temperature in 50 mM sodium phosphate buffer (pH 7.5) with insulin 
in various molar ratios of PTPI to insulin (1:1 to 1:10). Absorbance was 
taken from 200 to 320 nm. 
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Fig. 84 Far UV-CD Spectra of PTPI in complex with insulin 
Far UV-CD spectra of PTPI and insulin alone and insulin-PTPI 
complexes. The concentration of PTPI was 1.73 \JM and PTPI and insulin 
molar ratios were 1:0.05 to 1:2. The complexes were obtained after 
incubation at room temperature for 30 minutes in 50 mM sodium 
phosphate buffer, pH 7.5. Cells of 1 mm path length were used. The unit 
on the ordinate is mean residue ellipticity. 
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DISCUSSION 
Proteins are complex macromolecules that can adopt a large number of slightly 
different conformations within their native state, called conformational substrates. 
Even small structural differences between these substrates can lead to drastic changes 
in functional parameters. In addition, the marginal stability of the native conformation 
is delicate balance of various interactions in proteins (van der Waals, electrostatic, 
hydrogen bonds and disulphide bridges) [Sneppen and Zocchi, 2005] which is 
affected by pH, temperature or addition of small molecules such as substrates, 
coenzymes, inhibitors and activators that bind especially to the native state and alters 
this fragile equilibrium. In this regard, many drugs exert their activity by interaction 
with proteins. 
Drug accumulation at off-target sites in body, lead to unintended off-target adverse 
reactions [Taniguchi et al, 2007; Scheiber et al., 2008] and drug/ligand induced 
protein structure conformational alterations [Takeda et al., 1988] are prime problems 
complicating drug medical therapy. 
Numerous drugs have been implicated in the etiology of acute pancreatitis (referred to 
as drug induced pancreatitis), but reports unravelling its mechanism are sparse [Dhir 
et al., 2007]. Use of valproic acid (an antiepileptic agent) is associated with an 
elevated risk estimate for acute pancreatitis besides being incriminated as a potentially 
fatal hepatotoxic and teratogenic agent [Norgaard et al., 2006; Werlin and Fish, 2006]. 
Generally, no relationship between the occurrence of pancreatitis and duration of 
sodium valproate therapy, dosage, serum level, and the use of other anticonvulsants 
has been found [Werlin and Fish, 2006]. 
Commonly prescribed antidiabetic drugs are sulfonylureas (glimepiride) and 
biguanides (metformin), the former act by increasing the insulin release from the P 
cells of the pancreas and insulin sensitivity in peripheral cells and the latter by 
decreasing hepatic glucose production and increasing peripheral glucose uptake and 
use. Sulphonylureas are considered to cause P cell apoptosis, induce nitric oxide 
generation and reactive species production [Ansar and Ansari, 2006; Sawada et al., 
2008]. Synthetic insulin is another commonly prescribed hypoglycemic agent. 
Almost all the specific drugs have some side or adverse effects. Thus, study aimed at 
investigating the effects of above four drugs on purified goat pancreatic thiol 
proteinase inhibitor. Inclination for this study sprouted up as PTPI is shown to have 
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anti thiol proteinase activity. Cathepsin mediated trypsinogen activation is one of the 
initiator points of acute pancreatitis [Thrower et al, 2006; van Acker et al, 2002]. 
Also, insulin degradation is mediated probably by lysosomes [Sandberg and Borg, 
2006]. Thiol proteinase inhibitors /cystatins serve as the main endogenous regulators 
of lysosomal cathepsins [Turk et al, 2008]. 
To assess the effect of interaction of these drugs on functional integrity of PTPI, the 
purified inhibitor was incubated with increasing concentrations of VPA/ glimepriride/ 
metfromin hydrochloride and its antiproteolytic potential was determined. Estimation 
of protein activity provides a sensitive means to monitor the effect of ligands on the 
protein as even minute changes in active site region can considerably affect the 
protein function. VPA diminished the activity of PTPI with almost complete 
inactivation of the inhibitor at higher concentration [Fig. 74] within a short span of 
time. Glimepiride induced inhibitor inactivation was less drastic. Considerable 
activity (-50%) was retained by PTPI till 30 nM drug concentration. Even at 
maximum concentration of the drug (40 \iM) PTPI possessed 15% activity [Fig. 77]. 
Metformin hydrochloride was milder in inflicting inactivation on PTPI [Fig. 80]. 
Drug induced inactivation (functional derangement) of proteins has been reported 
earlier like horse liver alcohol dehydrogenase (ADH) activity was affected 
differentially by various drugs. Few like barbital, caffeine and diazepam exerted no 
effect, chlorpromazine, sulpiride, morphine etc. reduced the activity and phenytoin 
enhanced ADH activity [Roig et al., 1991]. Absence of any major drug induced 
conformational change in PTPI structure (as discussed later), suggest that inactivation 
of the inhibitor may be related to subtle changes in the conformation at the active site 
region induced by the drugs. Similar ligand binding induced functional changes have 
been shown for isocitrate dehydrogenase [Serry and Farrell Jr., 1990], 
Intrinsic fluorescence of proteins provides considerable information about protein 
structure and dynamics and has been used extensively to study protein folding and 
association reactions [Lakowicz, 2006]. Various measurable parameters of 
fluorescence viz. quenching, enhancement of intensity, spectral shift etc. are used for 
interpretation of related structure-dynamics in proteins [Lakowicz, 2006]. In the 
present study, fluorescence spectroscopic measurements were undertaken to gain 
insight into the interaction and complexation of VPA, glimepiride, metformin 
hydrochloride and insulin with PTPI [Figs. 75, 78, 81 and 82]. In the presence of all 
these drugs, fluorescence intensity increased (though not profoundly) except for 2 \M 
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VPA and 35 |JM glimepiride. Such a kind of change has been documented earlier. 
Interaction of ligands (phytohormones, cytokinins, abscisic and gibberellic acids) with 
wheat germ agglutinin resuhed in -60% increase in fluorescence intensity of native 
protein [Bogoeva et al., 2004]. Fluorescence enhancement of al antitrypsin on 
interaction with heparin and glucose has also been reported [Finotti and de Laureto, 
1997]. Except for PTPI-insulin complexation, no shift in X a^xwas noted. A 10 nm red 
shift was observed on formation of equimolar complex of insulin and PTPI, indicating 
exposure of aromatic residues to the solvent caused by conformational rearrangement 
of the two proteins [Monsellier and Bedouelle, 2005; Vivian and Callis, 2001]. When 
PTPI-insulin ratio was 1:2, there was a blue shift of 5 nm, suggestive of a change in 
environment of tryptophan residues to non polar. 
Absorption spectral measurements of PTPI in the presence of drugs provided 
information related to their interaction. Difference spectra were computed by 
subtracting the absorption of PTPI-drug complex fi"om the absorption of PTPI alone, 
for VPA/ glimepiride-PTPI complexes [Fig. 76 and 79]. The intense negative peaks at 
210 and 215 nm observed for PTPI-VPA complexes obtained at 6 and 20 pM VPA 
concentrations, respectively may contain contributions fi^om phenylalanine and 
histidine residues [Donovan, 1969]. The broad shoulders observed at 260 nm are also 
due to phenylalanine and may contain contribution form tryptophan [Donovan, 1969]. 
The peaks observed at 255 and 295 nm indicate the involvement of aromatic residues 
in interaction. A negative peak noticeable at 275 nm in difference spectra obtained at 
6 \JM VPA, suggest changes around tyrosine residues [Donovan, 1973 a]. For the 
difference spectra obtained at 2 pM VPA, positive peaks at 230 nm and 285 nm might 
have the contribution of mainly tryptophan and tyrosine residues [Donovan, 1973 a]. 
The negative peak at 275 nm and the difference peak at 295 nm are characteristic of 
blue shifts of tryptophan and tyrosine absorption bands and are usually interpreted as 
arising from increased exposure of these aromatic groups to the solvent [Donovan, 
1969]. Difference spectra of glimepiride-PTPI complex at 40 [iM glimepriride 
concentration, showed broad shoulder at 260 nm and a small negative peak at 280 nm, 
indicative of involvement of phenylalanine and tyrosine in complexation process. 
The interaction between insulin-PTPI was studied from UV-vis absorption spectral 
data. Complex spectroscopic changes were noticed. Equimolar complex of PTPI and 
insulin showed only a broad absorption band in the region of 200-300 nm, suggesting 
that the native structure of both the proteins is altered on complexation. The blue shift 
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observed for 1:2 molar ratio, indicates the changes in the environment of tyrosine 
residues towards hydrophobic. At higher ratios, shift of spectra towards longer 
wavelengths was observed. These evidences clearly indicated the interaction and 
some complex formation between insulin and PTPI [Cui et al., 2004; Hu et al., 2004]. 
Similar changes have also been shown for UV-vis absorption spectra of horse 
myoglobin on interaction with phenothiazines promazine and triflupromazine 
hydrochlorides [Cheema et al., 2008]. 
Alterations in secondary structure of PTPI on complexation with insulin were also 
analyzed by CD spectroscopy. Two negative absorbance peaks at 210 and 222 nm for 
insulin alone and at 222 nm for PTPI alone, are typical peaks of a helix [Fig. 84]. 
Slight enhancement in ellipticity at 222 nm was observed for all molar ratios of PTPI-
insulin, suggesting that binding of insulin to PTPI increased the a helical content of 
PTPI. Such enhanced ellipticity has also been reported for binding of femlic acid to 
cytochrome C [Yang et al., 2007]. 
When drugs bind to a globular protein, the intramolecular forces responsible for 
maintaining the secondary and tertiary structures can be altered, resulting in 
conformational change of the protein [Salvi et al., 2001]. Such conformational 
changes of varied magnitude have been reported [Guo et al., 2004a; Cheema et al., 
2008; Ahmed-Ouameur et al., 2006]. Thus, the resuhs indicate that the UV absorption 
and fluorescence emission changes on VPA, glimepiride and metformin 
hydrochloride mediated interaction, are due to minor conformational changes in PTPI 
and mainly arise from local interactions affecting the chromophoric groups of the 
protein. While in case of insulin-PTPI interaction, conformational rearrangement 
might have occurred. 
Drug induced changes in enzyme activities as their adverse effects have been an area 
of continual scientific investigation [Priyamvada et al., 2008]. Limited number of 
reports is available on effects of drugs on purified tissue proteins which do not 
function as carriers but are putative targets of the drug induced side effects or whose 
structural and functional modifications aid in drug mediated damage or are critical for 
the off-target tissue. This study has tried to explore the effects of few drugs on 
purified pancreatic thiol proteinase inhibitor. The drugs chosen are either incriminated 
or prescribed in pancreatic pathologies and thiol proteinase inhibitors are prime 
regulators of lysosomal cathepsins [Bohley et al., 1978]. 
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On complexation with VPA (a pancreatitis causing drug) PTPI activity was severely 
challenged suggesting cathepsin inactivation might be one of the factors in VPA 
induced pancreatitis. Glimepiride causes p cell apoptosis [Ansar and Ansari, 2006]. 
These antidiabetic agents are also known to cause nitric oxide and reactive oxygen 
species production in pancreas [Sawada et al, 2008]. PTPI function was also 
compromised on interaction with these two drugs though it was less severe with 
metformin. Functional insulin receptors are known to occur in pancreatic P cells. 
Studies have shown that exogenous insulin in the presence or absence of 
nonstimulatory concentrations of glucose evokes exocytosis mediated by the p cell 
insulin receptor. This autocrine action of insulin diminishes as the concentration of 
free insulin on cell surface decreases or receptors get blocked [Aspinwall et al., 1999]. 
Cystatin P has been found to be colocalized with cathepsin in insulin secretory 
granules in rat pancreas [Watanabe et al., 1988]. In the present work complexation 
with insulin increased the a helical content of PTPI. Thus it may be speculated that 
this increase in the native stability of the inhibitor on complexation with (exogenous) 
insulin, may allow more efficient regulation of cathepsin activity under diseased states 
and thus preventing insulin degradation. 
The possible implications of these results would be on designing therapeutic agents 
managing VPA induced pancreatitis, understanding of non responsiveness to 
antidiabetic agents after a period and provide a clue to increase insulin potency. 
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[IV] CONCLUSION 
The results obtained are important as, 
1. Isolation and purification of thiol proteinase inhibitors from specific tissue types 
would provide an insight into the in vivo regulation of the target proteinases. 
Studies delving into proteinases-PTPI interaction would possibly be informative 
for design of pharmacologically active synthetic inhibitors against cysteine 
proteinase/inhibitor malfunctioning derived pancreatic disorders. 
2. The conformational stability of the native proteins is a function of external 
variables, such as, temperature, pH, ionic strength and solvent composition. 
Studies that delve into the structural and functional properties of the proteins in 
response to various externally imposed conditions thus provide a good 
approximation of their conformational stabilities. 
3. Evidence for PTPI's susceptibility to fibrillate under experimentally induced 
conditions suggests that damage instigated by thiol proteinase inhibitor generated 
fibrils can't be ruled out in various pancreatic disorders. Prevention of fibrillation 
by copper and zinc point to the emerging possibilities against formation amyloid 
fibrils. 
4. With the known proclivity of pancreas towards oxidative damage and disturbed 
protease-inhibitor balance in the inflammatory processes, PTPI's vulnerability to 
oxidative/nitrosative stress was expected. However, the benefiting effects of 
flavonoids obtained in the data against radical/oxidant mediated damage suggest a 
positive role of natural antioxidant supplementation in slowing down severity of 
pancreatitis or free radical induced diabetic complications. These results are 
further consequential as they suggest alternate, cost effective and safe therapy 
against free radical induced damage. 
5. Sodium valproate induced loss of fimction change in the inhibitor could provide a 
rationale for the off target tissue injury caused by the drugs and for the design of 
agents against such an injury. Action of glimepiride and metformin on inhibitor 
point towards the mechanism that might be responsible for islet cell damage and 
hence to non responsiveness to these drugs on prolonged intake. Also, as in case 
of insulin, such studies provide a clue for enhancing drug potency. 
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Abstract A thiol proteinase inhibitor from Capra hircus 
(goat) pancreas (PTPI) isolated by ammonium sulphate 
precipitation (20-80%) and gel filtration chromatography on 
Sephacryl S-IOOHR, with 20.4% yield and 500-fold purifi-
cation, gave molecular mass of 44 kDa determined by its 
electrophoretic and gel filtration behavior, respectively. 
The stokes radius, diffusion and sedimentation coefficients 
of PTPI were 27.3 A, 7.87 x 10'"' cm^ s~' and 3.83 s, 
respectively. It was stable in pH range 3-10 and up to 70°C 
(critical temperature, £a = 21 kJ mop'). Kinetic analysis 
revealed reversible and competitive mode of inhibition with 
PTPI showing the highest inhibitory efficiency against 
papain (Ki = 5.88 nM). The partial amino acid sequence 
analysis showed that it shared good homology with bovine 
parotid and skin cystatin C. PTPI possessed 17.18% a helical 
content assessed by CD spectroscopy. The hydropathy plot 
of first 24 residues suggested that most amino acids of this 
stretch might be in the hydrophobic core of the protein. 
Keywords Goat pancreas cystatin • Kinetics of 
inhibition • Amino acid sequence • Mammalian cystatins • 
Characterization 
Introduction 
Proteolytic enzymes are essential for the survival of all 
kinds of organisms, and are encoded for by approximately 
2% of all the genes (Barrett et al. 2001). Despite their vital 
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functions, these proteases are potentially very damaging in 
living systems. Cells therefore have several distinct 
mechanisms to check their enormous hydrolytic potential, 
important among which are the interactions of the prote-
ases with inhibitors. The major proteases of the lysosomal 
pathway of protein degradation, cathepsins, are naturally 
regulated by cystatins. Cystatins (thiol protease inhibitors, 
TPI), reversible competitive inhibitors of thiol dependent 
(cysteine) proteases, are widely distributed in animals and 
plants and are also reported in some lower eukaryotes. 
Generally, they are classified into three distinct families 
based on their sequence homology, presence of disulphide 
bonds and molecular mass (Abrahamson et al. 2003; Turk 
et al. 1997). Family I—the stefins (mamtnalian cystatin A 
and B and bovine stefin C) are cytosolic proteins of about 
100-residue single chains, with no disulphide bonds or 
carbohydrates (Turk et al. 1997). Family II—the cystatins 
(chicken cystatin) are primarily extracellular and each has a 
single chain of about 120 amino acids with two disulphide 
bonds and no carbohydrates (Bode et al. 1988). Family 
in—the kininogens are blood plasma glycoproteins and 
have several cystatin like domains (Ohkubo et al. 1984). 
Physiologically important cystatins are known to act as 
defensive agents against bacteria, viruses, and plant eating 
insects (Ylonen et al. 1999). They can also regulate cell 
death, antigen presentation and their expression is altered 
in mahgnant processes (Ylonen et al. 1999). Cystatins have 
been purified and characterized from various sources 
including goat kidney (Zehra et al. 2005), goat brain 
(Sumbul and Bano 2006), sheep plasma (Shahid et al. 
2005), human placenta (Rashid et al. 2006), human spleen 
(Jarvinen and Rinnie 1982), human liver (Green et al. 
1984), and amyloid fibrils (Cohen et al. 1983), etc. The 
present investigation aimed at understanding the function-
ing of thiol dependent protease inhibitors in pancreas, the 
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A R T I 
Preventive Effect of Curcumin and Quercetin against Nitric 
Oxide Mediated IWodification of Goat Lung Cystatin 
MoHD SHAHNAWAZ KHAN, MEDHA PRIYADARSHINI, AND BILQEES BAND* 
Department of Biochemistry, Faculty of life sciences, A.M.U.AIigarh. U.P., India 
Cysteine proteinase inhibitors are of prime physiologic importance inside the cells, controlling the 
activities of lysosomal cysteine proteases. The present work aimed to realize the effects of nitric 
oxide on the structure and function of goat lung cystatin (GLC) and to evaluate antinitrostative 
efficacy of curcumin and quercetin. Nitric oxide induced structural modifications were followed by 
fluorescence spectroscopy and PAGE and functional inactlvation by monitoring the inhibition of 
caseinolytic activity of papain. Ten millimolar sodium nitropmsside (SNP) caused time dependent 
inactlvation of GLC-I with complete functional loss precipitating at 180 min. Curcumin (50 ^M) and 
quercetin (250 nM) opposed such loss in papain inhibitory activity of GLC-I. Loss in tertiary stnjcture 
of GLC-I (fluorescence quenching and 15 nm red shift) was observed on SNP treatment. Inhibition 
of functional and structural SNP mediated damage of GLC-I by curcumin (50 fiM) and quercetin 
(250 ^M) reaffirms their NO scavenging potency. 
KEYWORDS: NO; protease inhibitor; asthma; curcumin; quercetin 
INTRODUCTION 
Nitric oxide (NO) is an omnipresent intercellular messenger 
in all vertebrates, modulating blood flow (J), thrombosis (2) 
and neural activity (3). The production of nitric oxide is also 
important for nonspecific host defense, helping to kill tumors and 
intracellular pathogens. However, under pathophysiological con-
ditions, NO has damaging effects. It is found to be involved in 
neural disorders involving oxidative stress such as Parkinson's 
disease i4), Alzheimer's disease (5), ischemia (6), Huntington's 
disease (7), amyotrophic lateral sclerosis (8) and multiple sclero-
sis i9). Excessive production of NO (a known mediator of 
inflammation) is correlated with nilrostative stress in tissues. 
Although NO' is a free radical, it has selective reactivity and 
reacts predominantly with other paramagnetic species, including 
ferrous or ferric iron in heme proteins or iron-sulfiir centers, and 
other radical species such as molecular oxy^n (O2), superoxide 
anion ("Oj") and lipid or protein radicals (10-14). Reaction of 
NO with "Oa" at a near diffusion limited rate yields peroxynitrite 
(ONOO"), a powerful oxidizing species, to which many of the 
cytotoxic properties of NO' have been attributed (15). 
Lung diseases like cancer, emphysema and idiopathic pulmon-
ary fibrosis are known to be caused by an imbalance between the 
activities of endogenous inhibitors and cysteine proteinases 
(cathepsins) (16). Cyslatins, noncovalent competitive inhibitors 
of cysteine proteinases (cathepsins B, H, L and S) (17), are 
ubiquitously present in mammalian system. These inhibitors 
protect the cells from unwanted proteolysis which may otherwise 
cause a number of pathologies like purulent bronchitis (18), 
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Rheumatoid arthritis (19), osteoporosis (20), Alzheimer's dis-
ease (21), metastasizing cancer (22) and microbial invasion (23). 
NO is a thermodynamically unstable molecule and tends to 
reaa with other bio molecules especially proteins resulting in their 
oxidation, nitration and nitrosylation, with the concomitant 
effects on many cellular mechanisms. Increased ROS/RNS 
(NO') levels are consequential to chronic/acute lung inflamma-
tion. A common factor in inflammation is that the equilibrium 
between lysosomal enzymes released by macrophages or neutro-
philic granulocytes and their endogenous inhibitors in the extra 
cellular space is disturbed. This imbalance may originate from 
many reasons, one of which may be inactlvation by ROS/RNS 
released by neutrophilic granulocytes during the process of 
inflammation. 
Various researches have been undertaken to evaluate the 
potential benefits of complementary and ahernatives medicines 
(botanicals, flavonoids, herbs, etc.) to oppose the toxicity asso-
ciated with reactive species generated during various pathogenic 
states. 
Curcumin (diferuloylmethane), the major coloring pigment 
present in the rhizomes of Curcuma longa (turmeric), is a spice 
widely used in Indian cooking and for medicinal purposes (24). 
Curcumin has been shovm to possess many therapeutic properties 
including antioxidant (25), anti-inflammatory (26) and anticancer 
properties (27). It also protects DNA against singlet-oxygen-
induced strand break (28), lipids from peroxidation (29) and 
oxyhemoglobin from nitrite induced oxidation (30). 
Quercetin is the main flavonoid in the diet and is consumed as 
quercetin-3-rutinoside (in black tea about 40%), quercetin-
4'-glucoside (4.'5% in onions) and quercetin-3-glucoside (mainly 
in tea. apples and tomatoes) (31, 32). Flavonoids exhibit seve-
ral positive health aspects; they possess anticarcinogenic, anti-
mutagenic, antioxidant, immune-stimulating and estrogen-active 
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